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Abstract 
 Liver transplantation is a well-established, life-saving treatment for patients with 
end-stage liver disease. Liver transplantation is inevitably accompanied by some degree 
of ischaemia/reperfusion injury. Ischaemia/reperfusion injury (IRI) can have important 
implications for both short and long-term transplantation outcomes. Increasing demand 
for donor livers has necessitated the use of “extended criteria donor” organs. 
Frequently, these livers are affected by steatosis. Significant steatosis of the donor liver 
is associated with increased susceptibility to injury during donor brain death and warm 
ischaemia, and increased rates of primary graft non-function. Consequently, steatosis is 
the most common reason for procured liver grafts to be deemed unsuitable for 
transplantation. Better understanding of the mechanisms involved in these processes 
could help enlarge the pool of available donor livers and allow safer utilization of 
steatotic grafts. Approximately 20% of liver transplant recipients in the clinical setting 
can be safely weaned off immunosuppressive medications without the expected graft 
rejection. As an initial trigger of immune responses, IRI is an important factor which 
can impede the development of operational tolerance. Spontaneous liver transplantation 
tolerance has been consistently associated with the deletion or clonal exhaustion of 
alloreactive T cells following their initial activation, thus preventing their ability to 
mediate graft destruction. 
The first part of this study examined the hypothesis that the higher propensity 
for liver grafts to be tolerated compared with other organs, is due to a relative 
insufficiency of T cell survival signals, transmitted through the cytokines, interleukin 
(IL)-2, 4, 7, 9, 15 and 21 and their receptors, which incorporate the common gamma 
chain. Transplantation of hearts or kidneys in the PVG to DA rat strain combination led 
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to rejection of the graft. Livers transplanted in the same strain combination are tolerated 
without the need for immunosuppression. By examining the relative gene expression of 
the common gamma chain cytokines and their receptors, we found that an association 
exists between high expression of IL-2, IL-2Rα, IL-4 and IL-15Rα and rejection. In 
contrast to these, expression of IL-7Rα was significantly higher in tolerated livers than 
in rejecting hearts and kidneys. IL-7Rα expression is inversely related to the global 
levels of common gamma chain signalling, further supporting the postulate that graft-
infiltrating T cells in tolerated livers have been exposed to lower concentrations of 
common gamma chain cytokines. 
The second part of this study was aimed at establishing a model of partial, warm 
liver IRI in the steatotic liver and characterizing some of the factors contributing to the 
increased susceptibility of fatty livers to IRI. This was achieved through feeding male 
C57BL/6J mice a 45% fat diet for 12 weeks. Lean mice and those with steatotic livers 
were then subjected to a moderate ischaemic insult, followed by reperfusion. HMGB1 is 
a critical mediator of inflammatory signalling during liver IRI. We found that HMGB1 
was localised to the nucleus of hepatocytes in lean livers, whereas in steatotic livers a 
striking redistribution of HMGB1 from the nucleus to the cytoplasm had taken place. 
As early as 15 minutes post-reperfusion, serum levels of HMGB1 were significantly 
higher in the HFD-fed than in the lean mice, and the severity of ischaemic injury was 
considerably greater in the HFD-fed group as determined by increased serum alanine 
aminotransferase, more extensive liver necrosis and apoptosis, and increased synthesis 
and/or systemic release of proinflammatory cytokines such as IL-6, TNFα, IL-1β and 
IL-17. The damaging effects of IRI in steatotic livers were accentuated by a reduced 
rate of hepatocyte regeneration. Moreover, persistently elevated IL-7 levels in the HFD 
mice on d1 post-reperfusion may be a means of rescuing activated alloreactive T cells if 
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IRI is occurring in the context of an allogeneic liver transplant. IL-6 and IL-17 are also 
recognised contributors to the blockade of transplant tolerance induction, implying that 
the more intense innate immune response in steatotic liver not only engenders more 
severe tissue damage and poorer immediate graft function, but could oppose the 
development of operational tolerance in these grafts. 
The third part of this study examines the effect of overexpression of endogenous 
soluble Receptor for Advanced Glycation End-products (esRAGE) on the outcome of 
partial warm IRI in lean and fatty livers. esRAGE acts as a competitive antagonist to 
alarmins such as HMGB1 and reduces proinflammatory signal transduction. By 
administering an adenoassociated viral vector encoding esRAGE, persistent high 
systemic levels of esRAGE were achieved without the need for repeated intraperitoneal 
injections. An AAV vector encoding Green Fluorescent Protein (GFP) served as a 
control. Systemic esRAGE expression resulted in reduced serum HMGB1 and conferred 
protection from IRI in lean livers, but not in steatotic livers. In the esRAGE-transduced 
lean livers we found minimal necrosis, fewer apoptotic cells and subdued neutrophil 
infiltration, compared with GFP-transduced lean livers at day 1 and 3 post-reperfusion. 
Conversely, esRAGE expression in steatotic hepatocytes resulted in a greater incidence 
of frank necrosis, and hepatocyte apoptosis, associated with more intense neutrophil 
infiltration and increased expression of various components of inflammatory signalling 
pathways. 
In conclusion, liver-directed gene transfer of esRAGE to lean livers protects 
them against warm IRI. In the steatotic hepatocytes, esRAGE transduction increases 
susceptibility to tissue injury, possibly due to augmentation of pre-existing endoplasmic 
reticulum stress. An alternative approach to harnessing the potential hepatoprotective 
effects of AAV vector-mediated esRAGE gene transfer in the setting of hepatic 
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steatosis could involve choosing skeletal muscle rather than liver as the site for 
transgene expression.  
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CHAPTER 1. Introduction 
1.1 Brief overview of transplantation 
The idea of moving body parts between individuals to treat physical conditions 
has been present since ancient times. Folklore and art of various cultures throughout 
history have references to legends of creatures composed of parts from the bodies of 
different species or myths about saints and healers who could heal by changing diseased 
body parts with those from other individuals or species. One of the first documented 
instances of medical transplantation was described in the 2nd century BC in an 
Ayurvedic text by Sushruta Samhita, where the author used the patient’s own prefrontal 
skin flap to replace a lost nose. Since the 2nd century BC, skin and other superficial and 
readily accessible tissues like blood, teeth and gonads were the objects of 
transplantation exploration. The phenomenon of graft rejection was described in the 
works of the Italian scientist Giuseppe Baronio as early as 1804 [4]. Baronio showed 
that a piece of skin transplanted from one sheep onto another would shrink and be 
destroyed by the host, while the animal’s own transplanted skin would heal. However, 
Baronio did not explain the mechanism behind his observations. 
One of the early obstacles preventing successful solid organ transplantation was 
revascularisation of the graft. Solution of this problem using an approach developed by 
Alexis Carrel (published 1906) permitted technically-successful transplants, and was 
later rewarded with a Nobel Prize [5], but as with Baronio’s earlier skin grafts, a 
“biological incompatibility” resulted in subsequent graft destruction [6]. Charles 
Guthrie suspected that graft destruction was immune-mediated [7], and this was 
confirmed by the later work of Medawar and colleagues. Preceding this, Landsteiner, 
Levine, Wiener, Tyzzer and Little elucidated the nature of blood groups, while Gorer 
[8] and Snell [9] described the histocompatibility factors which were responsible for 
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discrimination between “self” and “foreign” by the immune system.   In 1944, Medawar 
published a landmark paper showing the allospecific nature of graft rejection. 
Moreover, he reported that that the responding animal will form an immunological 
memory of its encounter with foreign tissue and mobilise a second, and much faster 
rejection if such an encounter takes place again-the “second set” rejection [10]. 
Medawar’s work explained the reasons underlying the functional failures of grafts in 
earlier experiments, inaugurating the field of transplantation immunology. Further work 
from Billingham, Brent and Medawar established the concept of self-tolerance [11]. Sir 
Peter Medawar together with Sir Frank Macfarlane Burnet, received the Nobel Prize for 
their work on acquired tolerance in 1960.  
Advances in the understanding of basic transplantation immunobiology 
prompted attempts to manage acute rejection of organ transplants, such as the use of 
total body irradiation in 1960 [12], and the progressive introduction of azathioprine in 
1962 [13], cyclosporine in 1978 [14] and tacrolimus in 1990 [15]. As a result, 
transplantation of kidney in 1960 [13], liver in 1967 [16], heart in 1968 [17], pancreas 
in 1970 [18], lung in 1971 [19] and small bowel in 1992 [20] have followed. Passage of 
the first legislation defining brain-death in 1970 allowed transplantation to develop into 
an accepted mainstream treatment for various end-stage organ conditions. However, the 
maturation of transplantation medicine has opened up a growing demand for grafts that 
has far outstripped the increase in supply. 
 
1.2 Current status of clinical liver transplantation 
1.2.1 Principal indications for liver transplantation  
Liver transplantation is a lifesaving treatment for end-stage liver disease. In the 
current era, the post-operative 1 and 5 year primary graft survival rates can be as high as 
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83.3% and 67.3%, respectively [21]. The principal indications for liver transplantation 
in adults and children include: 
 Hepatitis C virus-induced chronic hepatitis-18.8% 
 Biliary atresia-10.7% 
 Alcoholic liver disease-10.3% 
 Acute liver failure- 8.7% 
 Primary sclerosing cholangitis- 8.7% 
 Hepatocellular carcinoma- 7.8%  
 Inborn metabolic diseases- 6.3% 
 Primary biliary cirrhosis- 5% 
 Hepatitis B virus-induced chronic hepatitis - 5% 
 Autoimmune liver disease- 3.5% 
 Other- 14.9% [22] 
 
1.2.2 Growth in demand for liver transplantation and donor organ shortage 
Disparity between the growing number of patients with end-stage liver disease 
and the availability of donor organs is one of the major challenges currently facing 
transplantation medicine. Developed nations are reporting an increasing shortage of 
transplantable organs (Table 1.1). The number of patients awaiting liver transplantation 
far outstrips the total number of liver transplants performed in those countries. To 
address this shortage, organs with suboptimal qualities have been accepted for 
transplantation as “extended criteria donor” (ECD) organs [23]. Typically this may 
include organs from donors >65 years of age, or with positive viral serology (hepatitis B 
or hepatitis C virus), prior neoplasms, variable degrees of hepatic steatosis and 
behavioural risks. More recently, donation of livers after cardiac death has been 
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introduced. Utilisation of ECD livers has decreased the number of deaths on waiting 
lists [23]. One of the most frequent reasons for donor livers to be considered “extended 
criteria” is the medium to severe hepatic steatosis associated with non-alcoholic fatty 
liver disease (NAFLD) [24-26].  
 
Country, year LTx 
performed 
LTx 
awaiting 
Source 
United States, 2009 5975 15625 United Network of Organ Sharing 
[27] 
Canada, 2010 442 501 Canadian Organ Replacement 
Registry waiting list [28] 
United Kingdom, 
2010 
675 510 UK Transplant [29] 
Eurotransplant area, 
2010 
1763 2588 Eurotransplant [30] 
Australia and New 
Zealand, 2010 
248 510 ANZLT Registry [31] 
Table 1.1 Demand for donor livers in countries with developed healthcare is high 
compared to availability. 
 
 
1.3 The liver tolerance effect and spontaneous liver transplant tolerance 
Operational tolerance refers to the phenomenon whereby an allograft is accepted 
by the recipient’s immune system without the need for immune suppression. Different 
organs vary in their susceptibility to rejection or propensity to induce spontaneous 
transplantation tolerance. Among these, the liver is notable for its special status, as 
summarised below:  
1. when grafted across a complete MHC barrier, the liver exhibits a greater 
likelihood of being accepted without immunosuppression, and  
2. when grafted, the liver is able to generate specific tolerance towards 
other organs from the donor or donor strain, that otherwise would be 
rejected.  
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Both in animal models and in the clinical setting, transplanted livers are less 
likely to be rejected. In pigs [32], many inbred rat strains [33] and mice [34] the liver is 
spontaneously accepted by the recipient, while other grafted organs from same strain are 
destroyed by an aggressive alloresponse. In the clinic, roughly 20% of adult, single 
organ LTx recipients can be completely weaned off immunosuppression without 
negative consequences for the graft [35].  
In experimental liver transplantation, the transfer of strain-specific immune 
tolerance to other transplantable organs is well-established [32, 33, 36, 37]. Subbotin et 
al. reported that liver transplantation 30 days prior to aortic transplantation in the 
C57Bl/10J to C3H mouse strain combination prevented the diffuse myointimal 
thickening, progressive concentric luminal narrowing, and patchy destruction of the 
internal elastic membranes which otherwise resulted in massive vascular obliteration by 
day 120 post-transplantation. Rejection of third-party aortae was unaffected, confirming 
the allospecificity of tolerance induced by liver transplantation [37]. 
 Moreover, liver transplantation can reverse or attenuate ongoing rejection of 
other organs. Wang et al. reported that established pancreas rejection in the PVG to DA 
rat strain combination was abrogated in the groups that received liver transplants from 
the PVG donor at 2, 4 or 6 days post pancreas transplantation [38]. Similar results were 
reported for heart grafts [39].  
One consistent observation in experimental liver transplantation is that graft 
reactive recipient T cells manifest early and vigorous activation, but that these cells 
subsequently undergo clonal exhaustion or deletion so that graft rejection does not 
occur [40-42].  
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A number of different factors have been proposed to contribute to the T cell 
inactivation which underlies the liver tolerance effect. One of the earlier hypotheses 
suggested that soluble MHC class I molecules from the grafted liver produced tolerance 
via the induction of deletion or anergy of CD8+ T cells [43]. Whereas soluble MHC may 
play a minor part in spontaneous liver transplant tolerance [44, 45], it was subsequently 
shown that the release of soluble MHC is not necessary for tolerance induction [46].  
The liver is richly supplied with passenger leukocytes which migrate to recipient 
lymphoid organs following transplantation and activate recipient T cells [47]. Depletion 
of donor passenger leukocytes by irradiation [48] or by parking the donor organ in an 
intermediate recipient [49] inhibits the development of tolerance, supporting the 
importance of donor leukocytes in liver transplant tolerance induction. Parenchymal 
cells also participate in T cell activation in the liver. The unique microvascular structure 
of the liver allows direct contact between naïve T cells and hepatocytes. Intrahepatic 
activation of responding T cells results in their engulfment by hepatocytes in a process 
which has been termed “suicidal emperipolesis” [50]. However, this process has not yet 
been demonstrated to occur in liver transplantation [51].  
The liver is approximately 10 times larger in tissue mass than other transplanted 
organs. Increasing the mass of transplanted tissue prolongs graft survival, sometimes 
indefinitely [52, 53]. Transplantation of one heart or kidney in the PVG to DA rat strain 
combination leads to rejection in 9 and 8.5 days, respectively. Two or three hearts 
survived for 15.5 days, two or three kidneys survived 60 days and >100 days, 
respectively [54]. A large mass of transplanted tissue may overcome rejection responses 
by exhausting alloreactive T cell clones. Survival of activated T cells is promoted by 
signalling through cell surface cytokine receptors that utilise a common subunit in their 
molecular structure- the γ chain. The common gamma chain (γc) cytokines (CGC) are 
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IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21. Receptors to these cytokines consist of a ligand 
specific α chain, a γ chain common to each receptor, and another common β chain in the 
case of the IL-2 and IL-15 receptors [55]. It is possible that the large liver mass 
contributes to T cell exhaustion by acting as a cytokine sink and restricting availability 
of these survival cytokines. 
 
1.4 Liver Regeneration 
The liver is an organ with substantial regenerative capacity. Experiments done in 
rats show that when 2/3 of the organ is surgically resected, the animal can restore its 
liver mass to ±10% of the initial mass within 7-14 days of the partial hepatectomy [56]. 
It should be noted that, in case of murine partial hepatectomy, animal anatomy allows 
removal of individual liver lobes without transecting the liver parenchyma and the 
regeneration involves hyperplasia of the remaining lobes without restoration of lobar 
anatomy. A different experimental model of regeneration utilising tissue-damaging 
carbon tetrachloride (CCl4) yields the same result [57]. Following clinical liver 
resection, liver function normalises by 2-3 weeks and liver mass is restored within 3-6 
months [58].  
 
In contrast to other regenerative organs, where a certain group of replicating 
cells replace lost parenchymal cells, and once fully differentiated, lose regenerative 
potency, the liver regenerates through two different groups of cells: bipotent oval cells 
and adult, yet, proliferating hepatocytes [59]. In partial hepatectomy, it is estimated that 
the remaining hepatocytes divide 2-3 times after the initial insult to reconstitute the pre-
resection mass. In vitro experiments show that adult mouse hepatocytes are able to 
undergo 60-80 rounds of replication to repopulate the organ without loss of the 
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differentiation potential [60]. Ninety-five percent of hepatocytes enter replication as 
early as 30-60 hours post-resection. Regeneration is thought to be initiated by the 
aggregate effects of increased blood flow to the remaining tissue and increased 
metabolite concentration in the incoming portal circulation triggering release of mitotic 
mediators [61]. Vascular Endothelial Growth Factor (VEGF), Endothelial Growth 
Factor (EGF), Transforming Growth Factor α (TGFα), Hepatocyte Growth Factor 
(HGF), Tumor Necrosis Factor α (TNFα) [57], Interleukin (IL)-6 [62], along with other 
mediators, activate NF-κB and STAT-3 transcription factors. Experiments show that 
TNFα receptor 1 chain mutant and IL-6-deficient animals suffer more liver damage and 
have slower, though ultimately complete, liver regeneration following partial 
hepatectomy [62]. The addition of exogenous recombinant IL-6 restored both the liver 
regeneration speed and survival rate to that of genetically unmodified animals [63]. 
Thus pro-inflammatory mediators such as IL-6 and TNFα can also have pro-survival 
effects depending upon the context in which they are expressed. 
 
Oval cells are so named for their nuclear morphology and are located close to 
portal tracts and in the canals of Hering [64]. Oval cells can differentiate to produce 
either hepatocytes or bile duct cells, depending on the conditions [59]. Oval cell 
replication is more prominent in chemical necrosis models than after partial 
hepatectomy [65].  
 
1.5 Ischaemia-reperfusion injury 
Ischaemia Reperfusion Injury (IRI) is one type of sterile injury. IRI consists of a 
first phase, when a tissue is ischemic for a relatively short period of time; and a second 
phase, when the blood supply is restored (reperfusion). Inflammation and further tissue 
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damage follows the restoration of blood circulation [66]. In the liver, IRI can arise 
during abdominal surgery due to traumatic or iatrogenic circulatory insufficiency or 
during liver transplantation when the graft is disconnected from the donor circulation 
and later revascularised in the recipient. IRI can be further divided into warm and cold 
types. In warm IRI, physiological temperature is maintained during the ischaemic 
period, (such as during suturing or prior to organ removal from the body). Cold IRI 
arises during hypothermic storage after the organ has been removed from the donor. 
Prolonged cold ischaemia frequently accompanies deceased donor liver transplantation. 
IRI is functionally important – the severity of perioperative tissue damage is one of the 
most critical determinants of liver transplant outcome [67]. The severity of IRI can be 
influenced by a number of factors, including the duration of ischaemia, organ 
temperature during ischaemia and/or pre-existing conditions affecting the liver. 
A tissue undergoing sterile injury emits cellular debris, macromolecules and 
proteins that, otherwise, would be inaccessible to the immune system. This debris can 
be lipoproteins from cell and organelle membranes, extracellular macromolecules such 
as fibrinogen and hyaluronan; and nuclear molecules such as RNA, DNA and the DNA-
binding protein High Mobility Group Box 1 (HMGB1). These are collectively known as 
Damage Associated Molecular Patterns (DAMPs) by analogy with the pathogen-
associated molecular patterns (PAMPs) which were the first type of ligands for pattern-
recognition receptors (PRRs) to be described. DAMPs bind to receptors such as Toll-
Like Receptors (TLRs) and the Receptor for Advanced Glycation End Products 
(RAGE) on the surface of parenchymal cells in the graft or of immune cells like 
macrophages, Natural Killer (NK) cells and dendritic cells (DC). PRR signalling is 
transduced through adaptor proteins such as myeloid differentiation primary response 
protein 88 (MyD88), and via pathways involving mitogen activated phosphokinase 
(MAPK) p38 and signal transducer and activators of transcription (STAT) 3, leading to 
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nuclear translocation of nuclear factor (NF)-kB and the expression of TNFα, IL-1, IL-2, 
IL-12 and IL-6, chemokines such as MiP-1α, IL-8 and RANTES and adhesion 
molecules such as Intercellular Adhesion Molecule (ICAM)-1, Vascular Cell Adhesion 
Molecule (VCAM)-1 and selectins. Subsequently, platelet and complement activation 
[68], leukocyte recruitment [69] and the release of reactive oxygen species (ROS) [70] 
propagate inflammatory processes and recruit further immune actors. Mechanisms 
contributing to the development of IRI and their individual components are described in 
more detail below. 
 
1.5.1 Damage-associated molecular patterns - High Mobility Group Box 1 
The High Mobility Group (HMG) is a highly conserved group of proteins 
associated with DNA transcription, replication, recombination and repair. These ancient 
proteins may have evolved more than 500 million years ago [71]. HMG proteins can be 
classified into three distinct groups, depending on the characteristic functional domain 
in the structure. HGMA proteins have an AT-hook domain. HGMB proteins have an 
HMG-box domain, whereas HMGN proteins contain a nucleosomal binding domain. 
Four proteins have been reported in the HMGB group so far. HMGB 1 and 2 have two 
homologous folded box DNA-binding domains consisting of approximately 80 amino 
acids each, and a long acidic tail containing 20-30 aspartic or glutamic acid residues, 
linked to the boxes by a basic region of about 20 residues [1] (Figure 1.1).  
 
 Under steady-state conditions, HMGB1 acts as a transcription regulator, loosely 
bound to DNA. However, when released from the cell, either passively or actively, 
HMGB1 acts as a cytokine with a variety of roles during inflammation [72]. Passive 
release results from necrosis, whereas HMGB1 can be actively secreted by cells like 
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Kupffer cells, monocytes and natural killer cells [73]. HMGB1 lacks a signal sequence, 
and similar to IL-1, is externalised via secretory lysosomes which fuse with the cell 
membrane [74]. Since every eukaryotic cell contains HMGB1, significant amounts of 
HMGB1 can be released during tissue ischaemia and other conditions of cellular stress. 
HMGB1 release from ischaemic liver follows a biphasic timecourse. The initial peak of 
HMGB1 in the systemic circulation results from the release of preformed protein from 
the cell, and occurs very rapidly after revascularisation [75, 76], whereas a subsequent 
rise in HMGB1 after several hours or days may result from increased HMGB1 
synthesis.  
 
By itself, HMGB1 acts as a potent inducer of cell proliferation, and as a 
leukocyte chemotactic agent [77, 78]. When injected in to mice, HMGB1 induces 
release of TNFα, IL-1α, β and IL-6 [79]. More recent reports suggest that the 
proinflammatory actions of HMGB1 derive largely from its ability to form complexes 
with other DAMP/PAMPs and thereby amplify signal transduction through a number of 
receptors [80]. Apart from RAGE [81], HMGB1 binds to TLR2 in concert with 
nucleosomes [82], TLR4 in association with LPS [83], TLR9 when complexed with 
single stranded DNA [84] and IL-1R together with IL-1β [85]. In this manner, HMGB1 
acts as a master sensor, integrating various signals of tissue damage and playing an 
important role in initiating and propagating inflammation [83, 85, 86].  
 
Mice subjected to 60 minutes of partial warm liver IRI are protected against 
liver injury by the administration of HMGB1-neutralizing antibodies, and manifest less 
tissue damage and lower expression of IL-6 and TNFα than non-treated animals. 
Conversely, administration of exogenous HMGB1 exacerbated the injury [75].  
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Figure 1.2 shows the domains of HMGB1 and the binding sites for RAGE and 
TLR4 that have been identified. 
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Figure 1.1 Structure of HMGB1 protein [1]. "HMG1 and 2: architectural DNA-
binding proteins." HMGB1 protein consists of A (a) and B (b) domains which 
facilitate high affinity, nonspecific binding to DNA (c). 
Figure 1.2 Schematic diagram showing the HMGB1 A and B box domains and TLR4 
and RAGE binding sites [3]. Note that both TLR4 and RAGE bind within the B-box 
domain, and their binding sites are separated by approximately 50 residues. 
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1.5.2 Pattern-recognition receptors 
Pattern recognition receptors (PRR) form part of an ancient system of innate 
immunity which participates in the detection of and response to infection and other 
forms of tissue damage. Rather than binding one or two specific ligands, the PRRs are 
able to bind whole classes of molecules based on conserved patterns in the molecular 
structure. These molecules can be of exogenous (PAMP) or endogenous (DAMP) 
origin. Different families of pattern recognition receptors include the Toll-Like 
receptors (TLRs) [87], Nucleotide-binding Oligomerisation Domain (NOD)-like 
receptors (NLR) [88], Retinoic acid-Inducible Gene (RIG)-I-like receptors (RLR) [89] 
and C-type Lectin receptors (CLR) [90]. PRRs are most frequently expressed in antigen 
presenting cells, but other cells are also known to carry PRRs [91].  
NLR are cytoplasmic PRR. They can be found mostly within immune cells, but 
also in somatic cells, such as vascular endothelium [92]. The main ligands of Nod1 and 
2 are peptidoglycans of Gram negative bacterial walls, but they also recognize Gram 
positive bacteria of Listeria and Bacillus species [93]. Activation of NLR leads to cross 
interaction with other PRRs, including TLR, due to signalling mechanism overlap and 
results in the release of interferon β [94].  
RLR are intracytoplasmatic PRRs tasked with detecting the cellular replication 
of viral agents. Three RLR have been described: RIG-I, Melanoma Differentiation 
Associated protein 5 (MDA5) and LGP2. The principal ligands of RLRs are double 
stranded RNA species produced during viral replication [95]. RIG-I was reported to be 
sensitive towards Vesicular Stomatitis Virus, Sendai Virus and Japanese Encephalitis 
Virus [96], while MDA5 was able to detect picornaviridae [97]. C-type Lectin 
Receptors are cell-surface PRRs that recognise the carbohydrate components of 
alarmins (glucans, mannoses etc.) [98, 99].  
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PRRs Localization Ligand Origin of the Ligand 
TLR 
TLR1 Plasma membrane Triacyl lipoprotein Bacteria 
TLR2 Plasma membrane Lipoprotein Bacteria, viruses, parasites, self 
TLR3 Endolysosome dsRNA Virus 
TLR4 Plasma membrane LPS Bacteria, viruses, self 
TLR5 Plasma membrane Flagellin Bacteria 
TLR6 Plasma membrane Diacyl lipoprotein Bacteria, viruses 
TLR7 (human TLR8) Endolysosome ssRNA Virus, bacteria, self 
TLR9 Endolysosome CpG-DNA Virus, bacteria, protozoa, self 
TLR10 Endolysosome Unknown Unknown 
TLR11 Plasma membrane Profilin-like molecule Protozoa 
RAGE 
RAGE Plasma membrane HMGB1, 
S100/calgranulin, 
amyloidβ, AGE 
Non-enzymatic  
glycated peptites, self, bacteria 
RLR 
RIG-I Cytoplasm Short dsRNA, 
dsRNA 
RNA viruses, DNA virus 
Melanoma 
Differentiation-
Associated protein 5 
Cytoplasm Long dsRNA RNA viruses (Picornaviridae) 
LGP2 Cytoplasm Unknown RNA viruses 
NLR 
NOD1 Cytoplasm iE-DAP Bacteria 
NOD2 Cytoplasm MDP Bacteria 
CLR 
Dectin-1 Plasma membrane β-Glucan Fungi 
Dectin-2 Plasma membrane β-Glucan Fungi 
Macrophage Inducible 
Ca-dependent Lectin  
Plasma membrane SAP130 Self, fungi 
Table 1.2 PRRs and their ligands. Modified from [90].  
 
1.5.2a Toll-like receptors 
TLRs were initially identified in Drosophila, but have subsequently been 
described in vertebrates including higher primates and humans [100]. Twelve 
mammalian and ten human TLRs have been described so far [91, 101]. Some TLRs, 
such as 1, 2, 4, 5 and 6, are expressed on the cell membrane, while TLRs, such as 3, 7, 9 
and 10 are intracellular. Leucine-rich repeat motifs are found at the N-terminus, while 
the intracellular (or intra-compartment) C-terminal domain of TLRs is similar to that of 
the IL-1 receptors. Due to this similarity, this portion is referred to as the Toll/IL-1R 
domain (TIR) [91]. TLR activation can lead to recruitment of one of several adaptor 
molecules MyD88, TIR-associated protein (TIRAP), TIR-containing adaptor protein-
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inducing interferon β (TRIF) or TIR-containing adaptor protein-inducing interferon β-
related protein (TRAM) [102]. Recruitment of adaptor molecules can result in the 
nuclear translocation of transcription factors NF-κB, and Interferon Regulatory Factor 
and in the activation of Mitogen Activated Protein kinases. This signalling pathway 
leads to the expression and release of proinflammatory cytokines IL-1β, TNFα and IL-
6; and of the inflammation moderating cytokine IL-10. Depending upon the cell type in 
which the TLR is expressed, TLR engagement may alter the pattern of chemokine 
receptor expression, influencing cell trafficking, or may induce the expression of stress 
ligands which render target cells susceptible to killing by NK cells or CD8+T cells 
[103]. Of the 4 TLRs that can recognize self (TLR2, 4, 7 and 9), only two are located on 
the cell surface- TLR2 and 4. These two receptors can play important roles in signalling 
tissue injury in the case of IRI. Desensitisation of TLR signalling pathways may occur 
in the setting of prolonged or repeated exposure to low concentrations of ligands, and 
this phenomenon may contribute to the effectiveness of various preconditioning 
strategies (see section 1.10.1 below) [104]. As well as hyporesponsiveness to repeated 
stimulation through the same ligand-receptor axis, a phenomenon of cross-tolerance has 
been described whereby exposure of cells to the TLR4 ligand LPS renders them 
refractory to subsequent stimulation through TLR2 [105].  
 
1.5.2b RAGE 
RAGE is a member of the immunoglobulin superfamily which binds multiple 
ligand families including advanced glycation end-products, amyloid β-peptide and β-
sheet fibrils, CD11b/CD18 (Mac-1), S100/calgranulins and HMGB1 [106]. The 
extracellular components of RAGE comprise an Ig variable domain (the principal site of 
ligand binding), VC1 and C2 domains, a transmembrane region and a short intracellular 
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tail. Cell types expressing RAGE include vascular endothelium, smooth, cardiac and 
skeletal muscle, neurons and glial cells, mesangial cells, podocytes and proximal 
tubular cells, DC, monocytes/macrophages and T cells, and many cancers. Within the 
liver, RAGE can be found on parenchymal and non-parenchymal cells including 
hepatocytes [107, 108], hepatic stellate cells [109-111], Kupffer Cells of normal and 
diabetic mice [108] and on various other leukocyte subsets.  
RAGE forms oligomers at the cell membrane, and dimerisation of RAGE via 
interaction of the V regions is essential for signal transduction through the cytoplasmic 
tail. Both RAGE and TLRs make use of the adaptor protein MyD88 in addition to 
alternate signalling pathways. MyD88 recruitment results in interaction with IL-1 
receptor associated kinase (IRAK) which eventually  phosphorylates and proteolyses 
the inhibitor of B (IB), permitting NF-B heterodimer activation and translocation to 
the nucleus with subsequent transcription of  cytokines, chemokines, acute phase 
proteins and other inflammatory mediators (Reviewed in [112]). In addition to their 
actions promoting inflammation and co-ordinating innate and adaptive immune 
responses, NF-B-regulated genes take part in the maintenance of general cell 
homeostasis, promotion of cell survival and inhibition of apoptosis [113]. Depending 
upon the context, RAGE signalling can give rise to apoptosis, but also cellular motility 
and migration, proliferation and antigen-specific T cell activation [114-116]. 
 
1.5.2c RAGE isoforms and the regulation of RAGE and TLR signalling 
RAGE exists in various isoforms [117, 118]. Soluble RAGE can be generated as 
a splice variant retaining the N-terminal ligand-binding region (endogenous secretory or 
esRAGE), or via cleavage of cell-surface RAGE by enzymes such as ADAM10 [119, 
120]. Whereas transcripts for the alternatively spliced esRAGE can be isolated from 
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both mice and humans, esRAGE is not detectable in mouse serum [119]. Although 
soluble RAGE with ligand-binding activity is present in mouse serum, this is the 
product of enzymatic cleavage rather than of secretion from cells. Soluble RAGE 
regulates signalling through the full-length receptor via two different mechanisms. 
esRAGE is a naturally-occurring decoy receptor which can bind to HMGB1, S100B, 
AGEs and other RAGE ligands. In healthy human subjects, plasma levels of HMGB1 
are inversely related to those of esRAGE, suggesting that esRAGE mediates the 
clearance of HMGB1 from the circulation. Soluble RAGE V domain binds to the V 
domain of transmembrane RAGE, preventing dimerisation and thus blocking signal 
transduction [121] (Figure 1.3). 
 
1.5.3 Pattern recognition receptors and liver IRI 
Amongst the various pattern recognition receptors, TLR4 and RAGE have been 
the most extensively studied in the setting of liver ischaemia-reperfusion injury, and 
both have been implicated in IRI pathogenesis. Conversely, TLR2-deficient mice did 
not manifest protection against liver IRI compared with wild-type control animals 
[122], suggesting a lesser role for this receptor. 
 
1.5.3a TLR4 in liver IRI and transplantation 
TLR4 is present on immune cells within the liver, and is also constitutively 
expressed on hepatocytes [123]. Partly due to its abundance on the surface of 
parenchymal cells and liver resident macrophages, TLR4 plays an important role in 
liver IRI. Animal studies involving partial warm IRI in TLR4-deficient mice  
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Figure 1.3 Transmembrane RAGE forms homodimers at the cell surface (A) 
and homodimerization is essential for signal transduction.  
By forming a heterodimer with TM RAGE through interaction of the V 
domains, soluble RAGE inhibits RAGE homodimer formation, and thus 
inhibits signal transduction.   
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demonstrate that without TLR4 signalling, the extent of liver damage is significantly 
less than that in wild type controls [122, 124]. Attenuation of liver injury was associated 
with decreased neutrophil sequestration and CD4+ T cell infiltration, and with reduced 
levels of IL-1β, TNFα and IFNγ [124]. Engagement of TLR4 by HMGB1 is critical to 
the pathogenesis of liver IRI [125]. 
TLR pathway signalling is important in allograft rejection for a number of 
reasons. TLRs act as the primary sensors of alarmins released during and after the 
transplantation procedure, activating dendritic cells and thus potentiating the initial 
adaptive immune response. Apart from participating in the priming of the immune 
response, TLRs have been reported to cooperate in mounting the effector alloresponse 
which culminates in graft destruction. TLR4 activation leads to the maturation of 
dendritic cells and migration of the latter to the draining lymph nodes which are the 
primary site of alloactivation of recipient T cells. Animal experiments show that when 
MyD88 is deficient, skin allografts in a minor histocompatibility mismatch model (male 
to female C57BL/6) are accepted long-term [126]. The inability to reject skin grafts was 
associated with reduced dendritic cell migration to draining lymph nodes. 
 
1.5.3b RAGE in liver IRI, regeneration and transplantation 
RAGE expression increases in liver non-parenchymal cells during ischaemia-
reperfusion injury [127]. Survival of mice subjected to total warm liver ischaemia-
reperfusion injury was improved from 30% to 80% when RAGE signalling was blocked 
by the administration of recombinant soluble RAGE. Promotion of survival was 
attributed to reduced hepatocyte apoptosis and a concomitant increase in liver 
regeneration. In a seeming paradox, nuclear translocation of NF-B was increased by 
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RAGE blockade. Transcription of IL-6 was reduced in mice receiving soluble RAGE 
whilst the kinetics of TNFα upregulation were delayed by RAGE blockade [127].  
Massive liver resection is another setting where interruption of RAGE signalling 
confers a survival advantage [128, 129]. Genetic deficiency of RAGE, or administration 
of either soluble RAGE or anti-RAGE antibodies were all effective in reducing 
mortality. The complex interaction of overlapping signalling pathways is evident in this 
model – whereas prevention of RAGE ligation was protective, this effect was abrogated 
in the absence of MyD88 [129]. Absence of RAGE signalling was linked with pro-
survival effects via increased NF-B activation, and increased expression of both TNF 
and IL-6 [128, 129]. In contrast to effects on hepatocyte proliferation, RAGE KO mice 
showed reduced oval cell activation in response to HMGB1, while administration of 
HMGB1 to RAGE-competent mice activated oval cells [130].  
RAGE expression is induced in both CD4+ and CD8+ T cells upon TCR 
engagement and persists in both activated and memory T cells [131, 132]. RAGE 
deficiency impairs T cell proliferation and cytokine production to both model antigens 
and alloantigens, and RAGE deficiency or blockade with soluble RAGE or other RAGE 
antagonists, prolongs the survival of islet or cardiac grafts [133]. RAGE-expressing T 
cells are stimulated by HMGB1 released by dendritic cells [134], and it is conceivable 
that T cell priming and especially the activation of allospecific memory cells may be 
enhanced by the presence of HMGB1 in the intercellular milieu, as occurs following 
revascularisation of solid organ transplants. 
 
1.5.4 Cytokines in IRI 
TNFα is a pleiotropic cytokine expressed by a range of cell types, including 
activated macrophages, Kupffer cells, CD4+ T cells, NK cells, neutrophils, mast cells, 
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eosinophils and hepatocytes [135, 136]. TNFα promotes apoptosis and inflammation, 
and is central to initiating and maintaining liver IRI. Treatment with neutralising anti-
TNFα antibodies significantly reduces the severity of liver IRI [137] as does siRNA 
knockdown of TNF receptor expression [138]. TNFα is one of the first cytokines to be 
released from Kupffer cells, macrophages, neutrophils and dendritic cells after exposure 
to reactive oxygen species, reaching high levels in serum within 1-2 hours after an 
ischemic insult, in what is termed early phase release [139]. The second  phase of TNFα 
expression occurs within 1-2 day post ischaemia [70]. TNFα expression is multifaceted; 
it promotes inflammation by upregulating IL-1β, IL-6, IFNγ, ICAM-1 and VCAM-1, 
but also leads to the expression and release of IL-10 and other anti-inflammatory 
mediators. Moreover, in addition to their pro-inflammatory and pro-apoptotic actions, 
both IL-6 and TNFα can mediate survival effects, depending upon the setting in which 
they are expressed.  
IL-1β is another proinflammatory cytokine released following PRR engagement. 
IL-1β upregulates the expression of adhesion molecules, other proinflammatory 
cytokines and chemokines [86]. IL-1β is cleaved to its active form within the 
inflammasome. This is a multiprotein complex comprising Nucleotide-binding 
oligomerisation domain-like receptor (NLR) and procaspase 1 [86].  
IL-5 is mainly secreted by activated T cells to promote B cell [140] and 
eosinophil differentiation [141]. IL-5 also acts as an IgA enhancing factor [142]. IL-5 
receptor binding leads to activation of Janus kinase (JAK) 2 and Signal transducer and 
activator of transcription (STAT) 5 signalling pathways. IL-5 is important in both 
adaptive and innate immune responses.  
Similar to TNFα, expression of IL-6 is moderated through the activity of NF-B 
in macrophages, lymphocytes and dendritic cells (DC), as well as in a number of 
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parenchymal cell types including renal tubular epithelium and hepatocytes [143-145]. 
The liver is a major site of IL-6 production and IL-6 has an important role in liver 
injury. In a seeming paradox, whilst IL-6 is pro-inflammatory, and antagonises the 
development of regulatory T cells [146] it can also exert hepatoprotective effects in the 
context of acute liver injury. IL-6 gene KO mice undergoing warm liver IRI manifest 
more severe liver injury [147]. Moreover, recombinant IL-6 was hepatoprotective when 
given before IRI [148, 149]. Both groups found decreased TNFα expression and 
upregulation of PPARγ, which these authors suggested to be the mechanism of 
hepatoprotection.  
IL-10 is an anti-inflammatory cytokine produced in lymphocytes, Kupffer cells, 
macrophages, neutrophils and dendritic cells and its expression is transcriptionally-
regulated by NF-B [150]. Previously known as Cytokine synthesis inhibitory factor, 
the major function of IL-10 is to moderate inflammation though a suppressive action 
upon the expression of Th1 cytokines [151]. IL-10 signals through the JAK/STAT3 
pathway and inhibits interferon-induced gene transcription [152], such as the 
upregulation of donor MHC molecules which can potentiate rejection. In the context of 
transplantation, administration of exogenous IL-10 prolonged survival in a mouse 
model of cardiac transplantation [153] as well as murine liver transplantation [154, 
155].  
 
1.5.5 Chemokines and their role in IRI 
Chemokines are small cytokine-like proteins secreted from cells that influence 
the motility of other, responsive cells. Chemokine is a contraction of the term 
“chemotactic cytokine”. Chemokines influence cell migration, regulate T cell 
development, and mediate tumor metastasis. Chemokines are 8-10 kD in size and 
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incorporate 4 cysteine motifs within their sequence. Chemokines can be grouped and 
classified according to the arrangement of the first two cysteines [156]. The CC and 
CXC chemokines comprise the largest groups, but CX3C and XC groups also exist. 
Thus far, there are approximately 50 known chemokines and 19 G protein-coupled 
chemokine receptors.  
CC chemokines are known to influence mononuclear cell migration. One of the 
best characterised CC chemokines is Monocyte Chemoattractant Protein (MCP) 1, also 
known as CCL2 (C-C chemokine ligand 2), which influences the movement of 
monocytes, dendritic cells, granulocytes and memory T cells. Other chemokines of this 
group include Macrophage inflammatory Protein (MiP) 1α (CCL3), MiP1β (CCL4) and 
RANTES (CCL5). MCP-1 attracts mononuclear cells, memory T cells and granulocytes 
[157] to the area of inflammation. Production of MCP-1 is initiated soon after an insult 
in response to ligation of PRRs and release of the first wave of cytokines, such as IL-1 
[157].  
CXC chemokines are named for the arrangement where the first two cysteines 
flank another amino acid.  Some CXC chemokines attract polymorphonuclear cells, and 
activate monocytes [eg IL-8 (CXCL8) and its murine orthologue KC [158]. IL-8 and 
KC promote inflammation in ischaemia-reperfusion injury primarily through the 
recruitment of neutrophils. 
 
1.5.6 The complement system in IRI 
The complement system is an integral participant in innate immunity, and 
synthesis of complement component C3 is upregulated following engagement of TLR4, 
including that occurring following ischaemia and reperfusion. Activation of the 
complement cascade leads ultimately to the assembly and deposition of the membrane 
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attack complex (MAC) on the target cell surface. Formation of the MAC results in the 
loss of cell membrane integrity and cell death ensues. The complement split products 
C3a and C5a, also termed “anaphylotoxins”, are neutrophil chemoattractants.  
C3b deposited on the surface of target cells can activate macrophages, via 
engagement of complement receptors [159]. Thus far, three macrophage complement 
receptor super families have been described [159]. The short consensus repeat (SCR) 
modules that code for CR1 and CR2, the β2 integrin family members CR3 and CR4, and 
the immunoglobulin Ig-superfamily member CRIg [160, 161]. Complement activation 
plays an important role in liver IRI. Animal experiments show that C3-deficient or 
complement-depleted animals manifest milder tissue injury following IRI than that seen 
in animals where the complement cascade is intact. For example, when soluble 
complement receptor type 1 treated rats were subjected to 45 minutes of partial warm 
liver ischaemia and 24 hour reperfusion, they exhibited significantly lower ALT and 
improved liver blood flow. Reduction of macrophage activation, oxidative stress and 
neutrophil accumulation were suggested to be the protective mechanisms [162-164].  
The actions of the membrane attack complex, and activated components C5a 
and C6a have been implicated in amplification of tissue damage during IRI. Genetic 
deficiency of C6 protein has a protective effect in murine models of liver IRI, as does 
C5a receptor antagonism [165-167].  
As with other components of the innate immune system, complement activation 
may enhance survival following liver injury. In liver transplantation, activation of C3 
and C5 complement proteins has been reported to be important in initiating liver 
regeneration [168], whereas in a murine C3 gene KO model of partial (70%) 
hepatectomy, restitution of C3a and C5a complement proteins after partial hepatectomy 
led to significant increase in animal survival and increased cell proliferation, compared 
to the non-restituted cohort [168]. Complement restitution was associated with NF-κB-
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dependent increased IL-6 and TNFα expression and release.  
A recent study examined the role that the MAC plays in IRI, against the 
regenerative effects of other complement components. Marshall et al. used a selective 
MAC antagonist CR2-CD59. This compound attaches to C8/C9 and prevents MAC 
assembly [169]. In both total hepatic IRI and partial hepatectomy models, the group 
treated with CR2-CD59 showed intact regeneration and improved histology compared 
with the control group. When compared to C3 and C5 inhibitor treated animals, the 
animals with selective MAC inhibition showed significantly increased cell proliferation 
following IRI. Similar to the findings with C3a and C5a restitution, the protective effect 
was associated with activation of STAT3 and Akt signalling, and with increased hepatic 
TNFα and IL-6. 
 
1.5.7 Cellular actors in IRI 
1.5.7a Neutrophils 
Neutrophils are rare in a normal liver. However, they are amongst the first cells 
to infiltrate the liver following IRI, and contribute significantly to IRI pathogenesis. 
Systemic neutrophil depletion reduces the severity of liver IRI [170]. The expression of 
neutrophil chemokines such as IL-8 (and its murine counterpart KC) is upregulated 
soon after reperfusion [171]. TLR signalling results either directly or via the action of 
cytokines and/or complement in augmented expression of neutrophil binding 
intercellular adhesion molecules (ICAM) and vascular cell adhesion molecules 
(VCAM) on the activated vascular and sinusoidal endothelium, facilitating neutrophil 
infiltration into the liver. CD11/CD18 (also known as Mac-1 integrin) is a neutrophil 
receptor which plays an important role in liver IRI [172]. In addition to its effects in 
promoting neutrophil accumulation within the liver, engagement of CD11b/CD18 
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increases the spontaneous production of reactive oxygen species such as superoxide, 
which contribute to tissue damage [173].  
 
1.5.7b Macrophages 
Macrophages are descendants of the granulocyte-myeloid cell lineage. After 
leaving the bone marrow, macrophages infiltrate various organs as monocytes and form 
long-term tissue-specific resident macrophage populations. These macrophages can be 
found in the lungs, central nervous system, peritoneal cavity, bone, adipose tissue, skin 
and the liver. Macrophages fulfil multiple functions within the immune system. They 
act as routine phagocytotic scavengers, involved in tissue house-keeping and apoptotic 
cell clearing. Macrophages mediate a rapid response to bacterial pathogens and necrotic 
debris, present antigens to lymphocytes as part of a wider network of antigen presenting 
cells and produce various cytokines and chemokines that amplify signals and regulate 
immune reactions.   
In its routine scavenging and house-keeping role the macrophage internalises 
particulate material bound to its cell-surface complement, scavenger or integrin 
receptors. This binding does not significantly alter macrophage function or phenotype. 
Conversely, ligand binding to TLRs, IL-1R or other PRR initiates a number of 
phenotypic and physiological changes. Through the MyD88-dependant signalling 
pathway, ligand binding leads to increased expression of various pro-inflammatory 
cytokines and chemokines, such as IL-6, IL-1 and IL-23 [174],  alterations in the cell 
surface expression of chemokine receptors and increased levels of adhesive and 
cytoskeletal molecules promoting phagocytosis. Phagocytosed antigens are 
subsequently processed and presented to helper T (Th) cells bound to MHC class II. T 
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cell activation results in the elaboration of cytokines such as IFN- or IL-4, which 
further modulate macrophage activation and function. Thus macrophage activity links 
the innate and acquired immune systems. 
Current consensus holds that there can be at least two broadly different types of 
macrophage activation which result in at least three different basic macrophage 
populations in terms of functions [175, 176]. Classical activation, as described by 
Mackaness, is dependent on IFNγ [177, 178] and TNFα [179] produced by NK and Th1 
cells. Chronic production of TNFα and INFγ is important in promoting, not only 
inflammation, but also insulin resistance in the liver (reviewed in [180]).   
In the alternative pathway,  macrophage activation by IL-4 and/or IL-13 results 
in a marked increase in the expression of mannose binding receptors and MHC II, and 
decreased production of pro-inflammatory cytokines [176, 181]. This macrophage 
population shows increased activity of the enzyme L-arginase 1 which promotes the 
production of extracellular matrix through conversion of arginine into ornithine [182]. 
Consequently, alternatively activated macrophages participate in wound healing and 
tissue remodelling but also in the fibrotic response to tissue injury.  
A third macrophage subpopulation are the so-called regulatory macrophages. 
Regulatory macrophages are said to be activated after exposure to a TLR stimulating 
and immune complex-rich environment [183]. Regulatory macrophages produce 
minimal levels of arginase [184], express high levels of immune suppressive IL-10, 
while expressing minimal IL-12 [175]. It is thought that regulatory macrophages play a 
role in limiting immune responses and safeguarding the organism from excessive 
inflammation.  
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Macrophages which have infiltrated post-ischaemic tissues secrete soluble 
mediators of inflammation, including TNF, IL-1, IL-6 and NO. Liver-resident 
macrophages isolated and cultured from rats which had been subjected to ischaemia and 
reperfusion elaborated increased quantities of these mediators compared with cells 
isolated from sham-operated animals [185]. They may present antigens derived from 
damaged tissues to T lymphocytes, thus triggering adaptive immune responses. 
Conversely, macrophages may limit the extent of injury via their production of the 
protective enzyme Heme oxygenase 1 (HO-1). Devey et al. reported that selective 
targeted deletion of HO-1 from the resident macrophages of livers undergoing partial 
warm IRI, or macrophage depletion using clodronate liposomes, resulted in increased 
susceptibility of the tissue to damage [186].  
 
1.5.7c Adaptive immune cells in IRI 
Both T cells and B cells participate actively in the pathogenesis of IRI. Suzuki et 
al first suggested a role for T cells in IRI when they showed that the severity of 
histological damage following warm liver IRI was reduced when mice were treated with 
tacrolimus or cyclosporine, systemic immunosuppresants targeting T cell activation 
[187]. Subsequently, Zwacka et al. reported that T cell-deficient nude mice were 
protected against warm liver IRI through inhibited neutrophil infiltration and that the 
reconstitution of the CD4+ T cell population by adoptive transfer restored the IRI 
phenotype. Restoration of CD8+ cells did not restore IRI effect [188]. Similar results 
were obtained in kidney [189], brain [190], myocardial [191] and intestinal [192] IRI 
models.  
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The mechanism whereby CD4+ T cells contribute to postischaemic liver injury 
in mice was suggested to involve CD4+ T cell interaction with both the sinusoidal 
endothelium and platelets. Khandoga et al. reported that the about 30% of all CD4+ T 
cells which had accumulated following ischaemia were colocalized with platelets within 
the hepatic microcirculation. Platelet inactivation by IIb/IIIa glycoproteins prevented 
sinusoidal perfusion failure and reduced ALT release [193]. Complement-fixing natural 
IgM species secreted by B cells may also contribute to microcirculatory and other 
damage during ischaemia-reperfusion injury [194, 195].   
 
1.6 Steatosis and Non-alcoholic fatty liver disease 
1.6.1 Overview of Non-alcoholic fatty liver disease 
Steatosis is a group of macroscopic and microscopic changes associated with 
lipid overaccumulation in the liver parenchyma. Steatosis and the inflammatory changes 
associated with it, in the absence of other morbidities, cause a spectrum of pathology 
that is collectively referred to as Non-Alcoholic Fatty Liver Disease (NAFLD). The 
benign end of this spectrum is known as the non-alcoholic fatty liver (NAFL) stage and 
is characterised by simple overaccumulation of lipid droplets in hepatocytes without 
significant histological damage. The lipid droplets consist of triglycerides [196], 
phospholipids and water insoluble long-chain fatty acids. Upon standard histological 
examination, droplets are seen as empty vacuoles of various sizes. The droplets increase 
in size as lipid accumulation progresses, and hepatocellular ballooning takes place. 
Macroscopic changes in NAFL involve increased overall liver size and the parenchyma 
acquires a pale appearance. At this stage the patients are mainly asymptomatic, apart 
from the possible feeling of fullness due to hepatomegaly [197]. Biochemically, 
elevated transaminase levels are the most frequent initial abnormality, but absence of 
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these does not rule out NAFL- Browning et al. showed that 79% of steatotic patients 
had normal alanine aminotransferase levels [198].  
The second significant pathological component in NAFLD is inflammation 
developing upon the steatotic background. This stage of non-alcoholic steatohepatitis 
(NASH) is marked by leukocyte infiltration, cell death and regeneration which may 
trigger fibrosis and cirrhosis. Cell damage and death lead to hepatitis, general malaise 
and upper right abdominal quadrant tenderness [199, 200]. NASH represents a more 
pernicious end of the NAFLD spectrum as it can lead to liver cirrhosis and 
insufficiency- a growing indication for liver transplantation in the USA and other 
countries with developed healthcare [196].  
Precise grading and diagnosis of NAFLD requires accurate assessment of the 
steatotic grade and extent of inflammatory change by histological examination of liver 
biopsies. Mild steatosis is diagnosed when <33% of the cells in the viewing field are 
affected by visible lipid droplets. Severe steatosis is diagnosed if >66% of the viewing 
field is affected and if 33-66% of the viewing field is affected by lipid deposition, it is 
referred to as moderate steatosis [201]. Steatotic grade, level of inflammation and 
parameters of hepatocyte degeneration are used in scoring liver damage to yield the 
NAFLD activity score (NAS) [201]. Specialized lipid stains such as Oil Red-O (ORO) 
and Sudan dyes can also be used to assess lipid content.  
Using Magnetic resonance spectroscopy as a non-invasive means of measuring 
hepatic triglyceride content, the prevalence of NAFLD has been estimated to be as high 
as 24%, 45% and 33% in African Americans, Hispanic Americans and European 
Americans respectively [198]. Using the same method, 28.6% of Hong Kong Chinese 
adults have been shown to have hepatic steatosis [202], whereas in the Scandinavian 
region, steatosis was estimated to affect 24% of the population based on examination of 
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tissue biopsies from otherwise unselected individuals killed in traffic accidents [203]. A 
review of studies in the Asia-Pacific region determined the prevalence of NAFLD to be 
between 16 and 30% (reviewed in [204]). Therefore, it can be said that NAFLD is the 
most prevalent chronic liver condition in countries with developed healthcare [196, 197, 
205]. Matteoni et al. estimated that over a 10 year period, 30% of NAFL patients 
progress to NASH, of which 20% develop cirrhosis and one third of that group die, 
either from liver failure or from supervening hepatocellular carcinoma [206].  
 
1.6.2 Aetiology of hepatic steatosis  
In a non alcohol-abusing population (those who deny using >20g alcohol per 
day) steatotic liver is more likely to be diagnosed in a patient who is overweight or 
obese [207-209] and who is insulin resistant [210-213]. The prevalence of NAFLD can 
be up to 45.9% [214] - 57.5% [215] in obese individuals.  
Hepatic lipid overaccumulation can be caused by increased dietary intake, 
genetic disorders affecting the lipogenesis/lipoxidation process or drug side effects. 
Diet-derived lipid deposition begins early in obesity. Under conditions of balanced 
caloric intake, the dietary lipids arriving from the gut as chylomicra are taken up by 
hepatocytes, and after incorporation into very low density lipoproteins (VLDL), are 
transported out to cells for storage and energy. Increased food intake distorts the 
physiological balance, initiating steatosis. Hyperinsulinemia and hyperglycemia 
upregulate transcription factors involved in lipid metabolism, including sterol regulatory 
element binding protein 1c (SREBP1c) which activates enzymes that promote 
lipogenesis [216]. Apart from lipogenesis, SREBP1c also activates other enzymes that 
inhibit lipid β oxidation of free fatty acids, thus increasing lipid levels through at least 
two different mechanisms [217]. The carbohydrate regulatory element binding protein 
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(ChREBP) is a transcription factor that promotes glycolysis/lipogenesis as well as 
inhibiting lipolysis [218].  ChREBP is required for induction of L pyruvate kinase, 
acetyl CoA carboxylase and fatty acid synthase [219]. Peroxisome proliferator-activated 
receptor γ (PPARγ) mediated lipogenesis is a third and an independent pathway 
contributing to hepatic lipid accumulation. PPARγ is a member of the intranuclear 
hormone receptor group, and its main function is to moderate adipose tissue 
differentiation, lipid storage and glucose metabolism. PPARγ gene knockout mice did 
not develop steatosis when fed a high fat diet, and PPARγ overexpression resulted in 
activation of monoacylglycerol O-acyltransferase 1, an enzyme which catalyses the first 
FFA to glycerol linkage in triglyceride synthesis  [220]. NAFL and NASH patients were 
found to have highly active PPARγ expression profiles [221]. Another family of 
intracellular transcription factors that play an important role in the pathogenesis of 
NAFLD is PPARα. These receptors are active in liver, muscles and kidney. Activation 
of PPARα initiates gene expression involved in fatty acid uptake, β-oxidation, transport 
into peroxisomes, and ω-oxidation of unsaturated fatty acids. Studies suggest that 
PPARα might increase fatty acid catabolism and that, in the pathophysiologic context of 
the metabolic syndrome or high-fat diet, PPARα-induced fatty acid catabolism might 
prevent hepatic fat deposition [222]. PPARα gene knock-out mice suffer hepatic 
steatosis, and disrupted adipose tissue differentiation due to faulty lipid β-oxidation 
[223]. Conversely, HFD administration in an experimental rat model decreased PPARα 
activity [224]. Overall, under conditions of energy excess and hyperinsulinaemia, 
steatogenesis is amplified by the convergent actions of SREPB1c, ChREPB and PPARγ 
in the absence of counter-regulation through PPARα. During normal metabolism, de 
novo lipogenesis constitutes small percentage of hepatic triglyceride content [225], but 
under condition of excess energy intake and hyperinsulinaemia, this percentage 
increases thanks to the convergent action of SREBP1c, ChREBP and PPARγ.  
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1.6.3 Steatosis and liver inflammation 
The “two hit” theory, proposed by Day et al. suggests that NAFL by itself does 
not trigger liver inflammation, and is largely a benign state. A second insult, one that 
wouldn’t have caused hepatitis on its own, is needed to trigger NASH. Drugs such as 
amiodarone and valproate, toxic agents such as alcohol, environmental circumstances 
such as dietary variation, individual genetic predispositions and enzymatic alterations 
are said to constitute that second insult [226]. Even though only a small percentage of 
NAFL progresses to NASH, fatty livers manifest increased susceptibility to a variety of 
insults [197, 205]. This susceptibility is said to be due to increased oxidative stress 
deriving from lipid oxidation and peroxidation, organelle dysfunction caused by lipids, 
activation of innate immunity and the interaction between the gut microbiome and the 
liver.  
 
 1.6.3a Oxidative stress in hepatic steatosis 
Normal lipid oxidation releases small amounts of ROS. Increased hepatocyte 
lipid levels in NAFLD, however, saturate the cell’s antioxidant mechanisms. 
Additionally, with the cell’s main lipid oxidation pathways operating at maximum 
capacity, supplementary, and often inefficient, oxidation pathways (peroxidation) in 
peroxisomes and endosomes are activated. These pathways produce a higher proportion 
of ROS [227] causing more damage. ROS target macromolecules and proteins. Among 
the first ROS targets are polyunsaturated fatty acids (PUFA). PUFA are important 
mitochondrial membrane lipids involved in the mitochondrial respiratory chain. 
Diminished oxidation through disruption to the respiratory chain could further derange 
    
 
35 
 
the cellular oxidative balance. PUFA peroxidation leads to the formation of aldehyde 
by-products malondialdehyde (MDA) and hydroxynonenal [228]. These compounds 
activate hepatic stellate cells- the cells that initiate hepatic fibrosis [229, 230] and 
induce neutrophil chemotaxis [231].  
 
1.6.3b Innate immunity and NAFLD 
Innate immunity plays an important role in the development of hepatitis within 
steatotic livers [122, 232]. TLR4 gene knockout mice did not develop NASH when kept 
on a methionine and choline deficient diet [233] and suppression of TLR4 signalling 
protected the liver from NASH [234]. Conversely, activation of TLR4 signalling 
resulted in deterioration of NASH symptoms [235]. Through the action of IL-6, TLR 
signalling can lead to the conversion of FoxP3 T regulatory cells into IL-17 producing 
Th17 cells, which may also contribute to the pathogenesis of inflammation in NASH. 
Animal experiments in high fat diet fed models of mouse obesity using neutralising 
anti-IL-17 antibodies have shown that blockade of IL-17 activity results in lower serum 
ALT, IL-6 and TNFα levels, reduced macrophage infiltration in livers and lower 
expression of IL-6 and TNFα mRNA [236]. Complement activation in NAFLD also 
contributes to the development of liver inflammation through the promotion of  
neutrophil infiltration into the liver by C3a and C5a [237].  
In the HFD-fed mouse model of obesity, HFD-fed animals have been shown to 
have significantly upregulated HMGB1 gene expression in the liver, and activation of 
the HMGB1/TNFα/NF-κB signalling pathway is associated with NAFLD progression 
[238]. In chronic liver injury, expression of RAGE within the liver is significantly 
increased [109, 239], and advanced glycation end-products also augment progression of 
NAFLD. Mice which received a methionine and choline-deficient (MCD) diet which 
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had been baked to increase the AGE content, manifested evidence of increased 
oxidative stress in the liver which was accompanied by increased expression of RAGE, 
IL-6, MCP-1 and TNF-along with increased collagen deposition and fibrosis [240]. 
When isolated hepatic stellate cells from mice receiving either the MCD or an amino-
acid replete diet were exposed to AGE in vitro, similar changes in gene expression were 
observed in cells from the MCD group, accompanied by increased proliferation, 
production of ROS, and alpha-smooth muscle actin, a hallmark of myofibroblast 
transformation [240]. Increased expression of RAGE, TLR4 and their ligands in 
steatotic livers may contribute to the increased severity of IRI and worse outcomes 
following transplantation of these organs.  
1.6.3c Intestinal microflora and NAFLD  
The human gut hosts 500-1000 different types of bacteria, comprising about 
90% of all the eukaryotic cells in the human body [241]. These bacteria help human 
hosts to digest food, protect against pathogen invaders, synthesise vitamins and 
moderate the immune system [242], amongst other functions. This microflora, or 
microbiome, also plays an important role in NAFLD.  
One of the changes that is associated with NAFLD is small intestinal bacterial 
overgrowth (SIBO) [243]. In a healthy human gut, the bacteria are predominantly 
concentrated in the large intestine and the small intestine hosts only <104 colony 
forming units (CFU)/ml. More than 105 CFU/ml is considered abnormal and is termed 
SIBO. Biopsy proven NAFLD patients exhibit increased rates of SIBO [244] and the 
severity of the SIBO is positively associated with the severity of the NASH [245].  
Disbiosys, or qualitative change in the microbiome is also associated with 
NAFLD. The normal human microbiome is acquired from the birth canal and during the 
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first breastfeeding and remains more or less the same throughout the person’s life. But 
external factors like diet, disease, drugs and bariatric surgery [246] can change the 
microbiome. In the case of NAFLD associated with obesity, the energy-rich western 
diet has been shown to change the human microbiome, as well as that of experimental 
animals. Obese individuals have increased Firmicutes spp., and Acinetobacter spp. and 
decreased Bacterioidetes spp. compared with lean individuals [247]. In laboratory 
animals which have been inoculated with human gut flora, the introduction of a high fat 
and high sugar diet changed the microbiome. Moreover, transfer of an “obese” 
microbiome to lean animals led to rapid weight gain and increase in adipose tissue 
[248]. Increased numbers of certain types of bacteria decrease hydrogen and increase 
methane concentration, aiding fermentation [247]. Fermentation of otherwise 
indigestible carbohydrates result in a higher concentration of short chain fatty acids, like 
butyrates that slow down intestinal peristalsis [249], further increasing energy uptake.  
The presence of short chain fatty acids triggers an inflammatory reaction that increases 
gut vascularity  (measured by capillary density) compared to germ free animals [250].  
Liver inflammation induced by the altered microbiome is thought to result from 
loss of intestinal mucosal integrity with subsequent entry of bacterial components into 
the systemic circulation. The intestinal lumen is host to as many bacteria as 1014-1015 
CFU/ml  [251]. A dynamic equilibrium between the gut wall and the microbiome in the 
lumen is established to contain toxic bacterial products. Any disturbance to this balance 
can lead to loss of protection. [252-255]. In NAFLD patients, intestinal permeability 
was abnormally increased [245] and the increase in permeability and presence of small 
intestinal bacterial overgrowth were correlated with the severity of NALFD. In animal 
studies normal subjects under physiological conditions have fluctuating amounts of 
bacterial components such as lipopolysaccharides (LPS) present in the serum at 
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different times in the diurnal cycle, with the peak occurring at the end of the dark period 
[256]. However, when animals received a high-fat diet, serum LPS remained elevated 
throughout the cycle. In NAFLD patients, serum LPS levels were significantly higher 
than those in the lean control group, with levels increased further in those patients in 
whom NASH had developed [257]. Engagement of TLR4 by LPS can trigger 
inflammatory signalling pathways [87].   
 
1.6.4 Mouse models of non-alcoholic fatty liver disease 
Approaches to modelling obesity in animals utilize genetic modification, altered 
nutrition, or various combinations of the two. Genetic modifications of processes 
regulating energy metabolism or feeding behaviour are widely used.  
Genetic models 
Ob/ob mice 
In the Ob/ob obesity model, a mutation in the mouse leptin gene renders this 
satiety signal inactive. As a consequence these mice exhibit excessive feeding 
behaviour and develop extreme obesity within a relatively short period of time on 
normal chow. Pathophysiologically, this model shows hyperinsulinemia, hyperglycemia 
and hepatic steatosis [258].  Steatohepatitis can be caused by additional insults, such as 
a choline deficient or high fat diet. This model is characterised by extreme obesity, and 
increasing difficulty in surgical procedures. 
Db/db mice 
In this model, a mutation in the receptor confers resistance to leptin signalling 
[259]. Phenotypically and pathologically Db/db mice show similarity to Ob/ob mice.   
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SREPB-1c transgenic mice 
Sterol regulating element binding protein -1c is an important transcription factor 
in lipid biosynthesis and fatty acid metabolism. Overexpression of this transcription 
factor in transgenic mice leads to steatosis and steatohepatits through lipodystrophy- a 
failure of adipose tissue to develop properly [260]. The development of NAFLD 
depends on the presence of abdominal adiposity as much as upon hepatic steatosis. 
Hepatic steatosis develops as a result of imbalance between lipid transport in energy 
consumption and in storage. As a result, lipid deposition develops in various locales 
around the body, but the presence of intraabdominal, mesenteric fat acts synergistically 
with the hepatic steatosis to damage the liver. This occurs through direct access of lipids 
to the liver via the portal system. Therefore, abdominal fat is a necessary requirement in 
closely representing NAFLD in animal models [261].  
KK-Av mice 
A mutation in the agouti gene results in loss of melanocortin function and 
ineffective suppression of hypothalamic appetite signals [262]. Male mice develop 
diabetic nephropathy at the age of 4 months [263].  
PPARα knockout mice 
Peroxisome proliferator-activated receptor α is an important player in fatty acid 
oxidation and lipid metabolism in mitochondria and peroxisomes. Disruption of this 
gene leads to steatosis when mice are starved, not when they are fed normally.  
 
ALMS1 transgenic mice 
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ALMS1 is a protein encoded in embryonic brain, aorta, eye, kidney, and testis. 
This protein is found within the basal bodies of cilia and cellular projections. Mutation 
of the ALMS1 gene in humans leads to a rare Alstrom syndrome, which is characterized 
by childhood onset obesity, retinopathy, sensory dysfunction and type 2 diabetes. In 
mice, mutation of the gene leads to obesity (the so called “fat aussie” mouse), infertility 
and islet cell dysfunction [264]. 
Zucker rat 
This animal is the rat equivalent of the Db/db mouse, and exhibits hyperphagic 
behaviour due to a deficient leptin receptor.  
 
Dietary models of obesity 
Methionine and choline deficiency 
One animal model of NAFLD involves feeding experimental animals a diet that 
is free of choline and/or methionine. Choline is an important molecule in the synthesis 
of ApoB and hence lipid transport out of the liver. Without choline, liver lipid export is 
impaired, leading to steatohepatitis and cirrhosis. Artificial feeding with a choline 
deficient diet was also found to be associated with dysbiosys [265]. This model is not 
suitable for use in studying the early stages of NAFLD where simple steatosis and lack 
of inflammation is key.  
 
 
High fat diet 
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Much of the literature deals with genetically altered models of obesity. Although 
these models provide a reliable outcome in a comparably short period of time, most 
human obesity and NAFLD is caused by increased energy intake and altered dietary 
composition. Much work has been done with different animal models of high fat intake 
induced obesity. It has been shown that various animal strains react differently to 
ingestion of a high fat diet. C57BL/6J mice are reported to be particularly sensitive to 
the development of obesity when consuming a high fat diet [266, 267]. Normal 
laboratory animal chow consists of agricultural byproducts, such as soybeans and corn; 
a source of protein, such as fish; and vegetable oil, complemented with minerals and 
vitamins. High fat diets, on the other hand, consist of supplemented casein, sucrose, 
starch and lard. A diet that provides 45% of the energy in the form of lipids mimics the 
consequences of the “western diet” best, compared to high carbohydrate-low fat diet 
[268] or very high (87%) fat diets [269]. 
 
1.7 Interplay between steatosis, liver regeneration and ischemia-reperfusion 
injury 
Steatotic livers have been shown to have impaired regeneration after partial 
hepatectomy [270, 271]. According to Yang et al. one of the reasons for this is that 
steatotic hepatocytes are arrested in G1 phase of the cell cycle due to oxidative stress-
related inhibition of cyclin D1 activity [270]. Partial hepatectomy in a genetically obese 
mouse model (ob/ob) revealed hyperactivation of the IL-6/STAT3 pathway [271]. 
Whereas hepatocyte proliferation after partial resection of steatotic liver is reduced, oval 
cell proliferation appears intact or even increased. Roskams et al. showed that 
expansion and activation of the oval cells reached a maximum at 36 hours post-
resection, before declining to baseline levels at 48 hours [272]. The effect of warm 
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ischemia and reperfusion on hepatocytes and oval cells within the steatotic liver has not 
been fully explored.  
ROS released during ischemia and reperfusion of steatotic livers cause extensive 
lipid peroxidation, amplifying tissue damage [273]. Further release of granules 
containing superoxide and other ROS accompanies neutrophil infiltration of the liver. 
[170], compounding the initial injury. Lipid peroxidation products which damage the 
mitochondria induce hepatocyte lipoapoptosis by activating the proapoptotic proteins 
Bim and Bax, which trigger the mitochondrial apoptotic pathway [274].  
Circulating levels of free fatty acids are increased in obesity [233]. Free fatty 
acids can signal through TLR4 on hepatocytes [233], and cultured hepatocytes treated 
with a free fatty acid (palmitic acid) released HMGB1 into the supernatant [238]. 
Release of free fatty acids into the circulation following ischaemia and reperfusion of 
fatty livers could amplify TLR4 signalling both independently and through increased 
release of HMGB1. 
 
1.8 Non-alcoholic fatty liver disease and the outcomes of liver 
transplantation 
The prevalence of NAFLD in the developed world is steadily increasing. In 
parallel with the rise of NAFLD as an indication for liver transplantation, fatty liver is 
an increasingly frequent incidental finding in deceased organ donors, and depending on 
the severity of steatosis, can render the donor liver unsuitable for transplantation.  
The level of steatosis influences liver transplant outcomes such as primary graft 
non-function and 1 year graft survival [275]. Unacceptable steatosis levels in the 
procured grafts comprise the primary reason behind donor livers being deemed 
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unsuitable for transplantation [24-26]. A single centre, retrospective study of 110 
instances of livers procured-but-discarded found that 44% were not transplanted due to 
perceived unacceptable steatosis levels [25]. Strategies to improve the outcomes from 
transplantation of steatotic livers could permit greater utilisation of donated organs and 
help in addressing the current shortage of donor livers.     
The lipid content of grafted liver affects the outcome of liver transplantation 
[276]. However, the importance of this effect remains under debate. Comparing the 
results of available studies is complicated by small sample sizes, poor separation 
between severe and moderate steatosis levels within these small groups and by the use 
of use of differing criteria to measure outcome. Studies by Verran et al. [277] and 
Angele et al. [278] report 0% and 4% primary non-function for moderate steatosis. This 
is comparable to 2.5% primary non-function (PNF) in non-steatotic grafts [279]. 
Conversely, Nikeghbalian reported 18% primary non-function for the same level of 
steatosis [280], clearly an unacceptable risk for liver recipients, given that primary non-
function results in recipient death unless immediate retransplantation is available.  
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Author N PNF % 1 year graft survival % 
Verran et al. 2003 25 0 60 
Nikeghbalian et al. 2007 34 18 73 
Angele et al. 2008 36 4 77 
Table 1.3 Comparisons of various studies of liver transplant outcome for moderately 
steatotic grafts. 
 
With regards to severe steatosis. studies also report differing results. Noujaim et 
al. examined the results of 21 grafts with severe steatosis and found 0% PNF [281]. 
McCormack et al. reported 5% PNF in 20 grafts, over the course of 4 years [282], 
whereas De Carlis et al. reported 66% PNF amongst 21 cases [283].  
 
Author N PNF % 1 year graft survival % 
McCormack et al 2007 20 5 84 
Noujaim et al. 2009 21 0 35 
De Carlis 1999 21 66 NA 
Table 1.4 Comparisons of various studies of liver transplant outcome for severely 
steatotic grafts 
 
1.8.1 Does the lipid vesicle size influence liver transplant outcome? 
 Worse outcomes have been ascribed to grafts with predominantly 
macrovesicular steatosis (MaS, a single large lipid droplet within each hepatocyte) than 
grafts with microvescicular steatosis (MiS, multiple smaller lipid droplets within 
hepatocytes) [275, 277, 280, 284, 285]. Studies by McCormack and Noujaim 
specifically examined the role of macrovesicular and microvesicular steatosis in graft 
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failure [281, 282]. However, their findings were inconclusive. This possibly  reflects the 
fact that MaS and MiS are frequently found together in a mixed form of steatosis [286], 
especially when specialized lipid stains are used for diagnosis [287]. Interpretation of 
the outcome variability is further confounded by the semi-quantitative methods used to 
assess steatosis by the explanting and implanting surgeons. Palpation and visual 
inspection are the most commonly used methods [288]. However, the positive 
predictive value of a macroscopic assessment of liver steatosis is moderate at best. This 
has been reported to be 71% for severe; 46% for moderate; and 17% for mild steatosis 
[279]. This means that surgeons are possibly failing to utilise some viable and available 
organs. Even when suboptimal quality of the graft is suspected, only 38% of the 
surveyed surgeons in UK and 47% of the US surgeons requested histological 
examinations [288].  
 
1.9 Inflammation and innate signalling as barriers to transplantation 
tolerance 
Innate immune responses which coincide with organ transplantation can 
potentiate rejection and perturb mechanisms which promote the emergence of 
transplantation tolerance. Either infection or sterile inflammation can block tolerance 
induction – under some circumstances, both conditions may be present simultaneously. 
This effect has been demonstrated largely using models which rely upon co-stimulatory 
blockade with anti-CD154 for tolerance induction.   
 
1.9.1 The effect of microbial infection on tolerance 
Organs that are substantially colonised by microflora, such as skin, lung and 
intestine, are more likely to be rejected than organs lacking such microflora, such as 
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liver. In animal models of transplantation, infections with bacteria (such as Listeria 
monocytogenes) [289] or viruses (such as lymphocytic choriomeningitis virus) [290] 
can abrogate graft tolerance. Administration of synthetic PAMPs which engage various 
toll-like receptors (Pam3CysK4 signals through TLR2, Poly I:C activates TLR3, LPS 
ligates TLR4 whilst CpG ODN binds to TLR9) recapitulates the effect of natural 
infection in blocking tolerance induction [291]. In the case of tolerance blockade 
through the administration of CpG ODN, TLR signalling results in the secretion of IL-6, 
and the conversion of FoxP3-positive Tregs to Th17 cells in the presence of IL-6 and 
TGFβ in the extracellular milieu [292, 293]. Th17 cells are a subset of helper T cells 
that is distinct from Th1 and Th2 cells. Th17 cells produce IL-17A-F, IL-21, IL-6 and 
TNFα [174]. Cytokines produced by Th17 cells can lead to neutrophil recruitment, 
inflammation and overt tissue damage [294], whilst the reduction in Treg numbers 
interferes with the development of antigen-specific tolerance. Notably, administration of 
CpG ODN to IL-6 deficient mice or in the presence of neutralising antibodies against 
IL-17 did not affect tolerance induction [293], confirming the role of these cytokines in 
tolerance blockade. 
 
1.9.2 Brain death as a barrier to tolerance induction 
It is increasingly being recognized that donor brain death is a potent trigger for 
the release of proinflammatory hormones, cytokines and alarmins [295]. Brain dead 
donors are the main source of solid organs for transplantation. Brain death involves 
catastrophic and irreversible damage to the cerebrum, cerebellum and brain stem. It is 
associated initially with excessive parasympathetic neural activity, followed by 
sympathetic activation: high levels of serum catecholamines, arterial hypertension and 
tachycardia. When the phase of sympathetic overactivity subsides, reduced vascular 
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tone,  erratic peripheral perfusion and ischaemic damage to transplantable organs ensue 
[296]. DAMPs, including HMGB1, are released from ischaemic tissues, and 
translocation of bacterial products such as LPS and bacterial DNA, across the 
compromised gut barrier, also occurs [297]. These bacterial products can complex with 
HMGB1, increasing their potency as proinflammatory ligands. TLR signalling results in 
further release of cytokines and chemokines, as well as enhancing donor antigen 
presentation by dendritic cells, which in turn, potentiates the T cell response [298]. 
Animal experiments with brain death models show that IL-6, MCP-1, e-selectins and 
KC were significantly elevated in the serum as early as 30 minutes after induction of 
brain death in mice [299]. Not surprisingly, donor brain death can interfere with the 
effectiveness of tolerance induction protocols [300, 301]. When brain death affects a 
steatotic donor liver, the potential for disruption of tolerance induction is likely to be 
even more significant. 
 
1.10 Strategies for the amelioration of liver ischaemia-reperfusion injury 
Some degree of ischaemia-reperfusion injury is inevitable in transplantation. 
Approaches which may limit the extent of the ischaemic insult include minimisation of 
cold and warm ischaemia time, whilst both local and remote ischaemic preconditioning 
and the administration of pharmacological or biological agents have been used in 
attempts to reduce organ damage.  
 
1.10.1 Ischaemic Preconditioning 
Local pre-conditioning by brief, intermittent occlusion and release of blood 
vessels supplying an organ prior to the application of more prolonged ischaemia, can 
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attenuate IRI [302]. Three cycles of alternating ischaemia and reperfusion prior to liver 
transplantation improved survival and reduced transaminase release in Sprague Dawley 
rats [303]. The effects were attributed to increased Nitric Oxide synthesis by hepatic 
blood vessels and reduced TNFα secretion. In human patients undergoing liver resection 
for cancer, ischemic preconditioning for 10 minutes followed by 10 minutes of 
reperfusion halved the peak post-operative levels of serum transaminases and reduced 
numbers of apoptotic cells in the remaining liver, as measured by terminal dUTP nick 
end labelling (TUNEL) [304].  
Remote pre-conditioning employs cyclical ischaemia and reperfusion of a 
different tissue, usually skeletal muscle, in order to protect the target organ from later 
ischaemic damage. The principle of remote pre-conditioning was first described by 
Przyklenk [305] when ischaemia of one coronary vascular territory was found to protect 
against subsequent ischaemic damage in a different territory. In animal models of 
remote ischaemic preconditioning, periodic occlusion and release of arteries supplying 
the hind limb is widely used. Remote ischaemic preconditioning confers substantial 
protection against ischaemic damage in livers subjected to partial warm liver IRI [306]. 
Depletion of nitric oxide using the NO scavenger-C-PTIO abrogated this protective 
effect [307]. Nitric oxide helps to maintain flow through the hepatic microcirculation.   
HMGB1 is critical to the pathogenesis of liver IRI, and yet when administered 
as a preconditioning agent, HMGB1 was able to inhibit tissue damage in a dose- 
dependent manner. Mice treated with exogenous HMGB1, one hour before the 
induction of 60 minutes’ partial warm ischaemia suffered significantly less liver damage 
than untreated control animals, as measured by ALT, serum TNFα, and IL-6 [308]. This 
protective effect was mediated by TLR4 as mice with a loss of function mutation in 
TLR4 (C3H/HeJ strain) were not protected by HMGB1 pretreatment. In accordance 
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with these findings, a short period (10 minutes) of hind limb ischaemia results in the 
release of HMGB1 into the systemic circulation, and attenuates liver injury from 
subsequent partial warm ischaemia [309]. When the duration of ischaemic 
preconditioning was increased to 60 minutes, protection was abolished, and the liver 
injury incurred during later ischaemia was exacerbated. Either TLR4 deficiency, or 
antibody blockade of HMGB1 abrogated protection.  The proposed mechanism for the 
effect of HMGB1 in ischaemic preconditioning involves inhibition of signalling through 
Interleukin 1 Receptor Associated Kinase 3 [308, 309]. 
 
1.10.2 Pharmacological approaches to IRI protection  
Various pharmacological agents have been used in attempts to reduce the 
severity of ischaemia-reperfusion injury. In some instances these have been 
administered to organ donors prior to transplantation, although for ethical and practical 
reasons, treatment of the recipient is more common in the clinical setting. Some of these 
agents are principally anti-inflammatory, whilst others support organ perfusion or have 
anti-oxidant or anti-apoptotic activity. Systemic administration of methylprednisolone 
to human brain dead donors from the time of consent for organ donation until liver 
procurement reduced both the severity of IRI and the incidence of acute rejection 
following transplantation [310]. Intraoperative, intraportal donor organ perfusion with 
tacrolimus had shown promise in reducing the severity of IRI in rodent models, but 
these effects were not able to be translated into a benefit in clinical liver transplantation 
studies [311]. Systemic administration of prostaglandin I2 to donors immediately before 
organ procurement improved sinusoidal perfusion and reduced peak post-transplant 
ALT levels [312]. Nitric oxide (NO) promotes flow through the liver microvasculature. 
L-arginine is an amino acid precursor to NO. Administration of L-arginine prior to the 
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onset of ischaemia reduced the level of myeloperoxidase activity (a marker of 
neutrophil activation) in the ischemic region and limited the area of tissue necrosis 
[313] in an animal model of IRI. Administration of NO to liver transplant recipients via 
the inhaled route both before and after revascularisation of the graft reduces hepatocyte 
apoptosis and improves immediate liver function post-transplant without affecting 
inflammatory markers [314]. Based on these encouraging results, at least three 
randomized clinical trials are underway in the United States studying effect of NO in 
LTx [315].  
The hepatoprotective anti-oxidant compound N-acetylcysteine was not effective 
in the prevention of IRI when administered postoperatively to liver transplant recipients 
[316].  
Caspases are vital enzymes in apoptotic pathways. Apoptosis is a major mode of 
cell death in IRI. Yaoita et al. studied the effect of a caspase inhibitor ZVAD-fmk on 
warm IRI in rat hearts. Administration of ZVAD-fmk both before and after the onset of 
ischaemia reduced the number of apoptotic cardiomyocytes and the area of myocardial 
infarction [317].  The caspase inhibitor Z-Asp-cmk significantly improved the survival 
of rats subjected to a prolonged period of warm liver ischaemia [318]. Ninety percent of 
caspase inhibitor-treated rats survived the observation period, while survival in the 
control group was only 30%. As expected, significantly fewer TUNEL positive 
hepatocytes were detected in treated group.  
Cisplatin is an anticancer agent which binds to DNA, forming adducts which 
exhibit increased binding affinity for HMGB1. Addition of low, non-toxic doses of 
Cisplatin to redox-stressed hepatocytes in vitro stabilised the interaction between 
HMGB1 and nuclear chromatin, and prevented egress of HMGB1 from the nucleus into 
the cytoplasm [319]. Moreover, when administered to mice prior to an ischaemic insult, 
    
 
51 
 
low-dose cisplatin attenuated the severity of ischaemia-reperfusion injury, reducing 
ALT release, histological parameters of liver damage, and serum levels of IL-6 and 
TNF-. Although Cisplatin treatment results in apoptotic cell death of cancer cells, 
increased hepatocyte apoptosis was not noted in mice receiving low-dose Cisplatin for 
the prophylaxis of IRI.  
 
1.10.3 Biological agents in IRI protection 
Blocking or neutralising antibodies, fusion proteins, and other decoys against 
proinflammatory ligands, receptors or downstream soluble mediators of IRI have been 
tested in a number of animal models of liver ischaemia and/or liver transplantation and 
to a lesser extent in clinical transplantation.  
 
1.10.3a Agents which target Alarmins 
Alarmins implicated in the pathogenesis of IRI include HMGB1 and S100B. An 
alternative to antibody blockade of these proinflammatory ligands is to use a soluble 
“decoy” form of a cell surface receptor to bind and sequester the ligands. Soluble 
RAGE exhibits same ligand promiscuity as membrane bound RAGE, binding HMGB1, 
S100 and other alarmins. This eliminates the need to develop decoy agents against each 
alarmin individually and increases effectiveness. Accordingly, administration of soluble 
RAGE was more effective in increasing survival than either the use of anti-HMGB1 or 
anti-S100 antibodies alone [128, 320]. As well as acting as a decoy receptor, soluble 
RAGE directly blocks signal transduction through cell surface RAGE by forming 
heterodimers with the full-length RAGE isoform and preventing its homodimerisation – 
a necessary prerequisite for the recruitment of signalling adaptors and downstream 
    
 
52 
 
signal propagation [117-119]. The principal effect of RAGE antagonism is to improve 
survival after extensive liver damage, either due to ischemia-reperfusion injury [127], 
massive hepatic resection [128] or lethal doses of acetaminophen [321]. Of note, levels 
of IL-6 and TNF were not reduced by treatment with soluble RAGE, and in this 
context, their pro-survival actions may predominate over their role as inflammatory 
mediators. Further, although serum ALT is frequently used as a marker of liver injury, 
ALT levels were not significantly reduced in mice receiving soluble RAGE, despite the 
unambiguous survival benefit conferred (increases in survival rates from 30% to 80-
90% at day 7 following either massive hepatectomy or total warm liver ischemia). 
 
1.10.3b Agents targeting downstream soluble mediators of inflammation 
Administration of 3mg/kg (but not 1mg/kg) neutralising anti-TNFα antibody 
prevented the rise in serum TNFα following warm liver IRI in a rat model. When 
compared with rats receiving remote ischaemic preconditioning , the higher-dose group 
showed similar levels of neutrophil activity (MPO) and ALT as did the preconditioned 
animals, and maintained flow through the hepatic microcirculation [322].  
 
1.10.3c Inhibition of leukocyte infiltration into ischaemic tissues 
P-selectin is required for neutrophils to infiltrate inflamed tissue. Busuttil et al. 
examined the safety and impact of the recombinant P-selectin glycoprotein ligand IgG 
(rPSGL-Ig) in human patients. rPSGL-Ig inhibits leukocyte adhesion to activated 
platelets and endothelia. When given as an intravenous bolus to liver graft recipients, 
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this agent improved early hepatic function (poor early graft function defined as 
ALT>2500 IU/L and bilirubin >10mg/dL) compared to placebo [323].  
Antithymocyte globulin is known for its T cell depleting action, but in addition, 
this agent decreases β2 integrin expression, and inhibits leukocyte adhesion and 
infiltration into inflamed tissues [324]. When administered perioperatively, 
antithymocyte globulin resulted in less hepatic damage and fewer episodes of primary 
non-function following liver transplantation [325].  
 
1.10.3d Increasing levels of protective molecules  
Heme oxygenase-1 (HO-1) is a rate-limiting enzyme in haemoglobin 
metabolism that breaks down heme to biliverdin. HO-1 up-regulation is an endogenous 
protective mechanism, and is a sensitive indicator of cellular stress. Heme oxygenase-1 
moderates TLR4-pathway signalling through activation of the phosphoinositide 3-
kinase/Akt pathway [123, 326], thus protecting against IRI. HO-1 also influences the 
function of CD4+CD25+ Tregs by up-regulating FoxP3 expression and the secretion of 
IL-10 [327]. Several different approaches can be used to increase HO-1 activity in 
tissues. Amersi et al. studied the effects of HO-1 up-regulation by cobalt protoporphyrin 
and over-expression through the administration of a recombinant adenoviral vector on 
orthotopic transplantation in fatty rat livers. HO-1 over-expression increased survival 
from 40% to 80% [328].  Statins may also exert a hepatoprotective effect in IRI via the 
induction of heme oxygenase-1 [329]. Intraperitoneal administration of atorvastatin in a 
rat model of partial warm IRI reduced both the ALT rise and the number of apoptotic 
cells compared to the control group. The atorvastatin treated group showed elevated 
expression and enzyme activity of HO-1. Ajamieh et al. tested the effect of atorvastatin 
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in warm liver IRI in the Alms1 genetic model of obesity. The ALT rise was attenuated, 
and the authors also reported that atorvastatin inhibited IκBα degradation and prevented 
nuclear translocation of NF-B, thus reducing release of TNFα and IL-6, and increasing 
expression of endothelial nitric oxide synthase [330].  
 
1.11 AAV vector biology and liver-directed gene transfer 
Vectors based on the adenoassociated virus (AAV) have many advantageous 
features for clinical and experimental gene transfer. AAV is a parvovirus with a single 
stranded DNA genome. It is naturally replication-deficient, and requires coinfection 
with a helper virus, usually Adenovirus or a Herpes virus, to replicate within infected 
cells [331, 332]. AAV vector administration is rarely associated with inflammatory 
responses, or with the risk of insertional mutagenesis, rendering these vectors safe for 
use in vivo. The AAV genome comprises approximately 4,700 nucleotides [333], 
encoding two open reading frames Rep and Cap [334]. In AAV vectors, Rep and Cap 
are replaced by the gene expression cassette, and these functions are provided in trans 
during vector packaging. 
Accurate tissue targeting can be achieved by several means. The route of entry 
of the viral vector is one important factor. Simple intraperitoneal injection was shown to 
be effective in hepatic targeting [335]. The tropism of AAV vectors for different target 
tissues is a function of the viral capsid, and can be altered by changing the capsid type, a 
process known as “pseudo-serotyping” or “cross-dressing”. More than ten capsid 
serotypes are described, with tropism for the liver, muscle, lung, brain and eye [336]. 
Further specificity in expression can be achieved by combining different capsids with 
regulatory elements whose activity is confined to particular cell types. For instance, the 
human alpha-1 antitrypsin promoter and ApoE enhancer incorporated into the vectors 
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used in this project are only active in hepatocytes and confer a high degree of specificity 
to transgene expression, when used in conjunction with the serotype 8 capsid [335, 
337].  
AAV gene transfer subjects the recipient to two foreign proteins: the transgene 
product and the viral capsid proteins. The recipient immune response to these two 
proteins can range from tolerance to a productive reaction and elimination. Both 
neutralising antibody production and cell-mediated responses to capsid and transgene 
have been noted [338]. The likelihood of triggering an immune response is influenced 
by a number of factors, including the site and level of transgene expression (reviewed in 
[339]). High level expression and lack of transgene expression in antigen-presenting 
cells are both important contributors to the development of tolerance. AAV infection of 
dendritic cells is not productive [340], but this does not preclude cross-presentation of 
internalised antigens from vector capsid or transgene. 
Adeno-associated virus (AAV) is well suited for liver-directed gene transfer 
thanks to its high affinity and low immunostimulatory potential. In our hands, AAV2/8 
gene transfer to the liver is safe, highly efficient, and leads to durable transgene 
expression for at least 100 days following administration [337, 341]. 
 
1.12 Advantages of gene transfer over conventional dosing 
Neutralisation of alarmins with recombinant soluble RAGE necessitates daily 
injection of sRAGE during the period of study [127]. Practical advantages exist in the 
use of rAAV vectors to endogenously over-express esRAGE in the liver. This approach 
avoids multiple injections of sRAGE at a time when absorption from the peritoneal 
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cavity into the systemic circulation might be compromised in the aftermath of 
abdominal surgery and provides a consistently high serum level of the decoy receptor.  
 
 1.13 Aims  
Understanding the mechanisms of spontaneous liver transplantation tolerance could 
potentially allow us to achieve tolerance in a higher proportion of graft recipients, 
eliminating the burden of lifelong immunosuppression. In addition, deepening our 
understanding of the mechanisms whereby hepatic steatosis exacerbates damage to 
donor livers during warm ischaemia and/or donor brain death and developing strategies 
to overcome these could have at least three potential benefits. Firstly, by enlarging the 
pool of potential donors whose organs could be used safely, more patients could have 
access to life-saving liver transplants. Secondly, strategies which attenuate ischaemic 
damage would improve short-term outcomes for patients receiving grafts with varying 
degrees of steatosis by reducing the likelihood of primary non-function or immediate 
poor function of the transplanted liver. Finally, reduction in pro-inflammatory signals 
within the graft microenvironment would favour the development of transplantation 
tolerance. Accordingly, this project comprises three aims: 
 
 
Aim 1 (Chapter 3): To explore the association between the expression of “survival” 
cytokines and their receptors and the fate of different organ grafts across the same 
allogeneic barrier. 
 
Aim 2 (Chapter 4): To study the severity of IRI increased in a mouse model of 
NAFLD and to study some of the contributing mechanisms. 
    
 
57 
 
Aim 3 (Chapter 5): To explore if the systemic overexpression of esRAGE can 
improve the outcome of IRI in lean and/or fatty livers. 
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Chapter 2: Materials and methods 
2.1 Animal models 
2.1.1 Obesity model 
A number of murine models of obesity exist, based on either genetic alteration 
of satiety and metabolic pathways, or provision of a nutritionally-altered diet [342]. 
This project required a murine model that mirrors the pathology of human NAFLD in 
terms of the aetiology of obesity, absence of inflammation or fibrosis and presence of 
both, macrovesicular and microvesicular steatosis. These requisites are fulfilled by high 
fat diet-feeding of C57BL/6J strain mice.  
Animals aged 4-6 weeks old were received from the Animal Resources Centre, 
Perth, Western Australia, and were kept in accordance with the guidelines of the Animal 
Care and Ethics Committee of the University of Sydney. Prior to the commencement of 
feeding animals are weighed and tagged under anaesthesia. At 6 weeks after birth, the 
average weight of male C57BL6/J mice was 21.37 ±0.6g (n=142). Animals are housed 
in cages with 5-6 individuals each. At the start of feeding cages of mice randomly 
assigned to HFD or chow-fed groups. During the feeding period of 12-14 weeks, 
animals were weighed and their well-being monitored twice weekly, as per the protocol. 
Animals were allowed unrestricted access to food and water. Mice were housed under 
temperature and humidity-controlled conditions, with a fixed dark-light cycle (12 hours 
daylight and 12 hours darkness). The high fat diet provides approximately 45% of total 
calories from fat of animal origin and was prepared in-house using commercially 
available consumer products, based on animal feed no. D12451 (Research Diets, 
Brunswick, NJ), as described elsewhere [266, 343] (Table 2.1). The control group of 
animals received normal mouse chow ad libitum. The HFD was provided fresh three 
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times a week to avoid food wasting by the animals and loss of quality due to prolonged 
exposure to room temperature. Any food remaining in the cage after 7 days is discarded.  
Composition of the 45% fat diet. 
 Weight 
(g) 
Total  
(%) 
Calories Total  
(%) 
Casein (Frontera, New Zealand) 261 22.94 1044 19.5 
Sucrose (ICN, USA) 224 19.69 896 16.73 
Starch (ICN, USA) 214.8 18.88 859.2 16.04 
Mineral mix (ICN, USA) 51 4.48   
Bran  57 5.01   
Methionine (Lifetechnologies, USA) 3.4 0.3   
Gelatine 23 2.02   
Choline bitartarate (Lifetechnologies, USA) 4.6 0.4   
Vegetable oil 34 2.99 306 5.71 
Animal lard 250 21.98 2250 42.02 
AIN Vitamins (ICN, USA) 14.8 1.3   
Total 1137.6 100 5355.2 100 
Table 2.1 Composition of the high fat diet. Amounts are given per production batch 
with percentages of weight and calories given for each ingredient. The lard is melted to 
a liquid state, then all dry ingredients are added and mixed. Before this mixture cools to 
room temperature, it is pressed into pellets for easy handling and stored at -20°C until 
use. 
 
 2.1.2 Mouse model of partial warm liver IRI 
Induction of partial warm liver ischaemia/reperfusion injury (IRI) was 
performed according to an established technique [2]. Animals were anaesthetised using 
isoflurane vapour in an enclosed chamber. Then transferred to the operating table in a 
dorsal recumbent position. 900 ml/minute of oxygen with isoflurane 2.5% was supplied 
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through a breathing mask. When anaesthesia is stable, the oxygen flow rate is lowered 
to 700 ml/minute and the isoflurane concentration is reduced to 1-1.5%. Body 
temperature was maintained using a feedback-controlled homeothermic warming 
system. Homeothermic systems consist of a rectal temperature sensor, central unit and 
source of heat (either a heat pad or a heat pad combined with a heat lamp, controlled by 
the central unit). Two different models of homeothermic system were used in the course 
of this project. The experiments described in Chapter 4 used a homeothermic system 
that consisted of a pad as the only source of heat (Right temp, Kent scientific, USA), 
while the experiments reported in Chapter 5 utilized a system which incorporated both a 
heat lamp and a heat pad (Physitemp TCAT-2, Physitemp Instruments, USA). The 
thermal sensor is coated with inert, aqueous-based lubricant to avoid internal damage 
and inserted into the rectum. After the body temperature has stabilized the abdomen is 
sprayed with 70% alcohol and shaved. 0.1ml buprenorphine (0.015mg/ml) is 
administered subcutaneously. After the temperature has stabilized once more, the 
abdominal cavity is opened through a 1.5-2cm median incision into the skin and the 
peritoneum. The intestines and other viscera are mobilized to reveal the inferior vena 
cava and the liver. The median and left liver lobes are gently lifted to allow 
visualization of the portal vein at the bifurcation between right and left lobar branches. 
The fine ligament between the left and quadrate lobes of the liver is divided using 
microsurgical scissors to better isolate the portal triad. An atraumatic microvascular clip 
is placed across the portal vessels just above the branching of the right lobar vessel in an 
antero-posterior orientation. Ischaemia is confirmed by blanching of the ischaemic left 
and median lobes (Figure 2.1a and b).  
The intestine is returned to the abdomen and the abdominal cavity is filled with 
a further 0.4ml warmed normal saline to keep the abdominal organs moist. The  
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Figure 2.1a Microvascular clamp in place 
(centre), ischaemic liver pale in colour (above 
the clamp), while non-ischaemic liver is livid 
(below the clamp) 
 
 
 
Figure 2.1b Diagram depicting a ventral view of 
the normal mouse liver in which the left and 
median lobes are retracted back to expose portal 
vein (blue), hepatic artery (red) and bile duct 
(yellow). Clamping of portal vein produces 
ischaemia in left and median lobes (figure taken 
from [2] Abe et al. 2009).  
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abdomen is temporarily closed, and a further 0.5ml normal saline is injected 
subcutaneously into each flank. The core temperature readings are documented at 3 
minutes intervals from the placement of the sensor to removal of the microvascular 
clamp, and were graphed using Excel software (Microsoft, USA). 
At the end of the ischaemic period (30 minutes), the abdomen is reopened, 
intestine retracted, and the clip is removed. At this point the liver should rapidly 
reperfuse and the normal liver colour should be restored. Failure to reperfuse is a 
criteria for immediate animal euthanasia. Antibiotic (ampicillin) is administered 
subcutaneously and the abdomen is closed using a continuous 4/0 vicryl suture in 2 
layers. After a period of reperfusion ranging between 15 minutes and 3 days, samples 
were collected under anaesthesia.  
 For the sham-operated mice, an identical procedure was followed, with 
the exception of portal vein occlusion.  
Sample collection: 
 Serum- Blood is collected through puncture of the inferior vena cava puncture 
using a 21G needle and 1ml syringe. The needle is removed from the syringe 
before blood is transferred into a 2 ml collection tube.  Blood is allowed to clot 
for 1hour before being spun in centrifuge at 3000rpm/min for 5 min. The 
supernatant is collected and additionally spun for 15 sec at 15000 rpm/min and 
then dispensed into 75µl aliquots and stored at -80°C until further use.  
 Liver- blunt forceps are used for extraction to avoid possible damage to the 
liver. The ischaemic left and median lobes are divided into three parts, and 
processed as described below: 
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o Formalin-fixed for 24 hours for paraffin-embedded sectioning;  
o Embedding in OCT (Tissue-Tek, Osaka, Japan), then frozen slowly in 
the vapour phase of liquid nitrogen and stored at -80°C until further use. 
o Snap-freezing of approximately 2 mm cubes of tissues in Cryovials 
(ThermoFisher Scientific, USA) in the vapour phase of liquid nitrogen.. 
These are then stored in liquid nitrogen until further use.  
 
2.1.3 Rat kidney, liver and heart transplantation procedures 
Rat orthotopic liver and kidney transplants and heterotopic heart transplants 
were performed as previously described [54]. Male PVG and DA strain rats weighing 
200-300g were procured from the Animal Resource centre, Perth, WA, and used as 
donors and recipients, respectively. Organs were sampled 3, 5 and 7 days after 
transplantation (3 animals per time point) and normal PVG strain heart, kidney and liver 
tissue was also collected. Tissues were stored in liquid nitrogen prior to processing for 
RT-qPCR amplification. Kidney transplantation was performed according to method 
described by Fabre et al. [344] and liver transplantations were performed according to 
the method described by Kamada et al. [345]. All transplant procedures were performed 
by Dr. Chuanmin Wang. 
  
2.1.3a Renal transplantation 
Both donor and recipient rats are weighed. Isoflurane in an enclosed chamber is 
used to anaesthetise the animal, after which it is placed on the operating table in a dorsal 
recumbent position. The induction dose of isoflurane is 3% v/v in 100% O2, supplied 
through a breathing mask for 10-15 minutes. 1.5% to 2% isoflurane is maintained 
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throughout the operation. The abdominal hair is shaved and the skin cleaned with 70% 
ethanol after induction. Aseptic conditions are used during the procedure.  
Donor procedure. Two hundred units of heparin are administered via the penile 
vein. A midline abdominal incision is made in the skin, following which the muscle and 
peritoneum are divided in the midline from the suprapubic region to the xiphisternum. 
The abdominal cavity is secured open with retractors, and the intestines are gently 
displaced. Mobilised intestines are wrapped in gauze moistened with warm saline. 
Magnification of 6-10x is used for the donor procedure. Using blunt dissection, the 
renal and suprarenal veins and renal artery are exposed to their junctions with the caval 
vein and aorta, respectively. The ureter and spermatic ducts are ligated. The kidney is 
mobilised. The aorta is clamped above the renal artery and close to the iliac artery 
bifurcation. The aortic wall is cut with microsurgical scissors to make a flap. A one 
inch, 20G cannula is inserted. The cannula is advanced until the tip lies 3-5 mm below 
the origin of the renal arteries. Perfusion solution is injected at a slow, constant rate 
until the kidney is evenly cold and pale. When perfusion is complete, the renal artery 
and vein are cut close to the aorta and vena cava, then the kidney is lifted free and 
placed in sterile saline on ice. The donor animal exsanguinates. In order to minimise 
damage to the donor organ from warm ischaemia, the steps from clamping of the aorta 
to completion of perfusion are performed as rapidly as possible, and ice-cold 
heparinised Hartmann’s solution is used as the perfusate. Kidneys with greater than 
30% surface mottling or other evidence of uneven perfusion are not suitable for use in 
transplantation.  
Recipient procedure. No heparin is given to the recipient, otherwise the 
operation proceeds as for the donor operation until the ureter is cut. The renal artery and 
vein are clamped with neurosurgical artery clips (artery first), then cut, and the recipient 
kidney is discarded. The renal vessels of the donor kidney and recipient are trimmed, 
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and any loose adventitia is removed from the ends of the arteries. The donor kidney is 
then placed in the renal bed. During the re-anastomosis, the kidney is cooled 
intermittently with 1-2 drops of ice-cold saline onto a small pledget of gauze draped 
over its surface. 10/0 nylon sutures (Johnson and Johnson, USA) are used for the 
anastomoses.  
The artery is anastomosed first. Stay sutures are placed 120° apart in the anterior 
wall of the artery, and retraction is applied with suture clips. Two more interrupted 
sutures are placed in the anterior wall, then the artery is turned over, and a further 3-4 
sutures are used to close the back wall. The vein is much thinner walled although larger 
than the artery. Stay sutures are then applied 180° apart, and retraction applied. A 
continuous suture is used to sew first the back, then the front wall of the vein. The end 
of the suture is not tied off, but left long. Once the vascular anastomoses have been 
completed, the clamps are removed. The venous clamps are removed first. The kidney 
should be pink and evenly perfused with blood. On the fourth post-operative day, the 
recipient’s remaining right kidney is removed.  
 
  
2.1.3b Liver transplantation 
 
Animal preparation and anaesthesia is as described above. A transverse 
abdominal incision is made and the liver is exposed. The bile duct is transected and 
cannulated with a Teflon catheter. The pyloric, splenic and inferior mesenteric veins are 
ligated close to their junctions with the portal vein (PV), and the infrahepatic vena cava 
(IVC) is divided from the right renal and suprarenal veins and removed. The left 
diaphragmatic vein is ligated close to its junction with the suprahepatic vena cava 
(SVC). The donor liver is perfused with heparinised saline via the abdominal aorta, and 
removed. After perfusion, the liver is placed in an ice-cold saline bath until 
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reimplantation. The SVC, IVC and PV are trimmed, and cuffs are prepared for the IVC 
and PV. After the anaesthesia and preparation, a midline abdominal incision is made. 
The bile duct is cannulated via a choledochotomy. The PV and IVC are dissected free 
from surrounding connective tissues, and the right suprarenal and lumbar veins are 
ligated. Following cross-clamping of the IVC and PV, the right branch of the PV is 
ligated, and the recipient’s liver is flushed via the portal vein with Hartmann’s solution. 
The SVC is then cross-clamped and the liver removed. The bile duct is reconstructed by 
end to end anastomosis of the recipient and donor ducts over a Teflon catheter. The IVC 
and PV of the recipient are re-anastomosed using a cuff technique. The SVC is 
anastomosed using sutures. The arterial blood supply to the graft is not re-established. 
Prophylactic ampicillin and analgesia are administered.  
 
2.1.3c Heart transplantation  
Heterotopic abdominal heart transplantation was performed using a technique 
modified from Ono and Lindsay et al.  [346].  
Donor procedure. For the donor procedure, a transverse incision is made at the 
level of the junction between the sternum and xiphoid process. An anterior chest wall 
flap is formed by cutting the rib cage bilaterally, and this was lifted and fixed to expose 
the heart. The IVC was clamped above the diaphragm. The heart was perfused by 
injecting 3ml of cold Hartmann’s solution (with 100U/ml Heparin) into the IVC above 
the clamp. Both superior and inferior venae cavae were ligated with 5-0 silk and divided 
distal to the ligatures. One blade of small scissors was inserted into the transverse sinus. 
The ascending aorta and main pulmonary artery were transected 2-3mm from the heart. 
The pulmonary veins were ligated with a 5-0 silk tie and divided distal to the ligature. 
    
 
67 
 
The heart was freed from the donor animal and placed in cold saline prior to 
transplantation.  
Recipient procedure. An incision is made in the abdominal wall from 
xiphisternum to pubis, mobile intestines were displaced, and the avascular mesentery of 
the sigmoid colon is divided. The abdominal aorta and the IVC of the recipient are 
visualised and freed from each other and from the surrounding connective tissue below 
the origin of the renal vessels. The recipient aorta is occluded proximally with a small 
vascular clip, and a 4-0 silk tie is placed around the distal vessels and placed on tension. 
A second silk tie is loosely placed around the proximal IVC. A small transverse incision 
is made in the isolated aortic segment and enlarged longitudinally, both proximally and 
distally, to match the diameter of the donor aorta. The lumen is flushed with normal 
saline until all clots are cleared. Afterwards, the donor aorta and pulmonary artery are 
anastomosed end-to-side with running 8-0 proline sutures (Johnson and Johnson, USA) 
to the recipient’s abdominal aorta and IVC, respectively. The graft is placed into the 
right lower abdomen of the recipient and protected by intermittent topical cooling. The 
bronchial arteries were ligated to avoid bleeding. The abdominal wall is closed with a 
running suture. 
 
2.2 Histological processing 
2.2.1 Paraffin embedded tissue sections 
A three-step process was used to prepare paraffin-embedded tissue blocks for 
sectioning: dehydration, clearing and paraffin wax infiltration. The dehydration step 
removes water from the tissue prior to further processing. This step involves soaking of 
the tissue in 70% C2H5OH for 24 hours after formalin fixation followed by passage 
through graded alcohols (80%, 95%, 100% and 100% C2H5OH) for two hours each. The 
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clearing process is aimed at removing C2H5OH from the tissue and replacing it with a 
substance miscible with paraffin. This is achieved through soaking the tissue in two 
changes of xylene for 1.5 hours each. The last step involves administering molten wax 
at 60°C to replace xylene and support the tissue during sectioning. Four changes of 
molten wax, each lasting for 1 hour, replace the clearing agent and allow paraffin to 
infiltrate into the tissue cavities and spaces. After cutting, the sections are floated on a 
42°C water bath before being transferred onto a pre-coated slide (SuperFrost®, Menzel-
Glazer, Germany) and baked at 45°C overnight to stabilize on the slide. Tissue paraffin 
embedding, cutting and hematoxylin and eosin staining was performed by Ms. Shanna 
Trollip and Ms. Sanaz Maleki, Histopathology Lab at the Central Clinical School, 
University of Sydney. Fresh paraffin embedded sections are stored at 4°C to preserve 
the antigenicity of delicate epitopes for prolonged periods of time.  
 
2.2.2 Deparaffinisation and rehydration of paraffin embedded sections 
Before the slides are stained, the paraffin residue in and around the tissue needs 
to be removed and the tissue needs to be rehydrated. For this, the slides are heated in an 
oven at 60°C for 2 minutes, soaked in two changes of xylene for 15 minutes each, and 
passed through two changes of graded ethanol with concentrations of 100%, 95% and 
70% for 2 minutes, each. Once rehydrated, the sections are not allowed to dry at any 
moment during staining. 
 
2.2.3 Preparing fresh frozen sections 
OCT-embedded liver blocks were cut in a cryotome (Thermo Shandon 
Cryotome E, Thermofisher, USA) at -13°C. 6µm thick sections were air-dried for 1 
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hour at room temperature then fixed in acetone for 8 minutes and left to air-dry for 30 
minutes. Slides were then stored at -80°C until further use. 
 
2.3 Tissue staining 
2.3.1 Histochemical staining 
 2.3.1a Haematoxylin and Eosin staining 
The Haematoxylin and Eosin (HE) staining of rehydrated sections was 
performed as described elsewhere [347]. This procedure commenced with placing the 
slides in Harris’s haematoxylin for 2 minutes and then washing in water to remove any 
excess. To differentiate the nuclei and cytoplasm, excess stain was removed by quickly 
dipping the slides in acid alcohol ten times and then washing in water again. The slides 
were then placed in Scott’s blueing solution for 30 seconds and then washed in water 
one more time. The slides were examined under a microscope to assess whether the 
nuclei were clearly stained and the cytoplasm was not. If the staining was not adequate 
then the slides would have to be passed through the same steps from the acid alcohol 
stage once more. If the staining of the nuclei was acceptable, the slides were placed in 
70% ethanol for 30 seconds. This was followed by staining the slides in two changes of 
eosin, 40 seconds each. Slides were then dehydrated and coverslipped.  
 
2.3.1b Oil Red O staining  
Oil Red O (ORO) was used to detect lipid droplets. A stock solution was 
prepared by dissolving 0.25g ORO dye in 100 ml absolute isopropyl alcohol.  A 
working solution was prepared one hour before use by diluting the stock solution in 1% 
dextrin at a 6:4 ratio. Fresh frozen sections were allowed to thaw for 30 minutes at room 
temperature and stained immediately for 15 minutes with the ORO working solution. 
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Slides were washed in 60% isopropyl alcohol and rinsed in tap water before being 
counterstained with haematoxylin and coverslipped using Aquamount (Thermo Fisher 
Scientific, USA). Lipids stain red. Nuclei stain purple.  
 
2.3.1c Picro-Sirius Red  
Picro-Sirius Red (PSR) staining was used to detect fibrosis. Rehydrated paraffin-
embedded sections 6 µm thick were washed in distilled water and stained in Wiegert’s 
haematoxylin for 7 minutes. After washing in distilled water, the slides were left in PSR 
dye for one hour. Next, the slides are washed in acidified water to remove excess stain 
and coverslipped. Collagen is stained in red. 
 
2.3.1d Tissue lipid quantitation using ORO 
A modified ORO technique was used to quantitate the lipid content in liver 
tissue as published previously [348]. 100 mg of snap-frozen liver was homogenised in 
1ml of ORO working solution and incubated for 60 minutes. After centrifugation at 
835g for 10 min, the suspension was washed with 60% isopropyl alcohol at room 
temperature to clear excess ORO dye. The tissue pellet was then transferred into a tube 
with 100% isopropyl alcohol and left for the ORO-bound lipids to dissolve into the 
solution for 60 min. After spinning the suspension for 5 min at 2319g, the supernatant is 
analysed for absorbance using a Multiscan plate-reader (Thermo Scientific, USA) at 
490nm (filter N5). Diluted supernatant (1:3-1:5) is assayed as well as neat supernatant 
to ensure that readings will fall on the linear part of the absorbance curve. Absorbance 
was converted to mg of bound ORO using the formula Y = 32.255x +0.0421, where y = 
average absorbance minus blank, m and b = are trend line coefficients generated by the 
computer. The quantity of bound ORO was divided by the exact weight of the liver 
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sample (approximately 100mg) to yield a concentration in µg/g liver, and then 
multiplied by the total weight of the liver at explantation to estimate the total liver lipid 
content, expressed in μg/liver. 
 
2.3.2 Immunohistochemical stains (IHC) 
2.3.2a Neutrophil detection with Ly6B.2 antigen staining 
Rehydrated paraffin-embedded liver sections 6 µm thick were first treated in a 
laboratory antigen decloaking pressure cooker (BioCare Medical, USA) at 2atm and 
125°C for 30 seconds in pH6 citrate buffer for antigen retrieval. After the slides are 
cooled to room temperature and washed in TBST (0.01% Tween-20) buffer three times 
for three minutes each, a wax pen (Dako, Denmark) was used to draw a liquid 
containment circle around the section. 20% normal goat serum (NGS)/TBST was 
applied to the sections for 20 minutes to block nonspecific antigen binding. The primary 
antibody (AbD Serotec, UK, cat. num. MCA771A) rat anti-mouse Ly6B.2 was diluted 
in 1% NGS/TBST to a concentration of 10µg/ml, applied to the sections for 1 hour at 
room temperature in a humidified chamber. Negative control slides only received 1% 
NGS/TBST solution without the primary antibody and the isotype control slide received 
IgG2a κ isotype antibody (AbD Serotec, UK, cat. num. MCA1212) at 10μg/ml 
concentration. After washing, the slides were incubated for 5 minutes in 3% 
H2O2/CH3OH solution to block endogenous peroxidase activity. A secondary 
biotinylated polyclonal goat anti-rat antibody (BD Biosciences, USA, cat. number 
559286) diluted in 1%NGS/TBST to a concentration of 3.33μg/ml was applied to 
sections and incubated for 1 hour at room temperature in a humidified chamber. The 
Vectastain ABC kit (Vector Laboratories, USA, cat. PK-4000) and Diaminobenzidine 
(DAB) (Dako, Denmark) were used for colour development. The Vectastain A and B 
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solutions were diluted in 1% NGS/TBST to concentrations of 1μl/ml each, applied to 
sections and incubated for 30 minutes at room temperature in a humidified chamber. 
DAB-containing chromogen solution was prepared from 1ml substrate and 1 drop of 
chromogen DAB. Following application, sections were incubated for 2 minutes. Slides 
were counterstained in haematoxylin, dehydrated and coverslipped.  
 
2.3.2b Macrophage detection with F4/80 antigen staining 
Fresh frozen liver sections were thawed to room temperature for 30 minutes. 
Each section was stained with FITC conjugated rat anti-F4/80 antibody (eBioscience, 
USA, cat. num. 11-4801-81) diluted in Immunoperoxidase (IP) diluent to a 
concentration of 1.25μg/ml. Sections were incubated with this primary antibody for 30 
min. After washing, anti-fluorescein isothiocyanate antibody conjugated with 
horseradish peroxidase (FITC:HRP) (Genway, USA, cat. num. 18-783-77098) diluted in 
IP diluent with 20% heat-inactivated normal mouse serum (NMS) to concentration of 
7.5µg/ml was used as the secondary antibody. Following application to the sections, 
slides were incubated for 30 minutes at room temperature in a humidified chamber. 
Negative control slides received IP diluent without the primary antibody and the isotype 
control slide received IgG2a κ isotype antibody (AbD Serotec, UK, cat. num. 
MCA1212) at 1.25μg/ml concentration. Staining was visualized with DAB (Dako, 
Denmark). DAB chromogen was diluted in IP diluent containing 18% sodium azide. 
Following 2 minutes incubation with the chromogen solution, slides were 
counterstained in haematoxylin, dehydrated and coverslipped.  
 
2.3.2c Macrophage detection with CD68 antigen staining 
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Fresh frozen liver sections were thawed to room temperature and treated with 
0.06% H2O2/PBS buffer, avidin solution (Dako, Denmark, cat. num. X0590) and biotin 
solution (Dako, Denmark, cat. num. X0590) for 10 minutes each. 20% normal horse 
serum (NHS)/PBS blocking solution was applied to the sections and incubated for 20 
min. Primary rat anti-mouse CD68 antibody was diluted in 1% NHS/PBS to a 
concentration of 2.5µg/ml (AbD Serotec, UK, cat. num. MCA1957) and polyclonal 
biotinylated secondary goat anti-rat antibody was diluted 1:200 in 1% NHS/PBS to a 
concentration of 2.5µg/ml (BD Biosciences, USA, cat. num. 559286). Sections were 
incubated for 1 hour at room temperature for each antibody solution, with washing in 
buffer in between steps. Negative control slides only received 1% NHS/PBS solution 
without the primary antibody and the isotype control slide received IgG2a κ isotype 
antibody (AbD Serotec, UK, cat. num. MCA1212) at 2.5μg/ml concentration. The 
vectastain ABC kit (Vector Laboratories, USA) and DAB (Dako, Denmark) were used 
to visualize staining as above. Slides were counterstained in haematoxylin, dehydrated 
and coverslipped.  
 
2.3.2d Monocyte specific staining with Ly6C antigen staining 
Fresh frozen liver sections were thawed to room temperature and, after washing 
three times 3 minutes each with TBST (0.05% Tween-20), were incubated for 30 
minutes with FITC conjugated anti-Ly6C&G (eBioscience, USA, cat. num. 17-5932-
80) diluted to 1:400 in IP diluent to a concentration of 0.5µg/ml at room temperature in 
a humidified chamber. Anti-FITC:HRP antibody (Genway, USA, cat. num. 18-783-
77098) diluted to 1:200 in 20% NMS/TBST to concentration 2.5µg/ml was used as the 
secondary antibody. Following washing, the secondary antibody was applied to sections 
and the slides were incubated for 30 minutes at room temperature in a humidified 
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chamber. Negative and IgG2c κ isotype controls were included in the procedure. 
Staining was visualized with DAB (Dako, Denmark). DAB chromogen was diluted in 
IP diluent containing 18% sodium azide. Following 2 minutes incubation with the 
chromogen solution, slides were counterstained in haematoxylin, dehydrated and 
coverslipped.  
 
2.3.2e Detection of hepatocellular regeneration with Proliferating Cell 
Nuclear antigen (PCNA) staining 
Paraffin-embedded liver sections were rehydrated, followed by antigen retrieval 
in a laboratory pressure cooker (BioCare, USA) in Tris buffer (pH9) at 2 atm and 125ºC 
for 30 sec. After washing three times in TBST wash buffer for 3 minutes each, sections 
were blocked with 20% NGS/TBST blocking solution for 20 min. Sections were then 
incubated for 1 hour with a polyclonal rabbit anti-PCNA primary antibody (Abcam, 
UK, cat. num. ab2426), diluted 1:500 in 1% NGS/TBST to a concentration of 0.4µg/ml. 
A 5 min incubation in 3% H2O2/CH3OH precedes incubation with biotinylated anti-
rabbit goat antibody diluted 1:300 in 1% NGS/TBST to a concentration of 3.33µg/ml 
(Dako, Denmark, E0432). Negative and rabbit IgG isotype controls were included in the 
procedure. Staining was visualized with the Vectastain ABC kit (Vector Laboratories, 
USA) and DAB (Dako, Denmark) as above. Slides were counterstained in 
haematoxylin, dehydrated and coverslipped. 
 
2.3.2f Detection of hepatocellular regeneration with Ki-67 antigen staining 
Paraffin-embedded liver sections were rehydrated. Antigen retrieval was 
performed in Tris buffer (pH9) using a laboratory pressure cooker (BioCare, USA) at 
2atm and 125ºC for 30sec. After 3 washes in TBST buffer for 3 minutes each, the 
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sections were blocked with 1 drop of avidin solution (Dako, Denmark, cat. num. 
X0590) for 30 minutes and 1 drop of biotin solution for 10 minutes (Dako, Denmark, 
cat. num. X0590), followed by blocking in 20% NGS/TBST (0.01% Tween-20) 
blocking solution for 20 min. Sections were then incubated for 1 hour in rabbit anti-
Ki67 primary antibody (Abcam, UK, cat. num. ab15580), diluted 1:200 in 1% 
NGS/TBST to a concentration of 5µg/ml. A 5 min incubation in 3% H2O2/CH3OH 
precedes incubation with biotinylated anti-rabbit goat antibody diluted 1:300 in 1% 
NGS/TBST to a concentration of 3.33µg/ml (Dako, Denmark, E0432). Negative and 
rabbit IgG isotype controls were included in the procedure. Staining was visualized with 
the Vectastain ABC kit (Vector Laboratories, USA) and DAB (Dako, Denmark) as 
above. Slides were counterstained in haematoxylin, dehydrated and coverslipped. This 
staining protocol was noted for its sensitivity to two factors. First, sections must be 
stored at 4°C between cutting and staining. The Ki-67 epitope may decay in slides 
stored at room temperature for prolonged periods of time. Secondly, wash buffers used 
in this protocol should contain no more than 0.01% Tween-20, as antibody binding can 
be disrupted by higher concentrations.  
 
2.3.2g Detection of apoptosis by staining for cleaved Caspase-3 antigen  
Paraffin-embedded liver sections were rehydrated, then boiled in a plastic 
Copplin jar in the microwave oven in citrate buffer at pH6 for 15 minutes at 75W to 
retrieve antigen. After cooling to room temperature and washing 3 times in dH2O for 3 
minutes each, the slides were left for 10 minutes in 3% H2O2/CH3OH. After a further 3 
washes in dH2O for 3 minutes each, sections were incubated in 5% NGS/TBST 
blocking solution for 30 minutes at room temperature in a humidified chamber. The 
sections were incubated at 4ºC overnight with polyclonal rabbit anti-cleaved caspase-3 
primary antibody (Cell Signalling Technology, Beverly, USA, cat. num. #9661) diluted 
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1:1000 in SignalStain® Antibody Diluent (Cell Signalling Technology, Beverly, USA, 
cat. num. #8112) to a concentration of 1µg/ml. After washing 3 times in TBST buffer 
for 5 minutes each, detection was performed by incubation with of 2 drops of 
SignalStain® Boost IHC Detection Reagent (Cell Signalling Technology, USA, cat. 
num. #8114) for 30 minutes. Rabbit IgG isotype control and negative control (no 
antibody) were included in the procedure. The sections were washed in dH2O, 
counterstained in haematoxylin, dehydrated and coverslipped. 
 
2.3.2h Detection of hepatic progenitor cells (oval cells) with an antibody 
against MIC1-1C3 
Fresh frozen liver sections were thawed to room temperature. After washing 3 
times in TBST (0.05% Tween-20) for 3 minutes each, the sections were treated with 
0.3% H2O2/TBST buffer for 15 minutes to block endogenous peroxidase activity. After 
a further wash, 10% NGS diluted in 1% BSA/TBS blocking solution was applied for 20 
min. Primary rat anti-mouse MIC1-1C3 (Thermoscientific, USA, cat. num. MA5-
16136) monoclonal antibody was diluted to 5µg/ml in 1% BSA/TBS, applied to the 
sections and allowed to incubate overnight at 4°C. After a wash, goat anti-rat:HRP 
secondary antibody (Abcam, USA, cat. num. ab97057) diluted 1:2500 in 1% BSA/TBS 
was applied for 1 hour. DAB (Dako, Denmark) was used to visualize staining, as above. 
Negative control and IgG2a isotype controls were included in the procedure. Slides 
were counterstained in haematoxylin, dehydrated and coverslipped.  
 
2.3.3 Immunofluorescence staining 
Anti-HMGB1 staining 
Freshly-cut frozen tissue sections were allowed to air-dry for 1 hour and then 
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fixed in ice cold 4% paraformaldehyde solution for 20 minutes. No surfactants were 
added to the wash buffers or diluent solutions to avoid extracting lipids from the liver 
tissue and degrading tissue quality. The sections were blocked in 20% NMS/TBS 
blocking solution with 0.3M glycine for 30 minutes. After 3 washes in TBS for 5 
minutes each with stirring, rabbit polyclonal anti–HMGB1 (Sigma, cat. H9664) diluted 
to 2μg/ml in 1% BSA/10% NMS/TBS was applied to the sections and incubated for 4ºC 
overnight in a dark and humid chamber. After 3 washes in TBS for 5 minutes each, 
donkey anti-rabbit:AlexaFluor594 (Abcam, UK, cat. ab150064) diluted to 1:200 in 1% 
BSA/10% NMS/TBS (concentration 1µg/ml) and phalloidin-Alexa488 (Life 
technologies, USA, cat. num. A12379) 5µl/section diluted in 1% BSA/10% NMS/TBS 
were applied to sections and incubated for 1 hour at room temperature in a dark, humid 
chamber. After further washing, freshly prepared Hoechst 33342 nuclear dye (Life 
technologies, USA, cat. 33342) diluted to 2µg/ml in TBS was applied to the sections 
and incubated for 15 minutes at room temperature in a dark, humid chamber. Slides 
were quickly rinsed in TBS to remove excess dye and 1 drop of Fluoromount G 
(Southern biotech, USA, cat. 0010-01) was applied to the sections before placing the 
coverslips. The slides were then allowed to dry in the dark for 5 minutes before clear 
nail polish was applied to seal the coverslips and then left to dry for a further 20 
minutes. Negative control and rabbit IgG isotype controls were included in the 
procedure. The slides were imaged immediately.  
 
The list of antibodies and dilutions used in this project is provided in Table 2.2. 
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2.3.4 Imaging stained sections using wide field microscopes 
Stained slides were photographed under x40, x100, x200 and x400 
magnifications using an Olympus BX-60 (Olympus, Japan) with Olympus DP72 camera 
(Olympus, Japan). Ten high powered viewing fields (HPF) (x400) were selected at 
random for cell counting. Manual counting of positive cells were done using Image J 
open source imaging software (NIH, USA). Cell counts were averaged for each animal. 
The average count for each of the biological replicates was used in further analysis. 
IF slides were imaged at x100 and x400 magnifications using a Nikon Ni-E 
microscope with Nikon NIS Elements Analyst software (Nikon, Japan).  
  
2.4 Serum assays 
2.4.1 Biochemical determination of Alanine aminotransferase and 
Aspartate aminotransferase 
One aliquot of the serum was kept on ice for biochemical analysis on the day of 
collection. Samples were tested for Alanine aminotransferase (ALT) and Aspartate 
aminotransferase (ASL) levels to determine the liver tissue damage using a Cobas 
Integra 400 bioanalyser (Roche Diagnostics, Switzerland). The sera were diluted 1:2 in 
PBS before testing and results thus obtained were well within the dynamic range of the 
assay. Results were adjusted according to the dilution factor. Serum was analysed on the 
day of collection to avoid freeze-thawing. 
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 Primary antibody 
Clone name 
Primary antibody 
Concentration 
Secondary antibody 
Clone name 
Secondary 
antibody 
Concentration 
Neutrophil staining 
with anti-Ly6B.2 
antibody 
Rat anti-Mouse Ly-
6B.2 monoclonal 
antibody, clone 7/4 
(AbD Serotec, UK, 
cat. num. 
MCA771A) 
10μg/ml diluted 
in 1% 
NGS/TBST 
Biotinylated polyclonal 
goat anti-rat antibody 
(BD Biosciences, USA, 
cat. num. 559286) 
3.33μg/ml 
diluted in 1% 
NGS/TBST 
 
Isotype control Rat IgG2a k Isotype 
antibody 
(eBioscience, USA, 
cat. num. 13-4321)  
10μg/ml diluted 
in 1% 
NGS/TBST 
  
Macrophage staining 
with anti-F4/80 
antibody 
FITC conjugated rat 
anti-mouse F4/80, 
clone BM8 
(eBioscience, USA, 
cat. num. 11-4801-
81) 
1.25µg/ml diluted 
in IP diluent 
Anti-FITC antibody 
conjugated with 
horseradish peroxidase 
(Genway, USA, cat. 
num. 18-783-77098) 
7.5µg/ml 
diluted in 
20%NMS/IP 
diluent 
 
Isotype control Rat IgG2a k Isotype 
antibody 
(eBioscience, USA, 
cat. num. 11-4321) 
1.25μg/ml diluted 
in IP diluent 
  
Macrophage staining 
with anti-CD68 
antibody 
Rat anti-mouse 
CD68 antibody, 
clone 1210 
(AbD Serotec, UK, 
cat. num. MCA1957) 
2.5µg/ml diluted 
in 1% NHS/PBS 
Polyclonal biotinylated 
secondary goat anti-rat 
(BD Biosciences, USA, 
cat. num. 559286) 
2.5µg/ml 
diluted in 1% 
NHS/PBS 
Isotype control Rat IgG2a k Isotype 
antibody 
(eBioscience, USA, 
cat. num. 13-4321) 
2.5μg/ml diluted 
in 1% NHS/PBS 
  
Monocyte staining 
with anti-Ly6C 
FITC conjugated rat 
anti-mouse Ly6C, 
clone RB6-8C5 
(eBioscience, USA, 
cat. num. 17-5932-
80) 
0.5µg/ml diluted 
in IP diluent 
Anti-FITC:HRP 
antibody (Genway, 
USA, cat. num. 18-783-
77098) 
2.5µg/ml 
diluted in 20% 
NMS/TBST 
Isotype control Rat IgG2c k isotype 
(Biolegend, USA, 
cat. num 400702)  
0.5µg/ml diluted 
in IP diluent 
  
Proliferating Cell 
Nuclear antigen 
staining (PCNA) 
Rabbit Anti-PCNA 
antibody, polyclonal 
(Abcam, UK, cat. 
num. ab2426)  
0.4µg/ml diluted 
in 1% 
NGS/TBST 
Biotinylated anti-rabbit 
goat antibody (Dako, 
Denmark, E0432) 
3.33µg/ml 
diluted in 1% 
NGS/TBST 
Isotype control Rabbit IgG isotype 
control (Dako, 
Denmark X0903) 
0.4µg/ml diluted 
in 1% 
NGS/TBST 
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Ki-67 antigen 
detection stain  
Rabbit anti-Ki67 
antibody, polyclonal 
(Abcam, UK, cat. 
num. ab15580) 
5µg/ml diluted in 
1% NGS/TBST 
Biotinylated anti-rabbit 
goat antibody (Dako, 
Denmark, E0432) 
3.33µg/ml 
diluted in 1% 
NGS/TBST 
Isotype control Rabbit IgG isotype 
control (Dako, 
Denmark X0903) 
5µg/ml diluted in 
1% NGS/TBST 
  
Cleaved Caspase-3 
antigen detection stain 
Rabbit anti-cleaved 
caspase-3 primary 
antibody, polyclonal 
(Cell Signalling 
Technology, 
Beverly, USA, cat. 
num. #9661) 
1µg/ml diluted in 
SignalStain 
Antibody Diluent 
SignalStain® Boost IHC 
Detection Reagent (Cell 
Signalling Technology, 
USA, cat. num. #8114) 
2 drops 
Isotype control Rabbit IgG isotype 
control (Dako, 
Denmark X0903) 
1µg/ml diluted in 
SignalStain 
Antibody Diluent 
  
Hepatic progenitor 
(oval) cell antigen 
staining 
Rat anti-mouse clone  
MIC1-1C3,  
(Thermoscientific, 
USA, cat. num. 
MA5-16136) 
5µg/ml diluted in 
1% BSA/TBS 
Goat anti-rat:HRP 
secondary antibody, 
(Abcam, USA, cat. num. 
ab97057) 
0.25µg/ml 
diluted in 1% 
BSA/TBS 
Isotype control Rat IgG2a k isotype 
antibody (AbD 
Serotec, UK, cat. 
num. MCA1212) 
5µg/ml diluted in 
1% BSA/TBS 
  
HMGB1 staining 
using 
immunofluorescent 
method 
Rabbit polyclonal 
anti–HMGB1 
(Sigma, cat. num. 
H9664) 
2ug/ml diluted in 
1% BSA/10% 
NMS/TBS 
Donkey anti-
rabbit:AlexaFluor594 
(Abcam, UK, cat. num. 
ab150064), 
 Phalloidin Alexa488 
(Lifetech, USA, cat. 
num. A12379)  
1µg/ml diluted 
in 1% 
BSA/10% 
NMS/TBS 
5µl/section 
diluted in 1% 
BSA/10% 
NMS/TBS 
Isotype control Rabbit IgG isotype 
control (Dako, 
Denmark X0903) 
2ug/ml diluted in 
1% BSA/10% 
NMS/TBS 
  
Table 2.2 List of antibodies used in immunohistochemical and 
immunofluorescence staining procedures. 
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2.4.2 Inflammatory cytokine and chemokine ELISA  
The MILLIPLEX® MAP Mouse Cytokine/Chemokine Magnetic Bead Panel 
(Merck, USA, cat. MCYTOMAG-70K) was used to quantify the following cytokines 
and chemokines: TNFα, RANTES, MIP-2, MIP-1b, MIP-1a, MCP-1, KC, IP-10, IL-17, 
IL-15, IL-13, IL-12p70, IL-12p40, IL-10, IL-9, IL-7, IL-6, IL-5, IL-4, IL-2, IL-1β, IL-
1α, IFNγ, GM-CSF and G-CSF. The assay was performed according to the 
manufacturer’s protocol by Ms. Moumita Paul. The proprietary technology of this kit 
allows colour coded microspheres with two fluorescent dyes to specifically bind to the 
target antigen through an attached primary antibody. A biotin conjugated antibody is 
then applied for signal amplification. This antibody complex is further amplified 
through incubation with Streptavidin-PE and a reporter molecule complex. The 
microspheres are passed through a laser which excites the internal dyes which identify 
the microsphere set. A second laser excites PE, the fluorescent dye on the reporter 
molecule. Finally, high-speed digital-signal processors identify each individual 
microsphere and quantify the result of its bioassay based on the intensity of fluorescent 
reporter signals. 
 
2.4.3 esRAGE ELISA  
A human esRAGE ELISA Kit (B-Bridge International, USA, cat. K1009-1) was 
used for quantitative determination of human esRAGE concentrations in mouse serum. 
The kit uses a sandwich ELISA format. The microplate is pre-coated with the 
anti-esRAGE capture antibody, which is specific for the unique 20 amino acids at the C-
terminus of esRAGE. The assay was performed by Ms. Moumita Paul according to the 
manufacturer’s protocol. In brief, 20µl of diluted samples or standards were added to 
each well with 100µl of esRAGE:HRP antibody and incubated at 4°C for 20 hours. 
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After incubation, the plates were washed with PBST with BSA (provided with the kit). 
Tetramethylbenzidine and hydrogen peroxide were added as substrates for colour 
development and the reaction was stopped after 30 minutes. Absorbance was measured 
at 450nm on a FLUOstar Omega plate reader (BMG Labtech, Germany). The assay was 
designed for the human physiological range of esRAGE concentrations. Overexpression 
of esRAGE in mouse liver led to serum levels reaching 5000 times the upper dynamic 
range of the assay (0.05-3.2ng/ml). Due to this, serum samples were diluted by 1:12500-
1:62500 ratios. Resulting readings were modified accordingly to account for the dilution 
factor.  
 
2.4.4 HMGB1 ELISA  
Serum HMGB1 concentration was measured using an HMGB1 ELISA assay kit 
(IBL International, Germany, cat. ST51011). HMGB1 ELISA is a sandwich-enzyme 
immunoassay for quantitative determination of HMGB1 in serum and plasma. The 
wells of the microtiter strips are coated with purified anti-HMGB1 antibody. HMGB1 in 
the sample binds specifically to the immobilized antibody and is recognized by a second 
enzyme-linked antibody. After reaction with the substrate, the HMGB1 concentration is 
determined by colour intensity. 10µl of sample was added to each well and incubated at 
37°C for 24 hours. After incubation, the plates were washed with PBST, and 100µl of 
HRP-conjugated secondary antibody was added. After 2 hours at room temperature, 
wells were washed and the signal developed using tetramethylbenzidine and hydrogen 
peroxide. The colour development reaction was stopped after 30 minutes. Absorbance 
was measured at 450nm on a FLUOstar Omega plate reader (BMG Labtech, Germany). 
The assay was designed for the human physiological HMGB1 range. Serum levels of 
HMGB1 sometimes reached 5 times the limit of the upper dynamic range of the assay 
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(2.5-80ng/ml). Due to this, serum samples were diluted 1:5 prior to assay. The resulting 
measurements were modified to take account of the dilution factor. 
 
2.5 Gene expression analysis 
2.5.1 RNA extraction 
Lab coat, facemasks and gloves were used throughout the procedures to avoid 
contamination by RNAse. Two different methods were used to isolate RNA. The first 
method was the acid-phenol-guanidinium method with RNAqueous Mini-kit column 
purification, Ambion (Applied Biosystems, Carlsbad, CA). This method was employed 
for the analyses presented in Chapter 3. Following this, the Isolate II RNA Mini Kit 
(Bioline, UK) was used to extract RNA according to the manufacturer`s instructions. 
The second method was used for the assays in Chapters 4 and 5. 
The acid phenol-guanidinium method was carried out as follows: lysis buffer 
was prepared using 2-mercaptoethanol and guanidinium isothiocyanate. Frozen tissue 
was placed into the lysis buffer and before thawing, the tissue was homogenised using a 
tissue homogeniser (T10 Basic Ultra Turrax, IKA, Germany) at speed number 4. The 
homogenate was then sheared by drawing through a 26G needle and syringe 15 times. 
Afterwards, 70µl of 2M sodium acetate and 700µl of RNA-grade phenol solution 
(Sigma, USA) were added in sequence and mixed. The solution was vortexed and left 
on ice for 5 minutes. 140µl of chloroform/isoamyl alcohol was added and vortexed for 
30 seconds. The solution was then left on ice for 15 minutes and centrifuged at 11000g 
for 45 minutes at 4°C. Subsequently, the upper phase of the solution was carefully 
removed into a new tube and 800µl of 65% ethanol was added. Then, 700µl of this 
solution was added to RNAqueous filter in the collection tube. The tube was centrifuged 
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for 15 seconds and the remainder of the solution centrifuged in the same manner and the 
flow-through was discarded. Twice, 500ml of the wash solution #2/3 (provided with the 
kit) was added to the column and the tube centrifuged. The filter was placed into a new 
collection tube and heated to 100°C for 30 seconds, following which 180µl of elution 
solution (preheated to 100°C) was added. The tube was then centrifuged for 30 seconds 
at 11000g at 4°C. 2µl of glycogen, 12µl of 7.5M ammonium acetate and 390µl of 100% 
ethanol were added and left overnight at -20°C. The next day the solution was 
centrifuged at 11000g at 4°C for 45 minutes. The supernatant was removed by gently 
pipetting all but the last 5µl. Then the last trace of supernatant was removed, after brief 
centrifugation, with a fine pipette. The resulting pellet was carefully handled so as not 
to be disrupted by the pipette tip. The pellet was washed with 1.5ml 70% ethanol and 
centrifuged at 11000g for 10 minutes. Supernatant was removed once again as above. 
Then the pellet is dissolved in 30µl of DEPC water for concentration determination. 
The Isolate II RNA Mini Kit (Bioline, UK) protocol was performed as follows: 
the tissue homogeniser (T10 Basic Ultra Turrax, IKA, Germany) at speed number 4 was 
used to homogenise the snap frozen, 1-2mm3 tissue in the lysis buffer. Lysis buffer was 
prepared by adding 10µl β-Mercaptoethanol to 1ml Lysis solution from the kit, and 
600µl of lysis buffer was used per sample. The homogenised tissue was then placed in 
an Isolate II filter and centrifuged for 1 minute at 11000g. Afterwards, this homogenate 
was further sheared 15 times by drawing through a syringe with a 26G hypodermic 
needle. Next, 600µl of freshly prepared 70% ethanol solution was added to the 
homogenate and centrifuged for 30 seconds at 11000g, loading no more than 600µl onto 
the filter at a time. The filter is placed into a new 2ml collection tube (supplied with the 
kit) and 600µl MEM membrane desalting buffer (supplied with the kit) was added. The 
solution was centrifuged for 1 minute at 11000g and 4°C. DNAse solution was prepared 
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by adding 10µl of reconstituted DNAseI to 90µl of reaction buffer RDN (supplied with 
the kit). It was mixed well without vortexing and placed onto to the centre of the Isolate 
II filter silica membrane. The membrane was incubated with the enzyme for 30 minutes 
at room temperature to remove any traces of DNA contamination. After incubation, 
200µl of wash buffer number 1 (RW1) was added and the filter was centrifuged for 30 
seconds at 11000g and 4°C. Following this step, the filter was placed into a new 2ml 
collection tube (supplied with the kit). 600µl of wash buffer 2 (RW2) was added and the 
filter was centrifuged for 30 seconds at 11000g and 4°C. Flow through was discarded 
and the filter was placed into the same collection tube. Then, 250µl of RW2 was added 
and centrifuged for 2 minutes at 11000g and 4°C to dry the silica membrane completely. 
Later, the filter was placed into a 1.5ml collection tube (supplied with the kit) and 50µl 
of DEPC treated water was added directly onto the silica membrane and incubated for 1 
minute at 4°C. The filter was then centrifuged for 1 minute at 11000g. 2μl of RNA was 
diluted in 18µl DEPC treated water for concentration determination.  
 
2.5.2 Assessment of RNA concentration, integrity and contamination 
RNA concentration was determined by optical absorbance using a NanoDrop 
1000 spectrophotometer (Thermo Scientific, USA) and RNA integrity was determined 
using an Agilent 2100 Bioanalyzer (Agilent technologies, USA) according to the 
manufacturer’s protocols.  
After the concentration of the RNA has been determined, the RNA was 
aliquoted into vials at 200ng/µl concentration, and stored in liquid nitrogen until further 
use.  
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The Agilent 2100 Bioanalyzer RNA kit consists of chips and reagents that are 
designed for analysis of RNA fragments. The RNA chip contains an interconnected set 
of microchannels that is used for the separation of nucleic acid fragments based on their 
size as they are driven through it electrophoretically. A 1µl tester sample of RNA/DEPC 
water solution, along with a nucleic base ladder sample, gel-dye mix and marker, were 
loaded onto a RNA chip and the chip was primed using a chip priming station (supplied 
with the equipment). To prepare the gel-dye mix, the dye concentrate (supplied with the 
equipment) was brought to room temperature for at least 30 minutes, then vortexed for 
10 seconds, centrifuged briefly and 1µl of dye was added to 65μl of filtered gel 
(supplied with the equipment). The gel-dye mix is vortexed thoroughly and centrifuged 
at 13000g for 10 minutes. The samples, gel-dye mix, ladder and markers are loaded 
onto the chip in the manner prescribed by the manufacturer. Machine readings give a 
measurement of RNA integrity number, based on the electrophoretic profile. RNA 
integrity numbers of 7 and above were accepted as indicating intact RNA for further 
analysis (Figure 2.2). 
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Figure 2.2 Absorbance spectrum of total RNA generated from 
electrophoresis in the Bioanalyzer. The first peak in the graph shows a 
distinct 18S ribosomal band, the second peak shows a distinct 28S 
ribosomal band. 
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2.5.3 cDNA synthesis 
1µl of Oligo dT at 50µM was added to 2 μl of dNTP mix at 10µM, 10µl of 
aliquoted RNA and 7 µl of dH2O and incubated at 65ºC for 5 min. Then, 4µl of first 
buffer strand, 1µl of 0.1M DTT (all from Roche, Switzerland) and Superscript III (Life 
technologies, USA) were added and, incubated initially for 5 min at 25ºC, then for 60 
min at 50ºC, for 15 min for 70ºC and, finally held at 4ºC. After completion of the 
reaction, the cDNA was diluted 1:5 with 80µl of DEPC water. Then, 5µl of the cDNA 
product was aliquoted into each well of a PCR plate (Roche, Switzerland) using a 
robotic liquid handling system the Tecan Evo75 (Tecan, Switzerland) and stored at -
80°C until further use. The protocol for Tecan Evo75 robot operation to aliquot cDNA 
was written and operated by Ms. Moumita Paul, whose help is gratefully acknowledged 
here. Two cDNA samples were synthesized from RNA in two separate procedures. -RT 
control samples received mastermix solution without reverse transcriptase. RNA control 
samples received no RNA aliquot. A no template (water) control was also included in 
the PCR plate layout.  
2.5.4 Real-time quantitative Polymerase Chain Reaction  
The following formula was used to prepare each PCR reaction (Table 2.3) 
Ingredients Volume (µl/reaction) 
Forward and reverse primer mix 
0.5 µl 
Probe 
SensiMix II probe (Bioline, UK) 5 µl 
dH2O 0.5 µl 
cDNA 4 µl 
Total volume per well 10 µl 
Table 2.3 RT-qPCR master mix content 
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Two types of primers and probes were used in this project: in-house designed 
forward and reverse primers and probes synthesized by Sigma-Aldrich (Sydney, 
Australia) and commercially available primers-on-demand produced by Applied 
Biosystems (Life technologies, USA). Commercial primers-on-demand were produced 
according to a proprietary method and no nucleotide sequence is available. Reference 
gene catalogue numbers are given in such instances (Table 2.4). The working solution 
of primers was made up from a mixture of reverse and forward primers at 30µM 
concentration each. The working concentration of the probe was 20µM. All aliquots 
were stored at -20°C.  
 The LightCycler 480 (Roche, Switzerland) machine was used to obtain RT-
qPCR readings. Cycling parameters were as follows: an initial denaturation step at 95°C 
for 10 minutes was followed by 55 cycles of melting for 10 seconds at 95°C and 
annealing-extension for 1 minute at 60°C. The starting template concentration was 
obtained from and analysed on the LightCycler480 software release version 1.5.0.39 
(Roche, Switzerland). The software incorporates the CtsampleX of the gene of interest into 
the linear regression formula calculated from the gene specific Standard Curve. PCRs 
were repeated for each cDNA synthesis and the starting template concentration of the 
two runs were averaged to yield data for further analysis. Expression of the 
housekeeping gene Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was 
measured with gene specific Taqman primers and probes, and expression of other genes 
of interest was normalized using the following formula for all cDNA samples: 
 
𝐺𝑒𝑛𝑒 𝑜𝑓 𝐼𝑛𝑡𝑒𝑟𝑒𝑠𝑡 𝐸𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 (𝑠𝑎𝑚𝑝𝑙𝑒𝑋)
𝐻𝑜𝑢𝑠𝑒 𝑘𝑒𝑒𝑝𝑖𝑛𝑔 𝐺𝑒𝑛𝑒 (𝑠𝑎𝑚𝑝𝑙𝑒𝑋)
=
𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑓𝑜𝑟 𝐺𝑒𝑛𝑒𝑠 𝑜𝑓 𝐼𝑛𝑡𝑒𝑟𝑒𝑠𝑡  
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Gene Sequence (5` to 3`) 
Γc (rat) Forward- 5′ -TGG TGC AGT ACC GGA GCA A 
Reverse- 5′ -GGA GAA TCT AGG CTC ATG ATC CA 
Probe- 5′ -ATT TGT TCC GTC CAG CTT CGA TCT CG 
Glyceraldehyde 3 -phosphate 
dehydrogenase (GAPDH) 
Forward- 5’ -CAG CAA TGC CTC CTG TAC CA 
Reverse- 5’ -GAT GCC GAA GTT GTC ATG GA 
Probe- 5’ -AAC TGC TTG GCA CCC CTG GC 
High Mobility Group Box 1 (HMGB1) Forward- 5’ -TGG GCG ACT CTG TGC CTC 
Reverse- 5’ -GCC TCT CGG CTT TTT AGG ATC 
Probe- 5’ -ATC TCT CCC AGT TTC TTT GCA ACA 
TCA  
IL-1β (mouse) Mm 00434228_m1 
IL-2 (rat) Forward- 5’ -CAG GAT GCT CAC CTT CAA ATT TT 
Reverse- 5’ -GCG AGA GGT CCA AGT TCA TC 
Probe- 5’ -TTG CCC AAG CAG GCC ACA GAA TTG 
IL-2Rα (rat) Forward- 5′ -TCA CCA TAG TAC CCG GCT GTT 
Reverse- 5′ -GGG CTT TGA ACG TGG CAT T 
Probe- 5′ -TCC GGT GGG TCA TAC AGA CAC AGC 
TCT 
IL-2Rβ(rat) Rn 00682353_m1 
IL-4 (rat)  Forward- 5’ -CAG AAA AAG GGA CTC CAT GCA 
Reverse- 5’ -GCT CGT TCT CCG TGG TGT TC; 
Probe- 5’ -AGA TGT TTG TAC CAG ACG TCC TTA 
CGG CAA 
IL-4Rα (rat) Forward- 5′ -CCT TTC GGG TCT GCT TCT C 
Reverse- 5′ -GGC TTC GGG TCT GCT TCT C 
Probe- 5′ -ACA CGA AGG TGC TCC T 
IL-5 (mouse) Mm 00439646_m1 
IL-6 (mouse) Mm 00446190_m1 
IL-7 (rat) Forward- 5′ -CCT TTG GGA GTG TGC TGA TGA 
Reverse- 5′ -TTG GGC AAT CAC TAT CAG TTC CT 
Probe- 5′ -AGC ATC AAT CAA CTG GAC AA 
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IL-7Rα (rat) Rn 01402421_m1 
IL-9 (rat)  Rn 01448718_m1 
IL-9Rα (rat) Rn 00566710_m1 
IL-10 (mouse) Mm 00439614_m1 
IL-15 (rat) Forward- 5′ -CCT TGC AAA CAG CAC TCT GTC TT 
Reverse- 5′ -AAC TCT GCA AAA ACT CCG TGA AGT 
Probe- 5′ -CAT TCC TTG CAG CCA GAC TCT ATT 
ACA TTC TTG 
IL-15Rα (rat) Rn 01487183_m1 
IL-21 (rat) Rn 01755623_m1 
IL-21Rα (rat) Rn 01510416_m1 
KC (mouse) Forward- 5’ -TTG GTT CAG AAA ATT GTC CAA 
AAG 
Reverse- 5’ -CAG GTG CCA TCA GAG CAG TCT 
Probe- 5’ -TGC TAA AAG GTG TCC CCA AGT AAC 
GGA 
MCP1 (mouse) Forward- 5’ -GAG CAT CCA CGT GTT GGC T 
Reverse- 5’ -TGG TGA ATG AGT AGC AGC AGG T 
Probe- 5’ -CAC CAG CAG CAA GTG TCC TAA AGA 
A  
RAGE (mouse) Forward- 5’ -GGA CCC TTA GCT GGC ACT TAG 
Reverse- 5’ -GAG TCC CGT CTC AGG GTG TCT 
Probe- 5’ -ATT CCC GAT GGC AAA GAA ACA CTC 
GTG 
T cell receptor β (rat) Forward- 5′ -AGG ACT CAC CCA AAC CTG TCA 
Reverse- 5′ -TGC TGA GGT AAT CCC ACA ATC TG 
Probe- 5′ -CCA GGC CTC CGC ACT GAT GTT CTG T 
TLR4 (mouse) Mm 00445273_m1 
Tumor Necrosis Factor α (TNFα) 
(mouse) 
Mm 00443258_m1 
Table 2.4 Sequences and catalogue numbers of Forward and reverse primers and probes 
used in RT-qPCR reactions.  
    
 
92 
 
2.6 Cloning and subcloning of esRAGE cDNA 
A cDNA encoding human esRAGE was obtained in two different ways. Firstly, 
esRAGE was amplified from normal human lung explanted in the course of resecting a 
pulmonary tumor. Amplification primers were: forward CAC CAT GGC AGC CGG 
AAC AGC AGT TGG AGC and reverse: GCG GAT ATC CTT GTT GAC CAT CCC 
CCC AG. PCR products were run on 1% agarose gel to confirm that a band of expected 
size was amplified, then sequenced using CAC CAT GGC AGC CGG AAC AGC AGT 
TGG AGC.  
In parallel, a codon-optimised cDNA sequence for esRAGE had been ordered 
from GeneArt (Life technologies, USA). 5µg of the pMA plasmid containing this 
cDNA was resuspended into 50µl of ultrapure water and then transformed into SURE-2 
competent E.Coli (Stratagene, USA) and allowed to grow on agar plates. A few 
colonies from the plate were selected for Mini-preparation and colony PCR using the 
Quick Mini-prep Kit (Invitrogen, USA) to verify that the plasmids contained the 
esRAGE cDNA. Once the inserts were verified, a colony was selected for Maxi-
preparation. The plasmid DNA concentration was estimated by measuring absorbance at 
260nm on a Nanodrop spectrophotometer (Thermo Scientific, USA).  
Restriction enzyme digestion with Not1 (New England Biolabs, UK) and 
EcoRV (New England Biolabs, UK) and agarose gel electrophoresis confirmed the 
presence of a band running at the expected size of 1113 base pairs. The esRAGE insert 
was amplified from the maxi-prepared plasmid DNA using esRAGE-specific primers as 
above, then both the GeneArt sequence and the native sequence were TOPO cloned into 
pcDNA3.2 (Invitrogen, USA), a mammalian expression vector. The pcDNA3.2 
plasmids containing each of the esRAGE cDNAs were then transformed into one shot 
Top-10 E.Coli. Correct sequencing was confirmed once again with Mini-preparation 
    
 
93 
 
and PCR. Following this, expression of the esRAGE protein from these constructs was 
tested in vitro by transfecting the mammalian cell line HEK293D with the pcDNA3.2-
esRAGE plasmid, collecting the supernatant at 48 and 72 hours after transfection and 
quantitating esRAGE using the commercially available human esRAGE sandwich 
ELISA (B-Bridge International, USA). The ELISA method is described above in “2.4.3 
esRAGE ELISA“. Protein expression in vitro was slightly higher from the GeneArt than 
from the native construct, and so the codon-optimised GeneArt construct was used in all 
further experiments. 
 
2.7 Production and packaging of rAAV 2/8-esRAGE and GFP constructs 
Recombinant Adeno-associated virus (rAAV) type 2/8-esRAGE and GFP 
vectors were produced by Ms. Moumita Paul, as described earlier [349]. In brief, 
packaging of rAAV 2/8 vectors involves a calcium phosphate triple transfection of the 
cell line HEK293D with the following plasmids: pAM2AA (encoding the gene of 
interest and the inverted terminal repeats of the AAV serotype 2 genome), p5E18VD2/8 
encoding the rep gene from AAV2 and the viral capsid protein from AAV serotype 8, 
and pXX6 which encodes adenoviral helper factors.  
To produce complementary sticky ends and ensure rapid directional ligation, the 
template expression vector pAM2AA-eGFP and PCR fragments of esRAGE were 
simultaneously digested with EcoRV and NotI to release esRAGE fragments, as well as 
to linearize the pAM2AA-eGFP vector.  
The digested pAM2AA and esRAGE fragments were run on 1% agarose gel and 
extracted using a Wizard Gel Extraction Kit (Promega, USA). These were the ligation 
products. The amount of PCR product used in the ligation was set at a 3:1 vector: insert 
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ratio, and the ligation was performed using Quick T4DNA Ligase (New England 
Biolabs, USA) in a 5µl volume for 5 minutes at room temperature.  
The products of the ligation were transformed into SURE-2 Supercomponent 
cells (Stratagene, USA). The transformed cells were plated onto agar plates with 
ampicillin (100µg/mL) at 2 different concentrations of 20µL and 200µL. A resistant 
colony was randomly selected for Mini-preparation and colony PCR to verify the 
sequence. Afterwards, correct clones underwent Maxi-preparation and then sequence 
confirmation. P5E18 and pXX6 were used along with pAM2AA-esRAGE for 
packaging. HEK293D cells were cultured at 37°C in 5% CO2 with DMEM medium 
supplemented with 10% fetal calf serum (FCS). These cells were seeded into 40x10cm2 
tissue dishes. The following day, the medium was refreshed in the morning and a triple-
transfection using calcium phosphate was performed 3 hours later. At 16 hours post-
transfection, standard medium was replaced with DMEM+2%FCS. Cells were then 
harvested 48 hours post-transfection and immediately stored at -80°C.  
Virions were separated from the cell lysate by caesium chloride gradient 
purification, and then concentrated. Vector quantification was performed using RT-
qPCR and vector was aliquoted at 5x1011 viral genome copies for future use.  
 
2.8 Injection of viral vector into the animal 
Aliquots of viral vectors were thawed on wet ice and reconstituted with 500µl 
sterile PBS per dose. The solution was drawn up into a syringe with a 21G hypodermic 
needle. The animal is anesthetised with inhaled Isoflurane in an enclosed chamber and 
restrained firmly in one hand, with the neck and back firmly stabilised to avoid needle 
damage. The needle is slowly inserted at the outer 2/3 of an imaginary line drawn 
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between the centre of the abdomen and the right hip joint and the piston is slowly but 
constantly pressed until the dose is injected.  
  
2.9 Statistical analysis 
GraphPad Prism v5.0 (Graphpad, La Jolla, USA) software was used for all 
statistical analysis. One-way ANOVA with the Bonferroni post-test or two-way 
ANOVA was used for comparison of three or more groups whiles the unpaired t-test or 
Mann-Whitney test were used to compare two groups.  
 The Mann-Whitney test was used in situations where the data were not normally 
distributed.  
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Chapter 3: Survival cytokines and the outcome of 
transplantation 
Signalling through the common gamma chain (γc) of cytokine receptors is 
obligatory for the survival of activated T cells [350]. Prosurvival effects of γc signalling 
are mediated through the upregulation of anti-apoptotic proteins such as Bcl-2 and Mcl-
1 (Reviewed in [351]). Interleukins (IL)-2, 4, 7, 9, 15 and 21, signal through receptors 
that consist of γc in association with an α chain that confers specificity for the individual 
cytokine (reviewed in [352, 353]). As a result, there is at least partial redundancy 
between the effects of each of these cytokines. The central role of γc in immune 
responses is highlighted by the observation that one form of severe combined 
immunodeficiency disease is due to a mutation in γc [353]. In the transplantation 
context, graft rejection is γc-dependant, and indefinite survival of a majority of islet 
allografts has been achieved after antibody blockade of γc signalling [351]. 
Different organs are not equally susceptible to rejection when transplanted 
across an identical MHC barrier. In particular, liver transplants are less likely to reject 
than hearts and kidneys and acceptance of a transplanted liver rapidly leads to donor 
specific tolerance [354]. The basis for the liver's ability to resist acute and chronic 
rejection has been extensively investigated, but remains incompletely understood. 
Spontaneous liver transplant tolerance depends on a number of factors including the 
liver's large population of passenger leukocytes [48, 49] and its ability to specifically 
kill CD8+ T cells by a process termed “suicidal emperipolesis” [50]. Other potential 
factors contributing to liver transplant acceptance are the large size of the liver, 
approximately 10 times larger than a heart or kidney [54], and the liver's ability to 
regenerate following injury.  
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Previous studies from our group demonstrated increased levels of apoptosis in 
the leukocyte infiltrate of tolerated PVG to DA liver grafts compared with that of 
kidney grafts in the same strain combination, which were destined to be rejected [355]. 
T cell apoptosis [356, 357] with consequent clonal deletion [41, 356, 358] appears to be 
a major mechanism of liver transplant acceptance. Differences in the ability of 
alloreactive T cells to survive and proliferate within grafts of different organs may 
reflect the availability of pro-survival cytokines within those organs, and the resultant 
extent of γc signalling in the T cells infiltrating each graft. Consequently, the aim of this 
part of the project was to compare expression of γc-signalling cytokines and their 
receptors in tolerant and rejecting models of organ transplantation across a constant and 
complete MHC barrier. To this end a well characterised rat model has been utilized 
where DA strain recipients of fully mismatched PVG strain grafts accept a liver 
transplant long-term without requiring any immunosuppression while heart or kidney 
transplants are rapidly rejected [54]. 
PVG strain donors and DA strain recipient rats were from the Animal Resources 
Centre, Perth, Australia. Animals were 200–300g in weight, male, and approximately 
12 weeks old at time of transplantation. Kidney, liver and heart transplantation was 
performed according to previously published methods [344-346] by Dr. Chuanmin 
Wang. Organs were collected 3, 5 and 7 days after transplantation (3 animals per time 
point) and normal PVG strain heart, kidney and liver tissue was also collected. Tissues 
were stored in liquid nitrogen prior to processing for RT-qPCR amplification. 
 The RNA was extracted using acid-phenol-guanidinium followed by column 
purification using the RNAqueous Mini-kit, Ambion (Applied Biosystems, Carlsbad, 
CA,USA) as previously described [359]. RNA was reverse transcribed with Superscript 
III (InVitrogen, Mulgrave, Australia) then amplified in a PCR reaction along with 
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serially-diluted cDNA which allowed construction of a standard curve and estimation of 
the relative level of gene expression in each sample.  
 
3.1 Similar levels of TCRβ and γc expression are found in tolerance and 
rejection 
Initial concentrations of T cells, quantified on the basis of TCRβ expression, and 
of γc in the normal tissues, were very low. Following transplantation, expression of 
these two receptor chains increased roughly in parallel (Figure 3.1). The level of TCRβ 
expression was similar in rejecting heart and kidney, and in accepted liver, with the 
exception of the peak of expression in kidney on day 5 (Figure 3.1a). Similarly, γc 
expression in the grafts increased progressively after transplantation, with no significant 
difference between rejection and tolerance (Figure 3.1b). 
  
    
 
99 
 
 
  
Figure 3.1 Infiltration with α/β T cells and expression of γc increases 
after transplantation. (a) The extent of infiltration by α/β T cells was 
assessed at the mRNA level and increased in rejection of kidneys and in 
hearts and acceptance of livers. (b) γc expression increased after 
transplantation in all three organs. The values obtained for mRNA 
expression in each sample were corrected for GAPDH expression. 
Graphs show the mean ±SEM of 3 replicate animals at each time point. 
Asterisks show results that are significantly different to liver. 
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3.2 Lower levels of IL-2 and IL-2Rα are associated with tolerance  
Interleukin-2 expression in the tolerated livers increased after transplantation to 
reach a modest peak at day 3 followed by a decline on days 5 and 7 (Figure 3.2a). In the 
rejecting hearts and kidneys, IL-2 expression increased to be significantly greater than 
that in tolerated livers on day 5. IL-2 expression was consistently lower in livers than in 
kidneys or hearts at all time points (Figure 3.2a). IL-2Rα expression increased markedly 
in kidney and to a lesser extent in heart and by day 5 both rejecting organs had 
significantly greater expression than tolerated liver (Figure 3.2b). IL-2Rβ expression 
increased in all organs after transplantation with no significant differences observed 
(Figure 3.2c). The ratio of IL-2/γc is an indicator of the amount of IL-2 mRNA 
compared to the amount of mRNA for its receptors. There was a moderate ratio of IL-
2/γc in all three normal tissues (Figure 3.2d). The ratio in transplanted liver was very 
low after day 3 and significantly less than in rejecting hearts.  
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Figure 3.2 Expression of IL-2 and IL-2Rα was significantly greater in heart or 
kidney rejection than in liver acceptance. (a) Expression of IL-2 mRNA in rejecting 
kidneys and hearts was greater than that in accepted livers on day 5 after 
transplantation. (b) IL-2Rα mRNA was expressed at higher levels in rejecting 
kidneys and hearts than in accepted livers on day 5. (c) IL-2Rβ, which is a 
component of both the IL-2 and IL-15 receptors, increased to a similar extent in all 3 
organs after transplantation. (d) The ratio of IL-2 mRNA to γc mRNA expression 
decreased to a greater extent in accepted livers than in rejected hearts on day 5. The 
values obtained for mRNA expression in each sample were corrected for GAPDH 
expression. Graphs show the mean ±SEM of 3 replicate animals at each time point. 
Asterisks show results that are significantly different to liver. 
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3.3 IL-4Rα and IL-7Rα levels indicate limited γc signalling in tolerance  
Expression of IL-4 increased considerably in rejecting heart and kidney samples 
on day 3, declining again by day 5 (Figure 3.3a). Conversely there was little change in 
IL-4 expression in tolerated liver, and IL-4 levels remained significantly less than those 
in rejecting kidney. IL-4Rα expression was significantly higher in normal liver than in 
normal heart but increased after transplantation in both hearts and kidneys while 
remaining unchanged in liver (Figure 3.3b). IL-7 increased markedly in rejecting 
kidneys on day 7 compared to the slight increase in hearts and livers (Figure 3.3c). IL-
7Rα increased to a significantly greater extent in tolerated livers than in rejecting hearts 
or kidneys (Figure 3.3d). Both IL-4Rα and IL-7Rα levels are known to be 
transcriptionally regulated by γc cytokine signalling, which augments levels of IL-4Rα, 
whilst reducing those of IL-7Rα [360]. Consistent with this pattern, IL-4Rα expression 
increased after transplantation in hearts and kidneys but not livers, while IL-7Rα was 
significantly greater in tolerated liver than in rejecting organs. 
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  Figure 3.3 Expression of IL-4, IL-4Rα and IL-7Rα mRNA is consistent with 
limited γc signalling in liver transplant acceptance. (a) IL-4 mRNA expression 
was greater in rejecting kidneys than in accepted liver. (b) IL-4Rα increased 
after transplantation in kidney and heart rejection but not in liver acceptance. 
(c) IL-7 was significantly higher in rejecting kidneys than in accepted livers. 
(d) IL-7Rα was higher in accepted livers than in rejected kidneys and hearts. 
The values obtained for mRNA expression in each sample were corrected for 
GAPDH expression. Graphs show the mean ±SEM of 3 replicate animals at 
each time point. Asterisks show results that are significantly different to liver. 
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3.4 IL-9, IL-15 and IL-21 are not associated with tolerance or rejection 
IL-9 was expressed at high levels in normal kidneys but was markedly reduced 
after kidney transplantation and by day 7 had dropped to the levels observed in normal 
or transplanted hearts and livers (Figure 3.4a). IL-9Rα was expressed in normal hearts 
but was barely detectable in normal kidney or liver (Figure 3.4b). After transplantation, 
IL-9Rα decreased in hearts and showed only transient or slight increase in livers and 
kidneys. There were no significant differences between any of the organs at any time 
after transplantation for IL-15 or IL-21 (Figure 3.4). IL-15 was expressed constitutively 
in all normal organs and its expression was not significantly altered after transplantation 
(Figure 3.4c). IL-15Rα was expressed at low levels in all normal organs and increased 
in all organs after transplantation (Figure 3.4d). The IL-15Rα level in rejecting organs 
was significantly higher than that in tolerated liver. IL-21 (Figure 3.4e) and its receptor 
(Figure 3.4f) were expressed at low levels in all three organs and increased to a similar 
extent in all after transplantation suggesting that there was no relationship between the 
level of expression of mRNA for IL-21 signalling components and the outcome of 
transplantation.  
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Figure 3.4 Expression of mRNA for IL-9, IL-15, IL-21 and their receptors after 
transplantation in rejection of kidneys and hearts and acceptance of livers. (a) IL-9 was 
expressed at high levels in normal kidneys but decreased rapidly after transplantation. 
(b) IL-9Rα was expressed in normal hearts but decreased after transplantation. (c) IL-
15 was expressed in all three normal organs and showed no significant differences after 
transplantation. (d) IL-15Rα increased to a greater extent in rejecting hearts than in 
accepted livers. (e) Expression of IL-21 increased to a similar extent in all three organs 
after transplantation. (f) IL-21Rα expression increased similarly in all three organs after 
transplantation. The values obtained for mRNA expression in each sample were 
corrected for GAPDH expression. Graphs show the mean ±SEM of 3 replicate animals 
at each time point. Asterisks show results that are significantly different to liver. 
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3.5 Discussion 
Different organs transplanted across the same MHC barrier are variably 
susceptible to rejection. Higher levels of apoptosis are found within the infiltrate of 
tolerated livers than within that of rejecting kidneys in the fully-mismatched rat strain 
combination, PVG donor to DA recipient [355, 357], suggesting that a relative 
deficiency in the ability of graft reactive T cells to survive and proliferate in the 
environment of the liver may contribute to liver transplant acceptance. Cytokine 
signalling through receptors utilising γc is crucial for T cell survival. In this study, we 
have determined the relative abundance of the various γc signalling cytokines and their 
receptors in hearts and kidneys undergoing rejection compared with that in tolerated 
livers in the PVG to DA model. While neither the extent of T cell infiltrate, nor the 
expression of γc itself were significantly different between tolerated liver transplants 
and rejecting heart grafts, the levels of several γc-signalling cytokines and their 
receptors were considerably greater in rejection than in tolerance. IL-2 and its receptor, 
IL-2Rα were expressed in rejecting hearts and kidneys at a greater level than in 
accepted livers. IL-4, but not its receptor, was expressed at higher levels in rejection 
compared to acceptance. IL-15 was constitutively expressed in all three organs and 
showed little difference in expression after transplantation, suggesting that it was not 
associated with transplant outcome. However, it is possible that the extent of IL-15 
signalling might be controlled at the receptor level, as there was less IL-15Rα, which 
completes the high affinity form of the receptor, in tolerated livers than in rejecting 
hearts or kidneys. Expression of the other components of the IL-15 receptor (IL-2Rβ 
and γc), was not significantly different between the three organs. There is, thus, an 
association between high expression of IL-2, IL-2Rα, IL-4 and IL-15Rα and rejection. 
Similarly, comparison of liver transplant acceptance with kidney or heart rejection in a 
mouse model showed reduced levels of IL-2, IFN-γ, perforin and Fas ligand in livers 
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[41]. In contrast to these, expression of IL-7Rα was significantly higher in tolerant 
livers than in rejecting hearts and kidneys. This is also consistent with our hypothesis as 
IL-7Rα expression is inversely related to the global level of γc-signalling received by T 
cells [360]. An alternative reason for increased expression of IL-7Rα in tolerated liver is 
that activation of T cells leads to their loss of IL-7Rα [361]. The higher levels of IL-7Rα 
seen in tolerated livers could therefore be due to either a reduced level of γc signalling 
or a lack of activation of T cells in the infiltrate or to a combination of both. IL-7, which 
is important for T cell survival but cannot be produced by T cells themselves [362] was 
increased markedly in rejecting kidneys on day 7 and much more modestly in rejecting 
hearts and accepted livers. Whether this IL-7 is the product of parenchymal cells, 
resident cells of non-parenchymal origin or infiltrating cells in the rejecting kidneys, 
and why its increase is confined to kidneys remains to be determined. 
IL-9 was constitutively expressed in normal kidney, but decreased by day 7 after 
transplantation to the virtually undetectable levels observed in livers and hearts. IL-9 is 
a Th2 cytokine which is involved in cross-talk between T cells and mast cells, but does 
not drive T cell or antibody responses per se [363, 364]. Consequently, its reduced 
expression during kidney rejection could reflect the reciprocal relationship that is often 
observed between Th1 and Th2 cytokines. Previous studies in murine islet and human 
renal allotransplantation have also reported the absence of IL-9 in rejecting grafts, 
consistent with the current findings [365]. IL-21 and its receptor were expressed at low 
levels in normal tissues and increased after transplantation in all three organs, with no 
significant difference between them, suggesting that IL-21 and its receptor are not 
specifically associated with the outcome of transplantation. The potential for IL-21 to 
influence the outcome of solid organ transplantation is difficult to determine, based on 
the existing literature about this cytokine. Whilst IL-21 has been implicated in 
autoimmunity and tumour immunity [352], the main immune defect in IL-21R-deficient 
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mice is in the antibody rather than the cell-mediated response [366, 367]. The individual 
cytokines which are most differentially expressed between tolerance and rejection, and 
which, by inference, are likely to make the greatest contribution to γc signalling, are IL-
2 and IL-4. In agreement with this finding, treatment of liver transplant recipients with 
exogenous IL-2 [368, 369] or IL-4 [370] is able to convert tolerance to rejection. 
Conversely, neither IL-2 nor IL-4 is an absolute requirement for graft rejection. In 
recipients lacking both IL-2 and IL-4, signalling through alternative γc cytokines 
including IL-7 and IL-15, but not IL-9, is sufficient to bring about rejection [365]. In 
this study, IL-15 was expressed constitutively in all three organs, with little change after 
transplantation. In this setting, regulation of the effects of IL-15 might be due to 
differential expression of its high affinity receptor, formed from γc, IL-2/IL-15Rβ and 
the IL-15-specific α chain, IL-15Rα, given that expression of the α chain was 
significantly higher in rejection than in acceptance. 
These results show that there is an association between a reduced level of γc 
signalling and liver transplant tolerance, although the factors responsible for this 
reduced signalling have not been determined. In part, the low level of signalling may 
reflect the “dilution” of a fixed clone size of alloreactive T cells within a large organ 
[41, 371]. In support of this hypothesis, increasing the mass of non-liver tissue 
transplanted prolongs heart or kidney transplant survival [54]. For example, in the PVG 
to DA strain combination, transplanting two kidneys and two hearts increased survival 
to more than 100 days, although when these were transplanted singly, they were 
rejected in less than 10 days [54]. Consistent findings have also been obtained in other 
animal models where increasing the amount of transplanted tissue [41] or decreasing the 
clone size of alloreactive T cells leads to graft acceptance [371]. In clinical 
transplantation there is evidence that increasing the amount of transplanted tissue 
reduces the incidence of rejection [372]. It is also possible that the different composition 
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of the parenchyma and resident non-parenchymal cells of the different organs, either 
directly or indirectly influences the levels of various γc cytokines, predisposing to the 
development of tolerance or rejection. 
The findings of reduced expression of γc signalling cytokines and receptors in 
liver transplant tolerance compared with rejection of heart or kidney grafts in the same 
rat donor/recipient strain combination accord with studies that compare liver tolerance 
with liver rejection in different strain combinations. In high-responder Lewis strain 
recipients, PVG strain livers are rejected. Comparison of expression of γc cytokines in 
liver transplant acceptance in DA strain recipients of PVG livers with rejection in Lewis 
recipients has shown that although there is no difference in expression of IL-2 and IL-
2Rα, there are significantly greater levels of IL-4 mRNA expression in rejection [373]. 
Consistent with this observation, injection of exogenous IL-4 into recipients of livers in 
the tolerant strain combination converts liver transplant acceptance to rejection [368]. 
The observational studies described in this chapter report cytokine mRNA 
expression. These data would be further strengthened by additional analyses of cytokine 
protein expression. Of note, future studies would need to use graft material and a 
technique that can adequately detect levels of these cytokines in tissue lysates. Serum or 
plasma studies might not give an accurate picture of what is happening in the graft as 
gamma chain signalling cytokines tend to be produced and consumed locally. There are 
techniques such as Luminex bead assays for rat cytokines, although these might not 
cover the complete range of cytokines and may not have been quality controlled for 
detection in tissues compared to serum.  
As was stated earlier, the injection of recombinant IL-2 or IL-4 converts liver 
acceptance in the low responder strain to liver rejection [368-370]. Moreover, 
exogenous administration of other recombinant gamma chain signalling cytokines such 
as IL-7 or IL-21 also coverted acceptance to rejection [374]. The scientific importance 
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of this study lies in the fact that this work is the first to compare expression of all the 
currently identified components of the gamma chain signalling complex in tolerated and 
rejecting organs across a uniform MHC barrier.  
In conclusion, this is the first study to compare expression of all the currently 
identified components of the γc signalling complex in tolerated and rejecting organs 
across a uniform MHC barrier. The results are consistent with a low level of global γc 
signalling in the tolerated grafts, as evidenced by the lower levels of IL-2 and IL-4, and 
confirmed by the up regulation of IL-7Rα in tolerance. The low levels of γc-signalling 
cytokines in tolerated liver grafts could be due to the large size of the graft and the 
limited clone size of alloreactive T cells. Low levels of γc-signalling cytokines can lead 
to the apoptotic death of infiltrating alloreactive T cells, thus permitting survival of the 
liver graft. 
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Chapter 4: Hepatic steatosis significantly increases the 
severity of ischaemia-reperfusion injury 
Hepatic steatosis is increasingly prevalent in developed countries and is a 
common incidental finding in deceased organ donors. Steatosis is associated with worse 
outcomes following liver transplantation, and is frequently cited as a reason for non-
utilisation of donated livers following procurement. Here, we aimed to establish the 
optimal duration of high-fat diet feeding in C57BL/6 mice to induce simple steatosis 
without liver inflammation or fibrosis, and to determine the effect of fatty liver on 
ischaemia-reperfusion injury using a well-characterised model of partial warm 
ischaemia and reperfusion. Male C57BL/6 mice were used for these experiments. All 
mice were obtained from the Animal Resources Centre, Perth, Western Australia, and 
were kept in accordance with the guidelines of the Animal Care and Ethics Committee 
of the University of Sydney. Mice were received at 4-6 weeks of age and, after baseline 
weights had been collected, were commenced on a high-fat diet after one week of 
acclimatization. The components of this diet are listed in table 2.1. To establish the 
optimal duration of feeding, groups of mice (n=6) were sampled at intervals between 6 
and 14 weeks to determine serum ALT levels, hepatic lipid content and the presence or 
absence of inflammation and fibrosis. 
 
4.1 Weight gain and liver lipid deposition on a 45% fat diet 
At the commencement of feeding, mice weighed 21.2 ±1.02g (n=24). Mice 
gained weight steadily during the period of feeding (Figure 4.1), and their rate of weight 
gain was considerably more rapid than that of chow-fed controls studied concurrently 
(Figure 4.1). Variability in the rate of weight gain was evident both between cages and 
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for individual mice within the same cage. The spread in mouse weights at different time 
points is shown in figure 4.2. At the time of tissue collection, no visual correlation 
between the amount of weight gained and a visual estimate of abdominal fat deposition 
was noted. As estimated by both routine histology on Haematoxylin and Eosin-stained 
tissues (Figure 4.3a) and by Oil Red O staining (Figures 4.3b and 4.4a), there was 
progressive accumulation of fat in the liver as high-fat diet feeding continued. A mixed 
pattern of microvesicular and macrovesicular steatosis was evident (Figure 4.3b). In 
addition to Oil Red O histology, liver lipids were solvent-extracted and quantitated by 
Oil Red O binding. After 14 weeks of feeding, liver lipid levels in HFD-mice (159.7 
±21.65µg/g) were approximately twice those in livers from chow-fed mice (107.9 
±15.89µg/g, P<0.005) (Figure 4.4b).  
H and E stained sections of mouse liver were assessed for the extent of steatosis 
according to the clinical scoring system for non-alcoholic fatty liver disease devised by 
Kliener et al. [201]. After 8 weeks of HFD feeding, One-third of mice had no evidence 
of steatosis, whilst 1/3 had mild steatosis (5-33% of the hepatic parenchyma affected) 
and 1/3 had moderate steatosis (33-66% affected). At 12 weeks’ duration of feeding, all 
mice had some degree of steatosis. This was mild in 50% of animals, moderate in 16% 
and severe (>66% affected) in 33% of mice (Figure 4.3c). None of the mouse livers 
examined showed the inflammatory or fibrotic changes associated with a diagnosis of 
NASH. 
Whilst there was some variability between mice in the degree of lipid 
accumulation in the liver after the same duration of feeding, this was not predicted by 
the weight gain. The collagen stain Picro-Sirius Red was used to identify any 
development of liver fibrosis (Figure 4.5a). No fibrosis was evident in the livers of mice 
receiving a high-fat diet for up to 14 weeks. Immunohistochemical staining for 
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macrophages [using the markers F4/80 (Figure 4.6) and CD68 (Figure 4.7)], monocytes 
(Ly6C, Figure 4.8) and neutrophils (Ly6B, Figure 4.9) did not reveal any cellular 
infiltration in mice which had received the high-fat diet. Serum levels of Alanine 
Aminotransferase were equivalent in HFD-fed and chow-fed mice (Figure 4.5b). We 
were thus able to conclude that a period of HFD-feeding of 12-14 weeks could reliably 
induce simple steatosis in most mice without provoking the development of supervening 
hepatitis. In subsequent experiments, inoculation with viral vectors and ischaemia-
reperfusion procedures were all carried out during this window. 
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Figure 4.1. Mice receiving a 45% fat diet and chow-fed 
controls were monitored and weighed twice-weekly for 12 
weeks from the commencement of feeding. HFD-fed mice 
gained weight more rapidly than controls throughout this 
period. Points represent the mean ±SEM for each group.  (a) 
The rate of weight gain in HFD animals was significantly 
greater than in lean animals (p<0.0001). 
Figure 4.2. Some variability in weight gain between mice 
receiving a high-fat diet at the same time was evident. The 
red line indicates the median of each group.      
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Figure 4.3a H and E staining demonstrates progressive accumulation without 
inflammatory infiltration in the livers of mice receiving a 45% fat diet (HFD). 
From top left, the panels show: control (a), 6 weeks (b), 8 weeks (c), 10 weeks 
(d), 12 weeks (e) and 14 weeks (f) duration of feeding, magnification x200. 
a b c 
d e f 
Figure 4.3b A mixed pattern of 
microvesicular and macrovesicular 
steatosis was present. Magnification 
x400. (c) Degree of steatosis, as 
measured by low magnification 
observation of HE sections, in various 
series of HFD-fed animals varied. 
b 
Figure 4.3c Extent of 
steatosis in mice after 8 or 
12 weeks of HFD-feeding.  
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Figure 4.4a Oil Red O was used to visualize lipid deposition in the livers of mice 
receiving a high fat diet. There is progressive accumulation of lipid as feeding 
proceeds. From top left to right Lean liver (a), at 6 (b), 8 (c), 10 (d), 12 (e) and 14 
(f) weeks of HFD-feeding, Magnification x200.  
a b c 
d e f 
Figure 4.4b A quantitative Oil Red O assay was used to estimate the lipid content 
of the livers of mice receiving normal chow (red bar) or a 45% fat diet for 14 
weeks. As anticipated, the livers of HFD-fed mice contained significantly more 
lipid than the livers of normal chow-fed controls. 
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Figure 4.5a The collagen stain Picro-Sirius Red was used to identify the 
development of liver fibrosis. No fibrosis was evident in the livers of mice 
receiving a high fat diet for up to 14 weeks. From top left to right Lean liver (a), at 
6 (b), 8 (c), 10 (d), 12 (e) and 14 (f) weeks of HFD-feeding. Magnification x100. 
a b c 
d e f 
Figure 4.5b Serum ALT was not significantly elevated in HFD-fed mice after 
either 12 or 14 weeks’ duration of feeding, compared with that in chow-fed mice 
n=6, the data are represented as mean ±SEM. 
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Figure 4.6 Immunohistochemical staining for the marker F4/80 was used to 
identify macrophages and Kupffer cells within the livers of mice receiving a high-
fat diet. No consistent alterations in F4/80 staining were noted during the period of 
feeding. From top left; Lean liver (a), at 6 (b), 8 (c), 10 (d), 12(e),14 (f) weeks of 
HFD-feeding and IgG2a κ isotype control (g). n=6, the data are represented as 
mean ±SEM. Magnification x400.  
a b c 
d e f 
g 
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Figure 4.7 Because no single marker reliably identifies all subsets of macrophages, 
immunohistochemical staining for the alternative macrophage marker CD68 was 
also performed. No consistent changes in CD68
+
 cell counts were identified. From 
top left to right Normal liver, at 6, 8, 10, 12, 14 weeks of HFD-feeding. 
Magnification x400 (except isotype control, which is photographed x100). 
a b c 
d e f 
g 
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Figure 4.8 Immunohistochemical 
staining for the marker Ly6C was used 
to identify monocytes within the livers 
of HFD-fed mice and chow-fed 
contraols. Monocytes were rarely 
found in the livers. From top left: 
Normal liver, at 6, 8, 10, 12,14 weeks 
of HFD-feeding. Magnification x400.  
Figure 4.9 Immunohistochemical 
staining for Ly6B was used to identify 
neutrophils within the livers of HFD-
fed and chow-fed mice. Neutrophils 
were rare in any livers. 
a b c 
d e f 
    
 
121 
 
4.2 Ischemia/reperfusion injury in mice with fatty or lean livers 
Partial warm liver ischaemia-reperfusion injury was carried out according to the 
method described by Abe et al. [2]. Occlusion of the left and median branches of the 
portal vein deprives approximately 2/3 of the liver of its blood supply, with the 
remaining 1/3 permitting survival of the animal. Due to the anatomical variability 
between mice, the extent of liver ischaemia is not identical between procedures. In these 
experiments, the duration of portal vein occlusion was 30 minutes, and serum and 
tissues were collected following reperfusion periods ranging from 15 minutes to three 
days. Prior to and during warm ischaemia, the core temperature of the mouse was 
continuously monitored using a rectal probe, and maintained between 36 and 38 degrees 
by a feedback-controlled far infrared-emitting warming pad (Right temp homeothermic 
warming system, Kent scientific, USA). Both the animal’s core body temperature and 
the temperature of the warming pad were digitally recorded, and representative plots 
from three mice are presented in Figure 4.10. Whereas the core body temperatures 
remained close to 37 degrees during the period of portal vein occlusion, the warming 
pad regularly reached temperatures of 45 degrees or above. It is therefore possible that 
the caudal portions of the mouse liver were subjected to a temperature that was greater 
than the recorded core temperature.  
Perioperative mortality of exclusion for technical reasons occurred in 4 animals 
from a total of 42 procedures in this experimental series (9.5%). One procedure was 
abandoned when mesenteric pathology became evident upon opening the abdomen, 
whilst a further procedure was terminated from further analyses due to abnormal liver or 
mesenteric perfusion or reperfusion following application of the vascular clamp (Table 
4.1).  
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Experimental group Number of animals used 
HFD Sham 2 
Lean Sham 2 
HFD IR15m 5 
Lean IR15m 2 
HFD IR1h 4 
Lean IR1h 2 
HFD IR4h 3 
Lean IR4h 5 
HFD IR1d 4 
Lean IR1d 2 
HFD IR3d 5 
Lean IR3d 2 
Table 4.1 Animal numbers in each experimental group. 
  
    
 
123 
 
 
  
Figure 4.10 Representative graphs showing the heat pad and body temperatures 
during mouse liver ischaemia. Whereas the core body temperature remained 
relatively constant during the period of ischaemia, the temperature of the heat pad  
often exceeded 45°C. Although the pad was covered with gauze to prevent direct 
contact with the mouse’s skin, it is possible that the temperature of posterior 
structures in the mouse’s body was greater than the core temperature measured 
by the rectal probe. This did not result in any injury to sham-operated animals, 
but may have contributed to the severity of liver ischaemia-repefusion injury. Y 
axis- temperature (°C), X axis- time (min), Blue line - heat pad temperature, Red 
– core body temperature. 
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4.3 The severity of ischaemia-reperfusion injury is amplified in mice with 
fatty livers  
4.3.1 Alanine Aminotransferase 
Serum levels of the liver enzyme Alanine Aminotransferase (ALT) were 
measured as a marker of liver injury. A rise in ALT levels was detectable in the serum 
from HFD mice as early as 15 minutes following reperfusion, with a more significant 
increase (from 39 ± 18 to 25906 ±1579 IU/ml) at four hours post-reperfusion (Figure 
4.11). Peak levels of ALT were significantly greater in the serum from HFD mice than 
in that from lean mice (4094 ± 1694 IU/ml, p<0.0001) at this time. ALT increased in the 
serum of chow-fed mice from baseline levels (mean = 39.9 ± 7) to reach a peak at 4h 
post-reperfusion (mean = 4094 ± 1694) (p<0.05) (Figure 4. 11a).  
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Figure 4.11. Alanine aminotransferase (ALT) levels in serum reach 
a peak at four hours post-reperfusion in both HFD-fed and lean 
mice. ALT levels were greater in HFD-fed than in lean mice at 
most time points examined – these differences were statistically 
significant at 4h and d1 post-reperfusion. The individual results 
and mean for each group are shown. 
Figure 4.11a Release of ALT in lean animals post-perfusion 
reached a peak at 4 hours (p<0.05). The data show mean ±SEM. 
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4.3.2 The alarmin HMGB1 
HMGB1 is an important inflammatory mediator in liver IRI. Systemic release of 
HMGB1 also followed a biphasic profile, with an early peak at 15 minutes post-
reperfusion and a subsequent rise after four hours (Figure 4.12a). Circulating HMGB1 
levels were approximately threefold greater in HFD mice than in lean mice at each of 
these time points (149.7 ± 23.24 v/s 37.54 ± 4.99ng/ml at 15 minutes, p<0.001, and 
140.3 ± 14.66ng/ml v/s 30.1 ± 10.40ng/ml at 4 hours, p<0.001). Serum HMGB1 levels 
in chow-fed animals increased from baseline (mean = 3.9 ± 0.13) to peak at 15 minutes 
post-reperfusion (mean = 37.54 ± 5), (p<0.05). HMGB1 is normally present in the 
nucleus, and migrates into the cytoplasm under conditions of cellular stress, whereupon 
it can be released extracellularly. Immunofluorescence staining was used to determine 
the distribution of HMGB1 in normal livers, livers from mice having received a high-fat 
diet for 12 weeks, and the livers of both chow-fed and HFD mice at 15 minutes after 
reperfusion. In the normal livers, as anticipated, HMGB1 was localised to the nucleus 
(Figure 4.12b, panel a). In HFD mice, even before any ischaemic stimulus, HMGB1 
was detectable within the cytoplasm (Figure 4.12b, panel b). HMGB1 redistribution to 
the cytoplasm was also evident within the livers of chow-fed and HFD mice at 15 
minutes post-reperfusion (4.12b, panels c-d). Even at this early time point, disruption of 
the extracelullar matrix (stained with phalloidin) and increased friability of the tissue 
are noted in ischaemic livers (Figure 4.12b, panels c-d). HMGB1 gene transcription 
appeared to be increased in the livers of HFD mice prior to ischaemia, though this 
difference did not reach statistical significance (Figure 4.13, panel a). 
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c 
Figure 4.12a. HMGB1 release into the systemic circulation 
showed a biphasic pattern, with an early spike at 15 minutes post-
reperfusion, followed by a secondary peak at 4 hours post-
reperfusion. Serum HMGB1 levels were greater in HFD-fed mice 
than in lean animals at most time points examined – these 
differences were significant at 15 minutes and at 4 hours. 
Individual results and the mean for each group are shown. 
Figure 4.12ab. HMGB1 serum levels in lean animals post-
perfusion. With the induction of perfusion, the serum HMGB1 
levels reached a peak at 15 minutes (p<0.05). The data show mean 
±SEM. 
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c 
Figure 4.12b Immunofluorescence staining for HMGB1 in the livers of 
chow-fed control mice (a), HFD-fed mice not subjected to ischaemia-
reperfusion injury (b), chow-fed mice sampled at 15 minutes following 
reperfusion (c) and HFD-fed mice sampled at 15 minutes after 
reperfusion (d). Representative images from each group are shown. 
HMGB1 signals are shown in the red channel, whilst Hoechst 33342 
nuclear counterstain is in blue and Phalloidin (used to visualise F actin 
in the extracellular matrix and demarcate hepatocyte boundaries) is in 
the green channel. In the livers of chow-fed controls, HMGB1 staining 
is largely confined to the nucleus (a). An overall increase in HMGB1 
staining intensity was noted in the livers of HFD-fed mice compared to 
those of control mice, and there was a striking redistribution of 
HMGB1 from the nucleus into the cytoplasm in these mice (b). Similar 
redistribution of HMGB1 was noted in both lean and steatotic livers at 
15 minutes after reperfusion. Even at this early timepoint, increased 
friability of the liver tissue and disruption of the ECM are noted. 
a b 
d c 
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4.3.3 The pattern-recognition receptors RAGE and TLR4 
Signalling through both RAGE and TLR4 are implicated in the pathogenesis of 
liver ischaemia-reperfusion injury. As for HMGB1, there was a suggestion of increased 
background expression of RAGE (Figure 4.13b) and TLR4 (Figure 4.13d) in the livers 
of HFD mice, compared with those of chow-fed controls. These changes were not 
statistically significant. RAGE transcription thereafter remained relatively constant. 
TLR4 expression remained close to baseline levels in the livers of either HFD or lean 
mice until 1 day post-reperfusion or later. TLR4 expression was greater in fatty than in 
lean livers at day 1 (p=0.057) (Figure 4.13c). 
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Figure 4.13 Gene expression for HMGB1, along with RAGE and TLR4 
pattern recognition receptors was marginally elevated in steatotic livers 
not subjected to IRI, compared with lean (a, b, d). HMGB1 gene 
expression remained stable following I-R, whereas there was a modest 
increase in RAGE expression on d1-d3 which did not differ 
significantly between fatty and lean livers. In contrast, TLR4 gene 
expression was strongly upregulated in steatotic livers on d1 post-
reperfusion, remaining elevated on d3 (c). The mean ±SEM of each 
group is shown.  
a 
b 
c d 
    
 
131 
 
4.3.4 Cytokines 
Interleukin-6 and TNF are pleiotropic actors in ischaemia-reperfusion injury. 
Depending upon the circumstances, they can fulfil pro-inflammatory or pro-survival 
roles. IL-6 is released into the systemic circulation rapidly following liver ischaemia 
and reperfusion. IL-6 levels in serum were elevated by 15 minutes post-reperfusion and 
peaked by one hour in HFD mice, and slightly later in lean animals. IL-6 levels 
increased many thousand fold above baseline in HFD mice, and were significantly 
greater than those in lean mice at both 1 hour (3768 ±490.3 v/s 638.2 ±59.53pg/ml 
p<0.0001) and 4 hours (1933±79.4 v/s 888.4±133.4pg/ml P<0.05) post-reperfusion 
(Figure 4.14a). Serum levels of TNFα increased in both lean and HFD-mice to peak 
between 1 and 4 hours after reperfusion. No significant differences in serum TNF 
between lean and HFD mice were noted (Figure 4.14b).  At the gene expression level, 
IL-6 transcription was barely detectable at baseline, but was strongly upregulated by 
four hours post-reperfusion and remained elevated on d1. Liver gene expression for IL-
6 was considerably greater in HFD than in lean mice at 4 hours post-reperfusion (Figure 
4.15a). Hepatic TNF- gene transcription appeared greater in HFD than in chow-fed 
mice at all stages, although these differences did not reach statistical significance 
(Figure 4.15b). 
Interleukin-1 levels increased in the serum of lean but not HFD mice over the 
first few hours post-reperfusion (p<0.01) (Figure 4.16a), whilst systemic levels of IL-1 
did not change greatly during the same period (Figure 4.16b).  In contrast, transcription 
of IL-1β was elevated in the livers of HFD mice by four hours post reperfusion and 
remained elevated on d1. IL-1 gene expression was significantly greater in HFD than 
in lean livers at both these time points (p<0.05, Figure 4.16c). Serum levels of IL-12p40 
did not change appreciably following ischaemia and reperfusion (Figure 4.17a), 
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whereas levels of IL-12 p40 were at the lower limit of detection in baseline samples 
from both lean and HFD mice and increased after reperfusion. Levels remained elevated 
in HFD mice at d1, whilst in lean mice they were declining by this time (Figure 4.17b). 
Cytokines which signal though receptors incorporating the common gamma 
chain (c) provide survival signals for activated alloreactive T cells. Spontaneous liver 
transplant tolerance is associated with low levels of the c-signalling IL-2 and IL-4, and 
with increased expression of the IL-7Ra chain, a marker of reduced c-signalling [375]. 
Increased systemic cytokine expression is one possible mechanism whereby liver 
ischaemia-reperfusion injury could interfere with the development of spontaneous liver 
transplant tolerance. Serum levels of five c-signalling cytokines were determined in 
lean and HFD mice during IRI. Interleukins 2, 4 and 15 were present at low levels in the 
systemic circulation. Levels of these cytokines appeared to peak around four hours post-
reperfusion, and did not differ between HFD and lean mice (Figure 4.18 a-c). 
Interleukin-7 and Interleukin-9 levels peaked at 4 hours in chow-fed mice and then 
declined, whereas in HFD mice, IL-7 and IL-9 continued to increase out to day 1 
following reperfusion (Figure 4.18d-e).  
Levels of the anti-inflammatory cytokine IL-10 increased substantially from 
baseline (23.28 ±5.095pg/ml) to peak at 1-4 hours in both HFD (169.5 ±30.23pg/ml, 
p<0.0001) and lean mice (145.1 ±21.93pg/ml, p<0.01). IL-10 levels were comparable in 
lean and HFD mice (Figure 4.19a). Conversely, levels of the pro-inflammatory cytokine 
IL-17 were greater in HFD than in lean mice at most sampling points, most noticeably 
at four hours following reperfusion 20.37 ±6.67, v/s 5.28 ±0.9, p<0.01, Figure 4.19c).  
Interleukin-5 was barely detectable in the serum of HFD mice until four hours 
after reperfusion, whilst substantial increases in serum IL-5 were observed in lean mice 
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over this interval (from 11.08 ±1.08 pg/ml at baseline to 252 ±92 pg/ml at 1 hour and 
430 ±125 pg/ml at 4 hours, p<0.01, Figure 4.20a). The source of this IL-5 is uncertain; 
liver gene expression for IL-5 varied little over three days after reperfusion (Figure 
4.20b). 
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a 
b 
Figure 4.14 Serum levels of IL-6 and TNFα. IL-6 increased in both 
lean and HFD-mice to peak between 1 and 4 hours after reperfusion.  
Serum IL-6 levels increased markedly in HFD-fed mice, and were 
significantly greater in HFD-fed than chow-fed animals at both 1h 
and 4h post-reperfusion (a). No significant differences in serum TNF 
between lean and HFD mice were noted (b). Graphs show the mean 
±SEM for each group.  
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Figure 4.15 Hepatic gene expression for IL-6 peaked in the 
steatotic livers at 4 hours post-reperfusion, at which time it 
was significantly greater than that in lean liver. By d3 post-
reperfusion, gene expression had returned to baseline (a). 
Hepatic TNFα gene transcription appeared greater in fatty 
than in lean livers at all stages (b). Graphs show the mean 
±SEM for each group.  
a 
b 
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Figure 4.16 Serum levels of IL-1α, peaked at 4h post-
reperfusion, and were not significantly different between 
lean or HFD-fed mice at any time (a). IL-1β was present 
at a low level in serum, and serum levels did not show a 
consistent pattern of upregulation (b) whereas hepatic 
gene expression for IL-1β was strongly upregulated in the 
steatotic livers, reaching a peak at 4h post-reperfusion 
and remaining elevated out to d3. IL-1β mRNA levels 
were significantly greater in fatty than in lean livers at 
both 4h and d1(c). Graphs show the mean ±SEM for each 
group.  
a 
b 
c 
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<3 
Figure 4.17 Serum levels of IL-12p40 did not 
change appreciably following ischaemia and 
reperfusion (a), whereas levels of IL-12p70 were 
at the lower limit of detection in baseline samples 
from both lean and HFD mice and increased after 
reperfusion. Levels remained elevated in HFD 
mice at d1, whilst in lean mice they were 
declining by this time (b). 
a 
b 
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a 
b 
c 
Figure 4.18 Serum levels of common gamma 
chain-signalling cytokines (see figure legend on 
following page). 
    
 
139 
 
 
  
Figure 4.18 IL-2, 4 and 15 were present at low levels in 
the systemic circulation. Levels of these cytokines 
appeared to peak around four hours post-reperfusion, 
and did not differ between HFD and Lean mice (a-c). 
IL-9 levels peaked at 4 hours in chow-fed mice and then 
declined, whereas in HFD mice, IL-9 continued to 
increase out to day 1 following reperfusion (d). A similar 
pattern of expression was noted for IL-7 (e). Graphs 
show the mean ±SEM for each group. 
d 
e 
    
 
140 
 
 
  
Figure 4.19 Serum levels of IL-10, 13 and 17. IL-10 levels in 
both lean and HFD-fed mice reached a peak between 1h and 
4h post-reperfusion. IL-10 levels were comparable between 
HFD and lean mice (a). IL-13 levels in both HFD and Lean 
groups rose modestly to peak at 4h post-reperfusion (b). IL-
17 serum concentrations were greater in HFD than in lean 
mice at most sampling points, most noticeably at four hours 
following reperfusion (20.37 ±6.67pg/ml v/s 5.28 ±0.9pg/ml, 
p<0.01) (c). Graphs show the mean ±SEM for each group.  
a 
b 
c 
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Figure 4.20 Serum levels and gene expression of IL-5. 
Serum levels of IL-5 were noticeably greater in lean 
mice than in HFD-fed mice at all time points 
examined, and reached a peak at 4h post-reperfusion 
(430 ±125pg/ml  vs 11.08 ±1.08pg/ml in sham-
operated lean mice, p<0.01) (a). Liver expression of 
IL-5 varied little over three days after reperfusion (b). 
Graphs show the mean ±SEM for each group.  
a 
b 
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4.3.5 Chemokines 
MCP-1, KC, RANTES and IP-10 are active in the recruitment of macrophages 
and granulocytes, neutrophils, T cells and NK cells, respectively. Serum levels of these 
cytokines increased to peak at 1-4 hours after reperfusion and at these early times, few 
differences between lean and HFD mice were noted (Figure 4.21). In contrast, liver 
gene expression for KC was considerably greater in lean than in fatty livers at 4 hours 
post-reperfusion (143.7 ±16.03 vs 38.99 ±9.516, p<0.0001, Figure 4.22a), whilst MCP-
1 expression was strongly upregulated (>1,000-fold compared to baseline) in the livers 
of HFD mice on d1 after reperfusion (p<0.05 lean livers on d1, Figure 4.22b). MIP-1 
and MIP-2 levels did not change dramatically following reperfusion (Figure 4.23 a, c), 
whilst MIP-1 increased over this time, peaking at 1-4 hours post-reperfusion (p<0.01). 
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Figure 4.21 Serum levels of the chemokines MCP-1, KC, 
RANTES and IP-10. MCP-1 and KC levels in serum peaked 
earlier in HFD-fed than in lean mice, but ultimately attained 
similar levels (a-b). RANTES and IP-10 levels increased 
moderately in both groups to peak at 4h post-reperfusion (c-d). 
Graphs show the mean ±SEM for each group.  
a 
b 
c 
d 
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Figure 4.22 KC and MCP-1 gene expression. Liver expression of KC in 
the lean group was significantly greater than that in the HFD group at 4h 
post-reperfusion (143.7 ±16.03 vs 38.99 ±9.516, p<0.0001)(a). MCP-1 
expression was strongly upregulated (>1,000-fold compared to baseline) 
in the livers of HFD mice on d1 after reperfusion (p<0.05) (b). Graphs 
show the mean ±SEM for each group.  
a 
b 
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Figure 4.23 Serum levels of MiP-1α, MiP-1β and MiP-2. 
The levels of these chemokines were moderately 
increased after reperfusion, particularly in the lean 
group. (a-c). MiP-1β reached a peak at 1h post-
reperfusion in the lean animals (176.5 +/-7.28pg/ml, 
p<0.05) (b). Graphs show the mean ±SEM for each 
group.  
a 
b 
c 
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4.3.6 Cellular infiltration 
Areas of necrosis and focal cellular infiltration develop in the livers of HFD 
mice over the three days following reperfusion of the ischaemic liver (Figure 4.24). On 
d1 post-reperfusion, necrotic areas were evident in all sections examined in both lean 
mice and those receiving a high-fat diet. On d3, areas of necrosis were detected in 50% 
of lean livers, and 80% of HFD livers. Neutrophil infiltration peaks at d1 after 
reperfusion, and neutrophils are more plentiful in the livers of HFD than lean mice at 
this time (Figure 4.25). An apparent drop in the number of F4/80-positive macrophages 
at four hours post-reperfusion (Figure 4.26a) is likely to reflect downregulation of this 
marker rather than a change in cell numbers, as the numbers of cells positive for another 
macrophage marker, CD68, did not change (Figure 4.26b). 
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See figure legends overleaf. 
b 
d 
a 
c 
e f 
g h 
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Figure 4.24 Representative images showing more extensive tissue damage after 
IRI in the HFD group (R), than in the lean group (L). Sham (a, b)  at 
magnification x100, and 4h (c, d), 1d (e, f) and 3d(g, h) post-reperfusion. 
Magnification x200. H and E. In 1d animals all sections examined in lean and 
HFD groups exhibited areas of necrosis, while at 3d necrotic areas were found in 
80% of HFD animals and 50% of lean livers (i, j).  
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Figure 4.25b Neutrophil infiltration reaches its peak at 1d after reperfusion in 
both HFD and Lean groups. The bar indicates the median of each group.  
Figure 4.25a Neutrophil infiltration in Lean IR1d (a and b) and HFD IR1d (c 
and d) Ly6B Magnification x400. 
a b 
c d 
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Figure 4.26 The macrophage markers F4/80 (a) and CD68 (b) were 
used to determine macrophage numbers during ischaemia-
reperfusion injury. The number of macrophages expressing F4/80 
declines at 4h post-reperfusion in both groups (from 54 ±4 in lean 
and 58.4 ±13 in HFD to 28.43 ±3.9 and 21.7 ±1.2, cells/HPF, 
respectively, p<0.05). Numbers of CD68+ cells do not change over 
this period. Graphs show the mean ±SEM for each group.  
a b 
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4.4 Hepatocyte proliferation is reduced and apoptosis is increased in fatty 
livers during ischaemia-reperfusion injury 
Two nuclear proliferation markers, proliferating cell nuclear antigen (PCNA) 
and Ki-67, were used to assess the proliferative response to ischaemia-reperfusion 
injury in lean and fatty livers. The numbers of PCNA-positive nuclei were expressed as 
a ratio to total nuclei, to control for cell loss due to necrosis. PCNA-positive cells 
reached maximum numbers on day 1 following reperfusion, and were significantly 
more numerous in lean than in fatty livers (0.6 PCNA+cells/total nuclei v/s 0.13 
PCNA+cells/total nuclei, p<0.0001, Figure 4.27). The number of Ki-67-positive cells 
peaked later, at d3 post-reperfusion, but as for PCNA, suggested that hepatocyte 
proliferation was substantially more robust in lean than in fatty livers (0.18 
Ki67+cells/total nuclei v/s 0.0048 Ki67+cells/total nuclei, p<0.0001, Figure 4.28). Oval 
cell proliferation and differentiation into hepatocytes and/or biliary epithelium is an 
additional mechanism for liver renewal after injury. In the resting state, oval cells were 
tightly clustered around the bile ducts (Figure 4.29 a, b) whereas during ischaemia-
reperfusion injury, oval cells became disseminated though the liver. This was more 
noticeable in fatty than in lean livers (Figures 4.29c, d). No significant change in Oval 
cell numbers was detected during IRI, but this may be partly explained by the 
differentiation of daughter cells into hepatocytes or bile duct cells such that they are no 
longer positive for the oval cell marker (MIC1-1C3). Cleaved caspase-3 detection was 
used to identify hepatocytes undergoing apoptosis in fatty and lean livers after IRI. Few 
apoptotic cells could be detected in the lean livers, whereas cleaved caspase 3-positive 
cells were considerable more numerous in the livers of HFD mice at d1 after 
reperfusion (0.28 cleaved caspase 3+cells/total nuclei v/s 0.011 cleaved caspase 
3+cells/total nuclei, p<0.0001, Figure 4.30). 
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c d 
a b 
Figure 4.27 Increased cell proliferation (assessed by nuclear expression of the 
marker PCNA) was noted in lean mice at d1 (c) and d3 (e) post-reperfusion, 
compared to the same time points in the HFD group (d) and (f). Lean sham (a) 
and HFD sham (b) sections are presented for comparison. Magnification x400. 
Graphed results show the mean ±SEM for each group.  
e f 
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Figure 4.28 The proliferation marker Ki-67 was used in addition to 
PCNA to assess liver regeneration. The appearance of Ki67-positive 
nuclei peaked at 3d post-reperfusion in the lean livers. Significantly 
fewer proliferating cells are detectable in HFD samples at d3 (0.0048 ± 
0.003) (b), compared to those in lean livers at the same time point (0.18 
± 0.003, p<0.0001) (a). The dotted line delineates the border between 
necrotic and viable liver areas. Proliferating cells are only counted 
within the viable areas of liver. Magnification x400. The graph 
represents the mean ± SEM for each group. 
a b 
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Figure 4.29 Oval cell numbers and distribution after IRI. In the lean (a) 
and HFD (b) sham groups, the oval cells are found tightly packed around 
bile ducts. During IRI, oval cells become more widely disseminated 
through the liver tissue in the HFD group by 3d post-reperfusion (d).  This 
altered distribution was not observed in the lean group at the same time 
(c). No significant changes in oval cell numbers were detected. 
Magnification x400. The graph shows the mean ± SEM for each group. 
a b 
c d 
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Figure 4.30 Staining for the cleaved (active) form of caspase 3 was used for the 
detection of apoptotic hepatocytes. Increased apoptosis was observed in HFD 
samples at d1 after reperfusion (d) (0.24 ± 0.07), compared to lean livers at the 
same time point (c) (0.011 ± 0.004, p<0.0001). Very few apoptotic cells are 
detected in sham –operated controls; lean (a) and HFD (b) sham-operated mice. 
Magnification x400. Graphs show the mean ± SEM for each group.  
a b 
c d 
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4.5 Discussion 
In this portion of the project we established a model of hepatic steatosis without 
superimposed inflammation in order to study the effects of fatty liver on the severity of 
partial warm liver ischaemia-reperfusion injury. Although there was some variability in 
the extent of lipid accumulation in the livers of different animals, a twelve week period 
of feeding male C57BL/6J mice with a 45% fat diet resulted in hepatic steatosis in 
almost all animals. Both macrovesicular and microvesicular patterns of steatosis were 
present, but no signs of inflammation or fibrosis were detected, indicating that the 
pathological changes in these mice were consistent with simple steatosis rather than 
NASH. At the gene expression level, there was a suggestion that transcription of the 
inflammatory mediator HMGB1, and its receptors TLR4 and RAGE was increased in 
HFD-fed animals which had not been subjected to ischaemia and reperfusion. Increased 
expression of TNF and IL-6 in NAFLD livers has been reported in the literature [376]. 
In this study, TNF gene expression appeared to be increased at baseline in HFD livers, 
but neither TNF nor IL-6 were elevated in serum prior to the onset of ischaemia. 
Conversely, serum levels of IL-17 were significantly greater in HFD-fed mice at 
baseline than in lean mice, consistent with previous studies [377].  
HFD-fed mice manifested more severe liver injury after an ischaemic insult than 
did lean controls. Accordingly, peak ALT levels, the extent of liver necrosis, and peak 
neutrophil infiltration were all greater in the HFD-fed cohort. Extracellular release of 
HMGB1 is critical to the pathogenesis of liver ischaemia reperfusion injury [125]. 
Whereas HMGB1 is a chromatin-binding protein which is usually located in the 
nucleus, under conditions of cellular stress it is redistributed into the cytosol, then 
released extracellularly. Immunofluorescence staining of livers for HMGB1 reveals that 
even prior to any ischaemic insult, HMGB1 is abundant within the cytoplasm of 
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hepatocytes from HFD-fed mice, whilst in lean mouse hepatocytes, HMGB1 is 
preferentially located in the nucleus. Following reperfusion, there is a rapid spike in 
HMGB1 levels in the systemic circulation, and serum HMGB1 levels in HFD-fed mice 
are approximately threefold those of lean mice at both 15 minutes and 4 hours after 
reperfusion. HMGB1 release and TLR4 signalling are linked by a positive feedback 
loop, such that engagement of TLR4 triggers the release of HMGB1, which, in turn, 
binds TLR4. Circulating levels of free fatty acids are increased in obesity [233], and 
these molecules are able to engage and signal through TLR4. Treatment of cultured 
hepatocytes with palmitic acid leads to the release of HMGB1 into the supernatant 
[238]. Free fatty acid release from steatotic livers has not been documented during 
ischaemia-reperfusion injury, but is a plausible mechanism for the amplification of 
HMGB1 release from fatty liver upon reperfusion. 
Gene expression for TLR4 peaked on day 1 in steatotic livers, remaining 
elevated on day 3, whilst a minimal increase in TLR4 expression was noted in lean 
livers. In contrast, RAGE in whole liver homogenate did not increase appreciably over 
the days following reperfusion. These differences may in part reflect the broader 
distribution of TLR4 which is constitutively expressed on hepatocytes whilst RAGE is 
most abundant on non-parenchymal cells, notably stellate cells. It is possible that gene 
expression measured in isolated HSCs would yield different results.  
Serum levels of cytokines and chemokines peaked between one and four hours 
post-reperfusion in both lean and HFD-fed animals, as did hepatic gene transcription for 
most of these molecules. Interleukin-6 and IL-17 serum levels were significantly greater 
in HFD-fed mice than in lean, and whilst the overall peak levels of MCP-1 and KC were 
similar in the sera of lean and HFD-fed mice, peak levels of these chemokines were 
attained earlier in the HFD-fed animals. High IL-17 serum levels in the HFD-fed mice 
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may reflect the influence of IL-6 in tipping the balance away from Treg generation and 
towards the production of Th17 cells [292]. At the level of hepatic gene transcription, 
IL-6, IL-1, TNF and MCP-1 were all expressed more abundantly in fatty livers than 
in lean. Somewhat surprisingly, expression of the neutrophil chemokine KC was greater 
in lean than in fatty livers at all the time points examined, particularly at four hours 
post-reperfusion. MCP-1 expression peaked on d1 post-reperfusion, coincident with the 
peak of neutrophil infiltration, and its expression at this time was more than tenfold 
greater in fatty than in lean livers. This suggests that MCP-1, IL-17 or other neutrophil 
chemoattractants such as complement split products are likely to be responsible for the 
increased neutrophil infiltration in steatotic livers on day 1 [378].  
Increased systemic or intrahepatic levels of common gamma chain signalling 
cytokines following ischaemia-reperfusion injury in the setting of allotransplantation 
may facilitate the survival of activated alloreactive T cells and oppose the induction of 
graft-specific tolerance. Serum levels of IL-2, IL-4 and IL-15 (produced by T cells) all 
increased following reperfusion, but there was no obvious difference between levels in 
HFD-fed and lean animals. Interleukin-7 is known to be produced by hepatocytes in 
response to TLR4 engagement during inflammation, and promotes intrahepatic T cell 
proliferation and survival [379]. Serum Interleukin-7 was increased on d1 post-
reperfusion in HFD-fed but not lean mice, coincident with the peak of TLR4 
upregulation in hepatocytes. In the context of an allograft, IL-7 produced by steatotic 
hepatocytes in response to an ischaemic insult could rescue activated alloreactive T 
cells from exhaustion or death, potentially impeding the induction of liver transplant 
tolerance. 
Animal survival was not used as an endpoint in these experiments. However, 
hepatocyte apoptosis was more obvious in the fatty livers following reperfusion, whilst 
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hepatocyte proliferation was more vigorous in the lean livers. Cell cycle arrest of 
steatotic hepatocytes has been reported [270], and may underlie the failure of 
proliferation observed here following ischaemic damage. These reciprocal changes 
point to a greater ability of lean livers to regenerate following an ischaemic insult, and 
hence a greater probability of survival. Oval cells may contribute to the restoration of 
liver mass following injury, and oval cells appear to have disseminated more widely 
through the steatotic livers than the lean livers at day three following reperfusion. Oval 
cell counts were not different between lean and fatty livers, though given that Oval cell 
proliferation is accompanied by differentiation into hepatocytes and bile duct cells, a 
difference in proliferation, even if present, may be difficult to detect. 
In summary, ischaemia and reperfusion of steatotic livers was associated with 
more severe injury and with greater release of proinflammatory mediators than was 
ischaemia and reperfusion of lean livers. Increased cytoplasmic concentrations of 
HMGB1 leading to a more dramatic spike in systemic HMGB1 levels after reperfusion 
is likely to contribute substantially to the susceptibility of steatotic livers to injury, 
especially when paired with an increase in expression of the pattern recognition 
receptors RAGE and TLR4 which bind HMGB1. Both increased intestinal permeability 
and dysbiosis are characteristic of HFD-fed animals [247, 380, 381]. Liver IRI can also 
compromise the gut barrier [382], and superimposition of liver IRI upon the altered 
intestinal microenvironment resulting from HFD-feeding may give rise to elevated 
levels of bacterial components such as LPS and CpG DNA which when bound to 
HMGB1 could further amplify its proinflammatory effects. Finally, though not 
examined in this project, release of FFA from steatotic hepatocytes during IRI may also 
play a role in the increased susceptibility of fatty livers to ischaemic damage. 
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Chapter 5: Does systemic overexpression of esRAGE 
attenuate IRI in lean and/or fatty livers? 
 In order to determine the ability of liver-directed esRAGE gene transfer to limit 
tissue damage and reduce inflammation in fatty or lean livers during 
ischaemia/reperfusion injury, we inoculated HFD-fed and control male C57BL/6J mice 
with AAV2/8 vectors encoding either human esRAGE or enhanced Green Fluorescent 
Protein (GFP).  
 
5.1 In vivo studies of esRAGE gene transfer 
 We used a commercial sandwich ELISA specific for the unique c-terminus of 
esRAGE to detect human esRAGE in mouse serum. esRAGE was not detectable in the 
serum of mice after 12 weeks of HFD-feeding, but was expressed rapidly after 
inoculation of HFD-fed mice with rAAV 2/8 esRAGE, approaching levels of 10μg/ml 
by 10 days post-inoculation (Figure 5.1a). A similar timecourse of expression was 
observed for AAV 2/8 GFP (Figure 5.1b). Liver transduction with esRAGE or GFP was 
well-tolerated by the mice; their weights remained stable post-inoculation (Figure 5.2) 
and serum ALT levels did not rise (Figure 5.3). No inflammatory infiltrates were noted 
within the liver (Figure 5.4). 
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Figure 5.1a Serum esRAGE levels increase 
following rAAV-esRAGE administration. A 
commercial sandwich ELISA specific for the 
unique c-terminus of esRAGE was used to 
measure human esRAGE levels in the serum of 
mice which had been inoculated with 5x10
11
 vgc 
rAAV-esRAGE ip, following 12 weeks of HFD-
feeding. 
No esRAGE was detected in the serum of 
uninjected mice, whereas serum esRAGE levels 
rose rapidly following inoculation to approach 
10μg/ml at day 10. Graphs represent the mean 
and SEM of each group. 
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Day 0 Day 2 
Day 5 Day 10 
Figure 5.1b eGFP expression was visualised in situ using 
395nm illumination and a Leica MZ16 F fluorescence 
stereomicroscope. Fields on the left show fluorescence + 
white light epi-illumination, whilst fields on the right 
show fluorescence alone.  
The time course of expression of eGFP following 
inoculation of mice with 5x10
11
 vgc rAAV-GFP ip is 
similar to that of esRAGE. Strong liver-specific GFP 
expression is apparent by day 5 post-inoculation.  
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Figure 5.2 Body weight remains stable after AAV 
injection. Graph shows the mean ±SEM. 
Figure 5.3 Serum ALT levels are not elevated in HFD-
fed, esRAGE injected mice, compared  with either 
normal C57BL/6J mice or uninjected HFD control 
animals. 
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Figure 5.4 The extent of liver lipid accumulation was greater in the 
esRAGE-injected HFD-fed mice (b) than in the uninjected controls (a), 
but other than this, no morphological abnormalities were detected in the 
liver of injected mice and no inflammatory infiltrate was present in the 
livers of either group. (Haematoxylin and Eosin stained sections, 
magnification x200). 
a b 
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Experimental group Total number of animals used 
HFD Sham 2 
HFD IR0 esRAGE 3 
Lean Sham 2 
Lean IR0 esRAGE 2 
Lean IR0 GFP 2 
HFD IR15m  5 
HFD IR15m esRAGE 7 
HFD IR15m GFP 5 
Lean IR15m  7 
Lean IR15m esRAGE 9 
Lean IR15m GFP 8 
HFD IR1h 3 
HFD IR1h esRAGE 6 
HFD IR1h GFP 5 
Lean IR1h 6 
Lean IR1h esRAGE 5 
Lean IR1h GFP 7 
HFD IR4h 8 
HFD IR4h esRAGE 9 
HFD IR4h GFP 10 
Lean IR4h 10 
Lean IR4h esRAGE 11 
Lean IR4h GFP 11 
HFD IR1d 6 
HFD IR1d esRAGE 10 
HFD IR1d GFP 10 
Lean IR1d 5 
Lean IR1d esRAGE 7 
Lean IR1d GFP 6 
HFD IR3d 4 
HFD IR3d esRAGE 5 
HFD IR3d GFP 4 
Lean IR3d 4 
Lean IR3d esRAGE 5 
Lean IR3d GFP 3 
Table 5.1 Animal numbers in each experimental group. 
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Perioperative mortality or exclusion for technical reasons occurred in 14 animals from a 
total of 226 procedures in this experimental series (6.2%). 5 animals died due to 
respiratory arrest, and a further animal underwent euthanasia following dehiscence of 
the abdominal wound. Eight animals were excluded from further analyses due to 
abnormal liver or mesenteric perfusion or reperfusion following application of the 
vascular clamp.  
5.2 Ischaemic injury to control lean and HFD mice was milder than during 
the previous series of experiments 
 Because of an equipment failure and discontinuation of supply of the Right-temp 
homeothermic warming system we had used in the previous series of experiments 
(Series 2), we conducted this series of experiments using a different warming system 
(Physitemp TCAT-2, Physitemp Instruments, USA).  
 We noted that the release of both ALT (Figure 5.5) and HMGB1 (Figure 5.6) 
into the serum attained lower levels in Series 3 than in Series 2. This was observed for 
the lean uninjected control animals (Figures 5.5b and 5.6b), but was even more striking 
when we examined the results of the HFD-fed uninjected control animals from the two 
series (Figures 5.5a and 5.6a). The temperature of the tissue during ischaemia is an 
important determinant of tissue damage. We examined graphs of the core body 
temperature of the mice during the ischaemic period (Figure 5.7) and found no obvious 
differences between the ability of the two warming systems to maintain core 
temperature. Nonetheless, it seems likely that the ischaemic insult delivered to mice 
during Series 2 was greater than that during Series 3. 
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  a 
b 
Figure 5.5 Serum ALT levels attained at different intervals after 
reperfusion differed between two experimental series. ALT levels 
in Series 3 were lower than those observed in Series 2 for chow-
fed control animals (b) and this difference was even more 
striking when ALT levels in HFD-fed mice were compared (a). 
In the lean animals, ALT release peaked at 4h post-reperfusion, 
dclining subsequently. However, whilst the ALT increase was 
sustained to d1 in Series 2 (4283 ± 272 IU/L), in Series 3, ALT 
levels had already returned to baseline (47.6 ± 8.6 IU/L) by this 
time (p<0.0001). 
In the HFD-fed mice ALT levels were significantly greater in 
Series 2 than in Series 3 at 15 minutes (6982 ± 2373 IU/L v/s 
482 ± 129.2 IU/L, p<0.05), 4h (25906 ± 1579 IU/L v/s 892 ± 
167.6 IU/L, p<0.05) and d1 (13814 ± 2712 v/s 803.7 ± 664.4, 
p<0.05) post-reperfusion. The red bar depicts the mean of each 
group. 
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Figure 5.6 Similar to the disparity noted between serum ALT 
levels in Series 2 and Series 3, peak serum HMGB1 levels 
also varied between series. These differences were not 
statistically significant for the lean animals, but for the HFD-
fed mice, HMGB1 levels attained in Series 2 were 
significantly greater than those reached in Series 3 at 15m 
(150 ±23.2 ng/ml v/s 12.1 ±2.6 mg/ml, p<0.001), 1h (52.63 
±10.46 v/s 10.91 ±3.38 ng/ml, p<0.05) and 4h (140.3 ±14.7 
v/s 4.2 ±0.9ng/ml, p<0.01) post-reperfusion. The red bar 
denote the mean of each group. 
b 
a 
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Figure 5.7 Graphs of core body temperature recordings during warm 
liver ischaemia for three representative experiments. Animal 
temperature during those experiments was maintained and recorded 
using the Physitemp TCAT-2 homeothermic warming system. Core 
temperature was tightly controlled between 36.5°C and 37.5°C during 
the ischaemic period.  
    
 
170 
 
5.3 Weight gain and liver weights varied significantly between experimental 
series 
 Because the disparity between results obtained during the two series was even 
more noticeable for the HFD-fed animals, we looked for additional differences between 
the HFD-fed series which might explain this observation. 
 Histological examination of livers sampled from sham-operated mice, and at 15 
minutes post-reperfusion, revealed that the lipid infiltration was greater in livers from 
Series 2 (Figure 5.8-1e-h) than in those from Series 3 (Figure 5.8-1a-d). When the 
extent of steatosis was graded using a clinical NAFLD score, a greater proportion of 
series 2 animals (85.7%) were categorised as having severe steatosis compared to 
animals in Series 3 (42.85%) (Figure 5.8b). Fresh frozen liver sections were stained 
with ORO to visualise lipid droplets in hepatocytes (Figure 5.8c). The total liver lipid 
content in these groups was measured using the quantitative ORO method (shown in 
5.8d and 5.10c). Mice from series 2 were found to have both higher total liver lipid 
content  (686.3 ± 79 g/liver) and larger sized lipid droplets in the tissues than mice 
from series 3 (380.1 ± 40.5 g/liver, p=0.0048). Moreover, within series 3, the liver 
lipid content in the uninjected HFD control animals (253.1 ± 15.2 g/liver) was 
significantly lower than that in the esRAGE-injected animals (297.9 ± 10.7 g/liver) at 
the early sampling point of 15 minutes post-reperfusion (p<0.05) (Figure 5.10c).  
 Mice in Series 2 were fed over the Autumn-Winter months, whereas mice in 
Series 3 were fed during Spring and Summer. When we examined the weight gains for a 
larger cohort of mice fed at these times, a seasonal variation in the rate of weight gain 
became evident (Figure 5.9).  
 
    
 
171 
 
5.4 Liver and body weights were comparable between HFD-fed mice 
injected with AAV-esRAGE or AAV-GFP 
 We next compared the weights of different experimental groups within Series 3. 
Of note, the liver weights of the HFD-fed uninjected control group were only 
marginally greater than those of the chow-fed controls, whilst being significantly less 
than the liver weights in the esRAGE-injected HFD group. Liver weights in the 
esRAGE-injected and GFP-injected HFD groups were comparable (Figure 5.10a). Body 
weights were always significantly greater in the HFD-fed groups than in the chow-fed 
groups (Figure 5.10b). 
 Baseline gene expression for RAGE (Figure 5.11b) and TLR4 (Figure 5.11c) 
was greater in the heavier livers of the esRAGE-injected HFD group than in uninjected 
HFD-fed mice, and expression of the proinflammatory molecules HMGB1 (Figure 
5.11a), IL-1β (Figure 5.11e), TNFα (Figure 5.11f), MCP-1 (Figure 5.11g) and KC 
(Figure 5.11h), but not IL-6 (Figure 5.11d), also appeared to be greater in the esRAGE-
HFD group than in uninjected HFD controls. Whether this represents an effect of 
transduction with rAAV2/8 esRAGE or simply reflects more florid underlying steatosis 
in the esRAGE group is not possible to determine.  
 
5.5 Alanine aminotransferase release did not differ between experimental 
groups 
 Peak release of alanine aminotransferase into the serum occurred at four hours 
post-reperfusion in all groups. In this experimental series, there was no difference in 
ALT release between lean and HFD-fed animals (Figure 5.12a). esRAGE expression 
did not reduce ALT release from lean or steatotic hepatocytes following reperfusion 
(Figure 5.12b and c).  
    
 
172 
 
 
 
  
a 
b 
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e 
f 
g 
h 
Figure 5.8-1a (see figure legend overleaf).   
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Figure 5.8-1a Lipid accumulation in the livers of Series 3 mice sampled after 
sham-operation (a) or very early after reperfusion before the outset of 
discernable morphological changes (b-d) was less extensive than that observed 
in Series 2 mice at the same sampling times (e-sham-operated, f-h-15 minutes 
post-reperfusion). 
This observation was supported by the finding that both liver weights at 
sampling (i) and body weights prior to the application of ischaemia (j) were 
significantly greater in the Series 2 mice than in the Series 3 control cohort. 
Red lines indicate the mean for each group. 
i j 
Figure 5.8b Severity of steatosis in Series 2 compared to Series 3 
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425.8 μg 
Total 
liver 
lipid 
content 
349.8 μg 
329.6 μg 
302.3 μg 
604.4 μg 
811.1 μg 
847.6 μg 
778.4 μg 
Figure 5.8c ORO staining of liver sections from the animals 
represented in figure 5.8a. Total liver lipid content was determined 
using the qORO method and values are given next to each panel. 
Note that all panels are at magnification x200.   
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Figure 5.8d Animals in Series 2 achieved higher lipid accumulation than animals 
in the Series 3, irrespective of liver (1) or body weight (2). Data represented as 
the mean ±SEM for each group.   
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Figure 5.9  Examining a larger cohort of HFD-fed animals, we noted that 
both the rate of weight gain (a) and the final body weight attained 
following 12 weeks of HFD-feeding differed, depending on whether or 
not the feeding was carried out during the Spring-Summer months, or in 
Autumn-Winter. 12 week weights were 40.0 ±0.5g for the spring-summer 
group and 44.73 ±0.4g for mice fed during Autumn-Winter (p<0.0001) 
The red line indicates mean for each group.  
a 
b 
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Figure 5.10 Liver weights at sampling (a) and body weights prior to the 
onset of ischaemia (b) were compared between experimental groups in 
Series 3. Both liver weights (1.56 ±0.05g v/s 1.356 ±0.04g, p<0.01) and 
body weights (43.17 ±0.6g v/s 39.94 ±0.7g) were significantly greater in 
the esRAGE-injected HFD group than in the uninjected HFD control. 
Notably, the livers of the HFD-control group were not significantly 
heavier than those of the lean control mice. Body weights were always 
increased in HFD-fed mice when compared with the corresponding lean 
groups (b). Bars denote the mean for each group.  
a 
b 
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Figure 5.10c Significantly lower lipid content in uninjected HFD animals 
as 15 minutes post-perfusion than injected (p<0.05). 
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Figure 5.11 see figure legend overleaf. 
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Figure 5.11 Relative gene expression was determined using quantitative reverse-
transcriptase PCR (qRT-PCR). Values are normalised to GAPDH expression.  
Baseline gene expression for various inflammatory pathway components was 
evaluated in the liver of esRAGE-injected HFD-fed mice and HFD-fed control 
animals. Expression of the pattern recognition receptors RAGE (10.49 ±1.26 v/s 
6.15 ±0.56, p<0.05) and TLR4 (16.31 ±6.97 v/s 3.9 ±0.88, p<0.05) was 
significantly increased in esRAGE-injected mice compared with uninjected 
HFD-fed controls. Transcription of HMGB1, and of the chemokines MCP-1 and 
KC, and cytokines IL-1β and TNFα but NOT IL-6 also appeared greater in the 
esRAGE-injected mice. It is not possible to determine whether these differences 
are due to a specific effect of esRAGE, or to more extensive steatosis in these 
heavier livers. Graphs depict the mean ±SEM for each group. 
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Figure 5.12 Serum ALT levels in lean and HFD-fed 
mice, uninjected or injected with rAAV-esRAGE or 
rAAV-GFP, during warm liver IRI. 
Peak serum ALT levels were reached at 4h post-
reperfusion. No significant differences between lean 
and HFD-fed mice (a) or between esRAGE-transduced 
and GFP-transduced animals (b-c) were noted. Black 
bars represent the median of each group. 
a 
b 
c 
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5.6 Serum HMGB1 levels after reperfusion are reduced by systemic 
esRAGE overexpression 
 Peak levels of HMGB1 were measured in serum at 15 minutes post-reperfusion 
in lean mice. In contrast to our earlier findings, peak levels of HMGB1 were not 
significantly greater in HFD-fed mice than in chow-fed uninjected control animals 
(Figure 5.13a). There was an significant trend towards reduction of serum HMBG1 in 
both lean treated esRAGE (p<0.047), while the p value for the overall trend was 0.078. 
Peak serum HMGB1 was reduced to 13.5 ±0.8ng/ml in lean esRAGE expressing mice 
v/s 25 ±6.8ng/ml in lean GFP-expressing controls. Of note, ELISA readings may not 
correlate with HMGB1 activity in all groups; HMGB1 in the serum of esRAGE-
expressing mice may be complexed with esRAGE and therefore not active. At the 
mRNA level, HMGB1 expression remained fairly constant in all groups following 
reperfusion (Figure 5.14). 
 
5.7 esRAGE expression protects lean mice against overt tissue necrosis 
following ischaemia/reperfusion 
 One of the most striking features of this study was the protection against liver 
necrosis conferred on lean animals by esRAGE expression in liver. Low-power 
(magnifications x40 and x100) images of Haematoxylin and Eosin-stained sections 
were examined for the presence of necrotic areas. Hepatocyte necrosis was only 
detected in one of 7 mice (14%) in the esRAGE-expressing group at d1 post-
reperfusion, compared with 50% of mice in the GFP-expressing group and 60% of 
uninjected, lean mice (Figures 5.15).  By day 3, these proportions had fallen; there were 
no mice with frank liver necrosis in the esRAGE expressing group, as opposed to 33% 
in the GFP-expressing group and 25% in the uninjected lean mice (Figure 5.16). Note 
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that Figure 5.16 shows representative images at x100 magnification, the set of x40 
images is provided in Appendix 2.  
   
5.8 Liver-directed gene transfer of esRAGE did not protect steatotic livers 
from necrosis following ischaemia/reperfusion 
 The proportions of mice with liver necrosis on d1 did not differ appreciably 
between the uninjected lean and uninjected HFD-fed groups (Figure 5.17). In contrast to 
the protective effect noted in lean mice, expression of esRAGE did not reduce the 
incidence of liver necrosis in HFD-fed mice on either d1 post-reperfusion (Figure 5.18a) 
or d3 (Figure 5.18b). 
 
5.9 esRAGE expression reduces hepatocyte apoptosis in lean but not in 
steatotic livers 
 Immunohistochemical staining using an antibody which specifically recognises 
the cleaved (active) form of caspase 3 was used to detect apoptotic cells in liver 
sections. There was considerable variability between individual mice in the number of 
apoptotic cells detected in lean uninjected or GFP-expressing mice on d1 or d3, whereas 
very few apoptotic cells could be detected at either time in lean esRAGE expressing 
mice (Figure 5.20). Conversely, esRAGE expression did not reduce the numbers of 
apoptotic cells in steatotic livers- if anything, there may have been more apoptosis in the 
esRAGE expressing livers (Figure 5.21). 
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Figure 5.13 Peak levels of HMGB1 in the systemic circulation were found at 
15 minutes post-reperfusion. 
The release of HMGB1 from lean or uninjected control livers appeared to be 
greater than that from steatotic uninjected controls (particularly at 15m), but 
this difference was not statistically significant (a).  
esRAGE expression was associated with reduced HMGB1 levels overall in 
both lean (b) and HFD-fed mice (c). The peak serum HMGB1 was reduced 
from 24.9 ± 6.8ng/ml in lean GFP expressing mice to 13.56 ± 0.84ng/ml in 
the lean esRAGE-transduced group. Data is represented as the mean ± SEM 
for each group. 
a b 
c 
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Figure 5.14 Relative gene expression for HMGB1 was 
determined using qRT-PCR. 
Gene expression for HMGB1 remained relatively 
constant in all experimental groups during IRI. Graphs 
show the mean ±SEM for each group. 
a 
b 
c 
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Lean IR1d esRAGE x100 
Lean IR 1d GFP x100 
Figure 5.15 see figure legend overleaf. 
    
 
187 
 
 
   
Lean IR1d uninjected IR1d x100 
Figure 5.15 H and E-stained sections from esRAGE-transduced, GFP-
transduced or uninjected lean controls were examined under low (x40) and 
medium (x100) magnification.  
Representative images from four different animals/group at x100 
magnification are shown here. The set of x40 images is provided in 
appendix 2. Only 14% of the livers from esRAGE-injected animals had 
areas of frank necrosis detectable on histological examination, compared 
with 50% of GFP-expressing and 60% of uninjected lean controls.  
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Lean IR3d esRAGE x100 
Lean IR3d GFPx100 
Figure 5.16 see figure legend overleaf. 
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Lean IR3d uninjected x100 
Figure 5.16 Liver sections from lean animals sampled at d3 were evaluated 
for the presence of necrosis as above. 
No overt necrosis was detected in any esRAGE-injected animals on d3, 
whilst the proportion of livers with necrosis was 33% and 25% in the GFP-
injected and uninjected animals, respectively. 
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Figure 5.17 No difference was noted between the 
proportion of lean control livers and steatotic control 
livers with necrosis on d1 (a) or d3 (b). 
a 
b 
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HFD IR1d esRAGE x100 
Figure 5.18 see figure legend on later page. 
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  HFD IR1d uninjected HEx100 
Figure 5.18 see figure legend on later page. 
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HFD IR1d GFP x100 
Figure 5.18a Liver sections from HFD-fed animals sampled on d1 were 
evaluated for the presence of necrosis as above. 
No difference between groups in the proportion of livers with necrotic areas was 
discerned.  
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  HFD IR3d esRAGE x100 
Figure 5.18b see figure legend on later page 
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  HFD IR3d GFPx100 
 
HFD IR3d uninjected x100 
Figure 5.18b see figure legend on later page 
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Figure 5.18b Liver sections from HFD-fed animals 
sampled on d3 were evaluated for the presence of 
necrosis as above.  
Whereas in GFP-injected and uninjected animals, the 
incidence of frank liver necrosis was declining by d3, 
there had been no such reduction in the esRAGE-
expressing mice.  
Figure 5.18c Rates of necrosis at d1 post-reperfusion 
in lean and fatty livers transduced with either rAAV-
GFP or rAAV-esRAGE.  
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Figure 5.19 Immunohistochemical staining for the cleaved (active) form 
of caspase 3 was used to detect apoptotic cells in liver sections. 
Fewer apoptotic hepatocytes (arrows) were detected in esRAGE-injected 
lean animals on d1 post-reperfusion (a,b), compared to GFP-injected 
(c,d) and uninjected (e,f) lean animals at the same time point, 
(Magnification x400).  
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Figure 5.20 The presence of apoptotic cells in lean livers sampled on d3 post-
reperfusion was assessed as above. Fewer apoptotic cells (arrow) were detected 
in esRAGE-injected lean livers (a-c), compared to GFP-injected (d-f) and 
uninjected (g-i) lean animals at same time point. (Magnification x400). Data are 
represented as the ratio of caspase positive cells to the total number of nuclei in 
each field counted. The graph (j) shows the mean ±SEM for each group.   
f 
g h i 
j 
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Figure 5.21 The presence of apoptotic cells in liver sections from HFD-fed 
animals was determined as above. Representative images of livers from 
esRAGE-injected (a), GFP-injected (b) and uninjected (c) mice at d1 post-
reperfusion are shown. (Magnification x400). Data are represented as the ratio 
between the number of apoptotic cells and the total number of nuclei counted in 
each field. The numbers of apoptotic cells were greatest in steatotic liver on d1 
post-reperfusion. There appeared to be more caspase-positive cells in the livers 
of esRAGE-transduced mice than in those of either GFP-transduced or 
uninjected HFD-fed control mice on both d1 and d3 post-reperfusion. This 
difference was not statistically significant. 
a b c 
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5.10 Neutrophil infiltration in lean and steatotic livers 
 Unlike many other parameters which were directly compared between lean and 
steatotic livers, the extent of neutrophil infiltration appeared to be greater in the livers of 
HFD-fed uninjected animals compared to those of lean uninjected mice on both d1 and 
d3 post-reperfusion (Figure 5.22). Few neutrophils were detected in the majority of the 
esRAGE expressing lean livers on day 1 or day 3 whereas neutrophil numbers in the 
GFP-expressing groups were more variable (Figure 5.23). Neutrophil numbers were not 
reduced by esRAGE expression in steatotic livers (Figure 5.24) and on d3 there 
appeared to be more neutrophils in esRAGE expressing than in GFP-expressing fatty 
livers.  
 
5.11 esRAGE expression promotes liver regeneration 
 Hepatocyte proliferation was assessed using the markers PCNA and Ki67. In 
lean and HFD control mice peak numbers of PCNA-positive cells were noted on d1 
post-reperfusion, and did not obviously differ between groups (Figure 5.25). There 
appeared to be an increase in the proportion of proliferating hepatocytes in esRAGE 
expressing lean mice on d1 (Figure 5.26). Whereas esRAGE expression did not alter 
hepatocyte proliferation in steatotic liver on d1 (Figure 5.27), by d3 post-reperfusion 
there were significantly greater PCNA positive nuclei in esRAGE-expressing steatotic 
livers than in the GFP-expressing group (Figure 5.28) (0.09 ±0.02/HPF v/s 0.0005 
±0.004/HPF, p<0.01). This was consistent with the finding of increased Ki67-positive 
nuclei in esRAGE transduced steatotic livers compared with those in the GFP-
transduced steatotic control group (Figure 5.29) (0.06 ±0.018 v/s 0.008 ±0.003, p<0.05).  
 
    
 
201 
 
 
  
a b c 
d e f 
  
 
 
 
Figure 5.22 Immunohistochemical staining for the neutrophil marker Ly6B was 
used to assess the number of infiltrating neutrophils in the livers of uninjected 
and HFD-fed mice during IRI. Neutrophil infiltration reached a peak on d1 post-
reperfusion, and appeared greater in HFD-fed mice (d-f) than in lean controls (a-
c) (magnification x400). These changes were not statistically significant. The 
graph depicts the mean ±SEM for each group.   
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Figure 5.23 Neutrophil infiltration appeared to be less intense in lean 
esRAGE-injected mice at d1 post-reperfusion (a-c and j) than in GFP-
injected (d-f and j) or uninjected (g-i) animals sampled following the same 
interval (magnification x400). These changes were not statistically 
significant. Black bars show the median for each group.  
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Figure 5.24 Neutrophil infiltration of the livers of HFD-fed mice during IRI was 
assessed as above. Images show representative fields from uninjected (a, d), 
esRAGE-injected (b, e) and GFP-injected (c, f) mice at d1 and 3d post-
reperfusion, respectively. (Magnification x400). The numbers of neutrophils 
infiltrating esRAGE-expressing and GFP-expressing livers on d1 was similar, 
though on d3 the extent of neutrophil infiltration was greater in the esRAGE-
injected mice (8.15 ±2/HPF) than in the GFP-injected group (0.91 ±0.13/HPF, 
p<0.05). Results show mean and SEM for each group.  
 
 
g 
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Figure 5.25 Immunohistochemical staining for the proliferation marker PCNA 
was used to assess hepatocyte proliferation in uninjected lean and HFD-fed 
control animals during liver IRI. Representative images of liver sections from 
HFD-fed mice, either sham-operated (a-b), at d1 (c-e) or d3 (f-h) post-
reperfusion. Dotted lines separate necrotic areas from viable liver. Cells are only 
counted in the viable areas. (Magnification x400). Data are represented as the 
ratio between the number of PCNA positive nuclei and the total number of 
nuclei counted in each field. PCNA-positive nuclei increased on d1, declining 
slightly by d3 post-reperfusion. The graph shows the mean ±SEM for each 
group.   
d e 
f g h 
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Figure 5.26 Hepatocyte proliferation in the livers of lean mice transduced with 
esRAGE or GFP were assessed using PCNA-staining as above. The number of 
PCNA-positive cells in the esRAGE-injected lean livers (a-c) varied 
substantially between mice, being greatest in the one animal with evidence of 
liver necrosis. The dotted line demarcates a necrotic area from the viable liver. 
Cells are only counted in the viable areas. PCNA staining of the livers from lean 
GFP-expressing mice are shown in (d-f) (magnification x400). 
Data are represented as the mean ±SEM for each group.    
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Figure 5.27 Hepatocyte proliferation in the livers of HFD-fed mice sampled on 
d1 post-reperfusion was evaluated using PCNA-staining as above. No obvious 
differences between the number of proliferating hepatocytes in esRAGE-
transduced (a-c) and GFP-transduced (d-f) livers was observed (magnification 
x400).  
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Figure 5.28 In contrast, many more proliferating hepatocytes were counted in 
liver sections from esRAGE-expressing HFD-fed mice on d3 after reperfusion 
(a-c) than in those from GFP-expressing mice sampled after the same interval 
(d-f) (magnification x400). Dotted lines separate necrotic areas from viable liver. 
Proliferating cells are only counted in the viable areas. Data are represented as 
the ratio between PCNA-positive nuclei and the total number of nuclei counted 
in each field (g). This ratio was significantly higher for esRAGE-injected mice 
on d3 post-reperfusion (0.09 ±0.02) than for GFP-injected mice sampled on d3 
(0.0005 ±0.0004, p<0.01). The graph show the mean ±SEM for each group. 
a b c 
d e f 
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Figure 5.29 An additional proliferation marker, Ki67, was used to assess 
hepatocyte proliferation during warm IRI of lean and steatotic livers (a).  
Data are represented as the ratio of Ki67-positive cells to the total number of 
nuclei counted in each field. Ki67-positive nuclei were most numerous on d3 
post-reperfusion in both the lean and steatotic livers. In the HFD-fed groups, 
more Ki67+ nuclei were found in the livers of esRAGE expressing mice (b) than 
in those of GFP expressing animals (c) on d3 (magnification x400). The dotted 
line demarcates necrotic tissue from viable liver tissue. Proliferating cells are 
counted only in the viable areas. The Ki67 ratio was 0.06 ±0.01/HPF in esRAGE-
injected mice and 0.007 ±0.003/HPF (p<0.05) in GFP-injected controls at this 
time. The graphs shows the mean ±SEM for each group. 
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 5.12 Oval cell proliferation may be augmented by esRAGE expression in 
steatotic livers 
 Oval cells were detected by staining for the marker MIC1-1C3. No changes in 
the numbers or distribution of oval cells were noted in any lean liver group during IRI 
(Figure 5.30). In steatotic livers, the numbers of oval cells were greater on d3 in 
esRAGE expressing livers than in GFP-transduced livers (17.26 ±0.94 v/s 12.70 
±0.98/HPF, p<0.05), and they appeared to be more widely disseminated throughout the 
liver tissue than those in the HFD control or GFP-expressing livers (Figure 5.31).  
 
5.13 Macrophage numbers 
 The numbers of F4/80-positive macrophages and Kupffer cells within the liver 
did not change substantially during ischaemia-reperfusion injury (Figure 5.32).  
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d 
g 
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e 
h 
c 
f 
i 
Figure 5.30 Oval cells were detected by immunohistochemical staining for the 
marker MIC1-1C3. No differences in oval cell numbers or distribution were 
detected between the experimental groups on d3 post-reperfusion. esRAGE 
injected lean animals (a-c) GFP-injected (d-f) and uninjected (g-i) lean animals 
(magnification x400). The graph shows the mean ±SEM for each group.  
j 
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Figure 5.31 In HFD-fed mice, oval cells were more widely disseminated through 
the liver tissue in the esRAGE-expressing group (c-d) than in the GFP-expressing 
mice (a-b) (magnification x400). Oval cell counts were 17.26 ±0.93 v/s 12.7 
±0.98/HPF in the esRAGE and GFP groups on d3, respectively (p<0.05). The 
graph shows the mean ±SEM for each group.  
a b 
c d 
e 
    
 
212 
 
 
   
Figure 5.32 Immunohistochemical staining for the macrophage marker 
F4/80 was used to determine macrophage and Kupffer cell numbers in 
the liver during IRI. No substantial changes were noted in any 
experimental groups. The graphs show the mean ±SEM for each group. 
a 
b 
c 
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5.14 Gene expression for various inflammatory pathway components is 
increased in steatotic livers transduced with esRAGE 
 Quantitative RT-PCR was used to determine changes in gene expression during 
IRI for the pattern recognition receptors RAGE and TLR4 and for a range of 
downstream cytokines and chemokines in lean or steatotic liver of uninjected control 
mice, or mice transduced with AAV-esRAGE or AAV-GFP.  
 Expression of both RAGE and TLR4 appeared to be increased in lean control 
livers compared to steatotic control livers during IRI (Figures 5.33a and 5.34a). For 
RAGE, relative mRNA expression was 10.96 ±0.99 in lean mice v/s 5.8 ±0.52 in the 
HFD-fed group at 4 hours post-reperfusion (p<0.01) (Figure 5.33a). Expression of both 
pattern-recognition receptors increased following ischaemia/reperfusion in lean 
animals- no obvious differences were noted between the esRAGE expressing and GFP-
expressing groups (Figures 5.33b and 5.34b).  
 Somewhat surprisingly, expression of RAGE and TLR4 was shown to be greater 
in steatotic livers transduced with esRAGE than in those expressing GFP (Figures 5.33c 
and 5.34c). Relative gene expression for TLR4 in liver was 16.46 ±2.25 in the HFD-
esRAGE group at 4h post-reperfusion, compared with 6.6 ±1.09 in the HFD-GFP cohort 
(p<0.01).  
 Interleukin 6 gene expression increased rapidly in lean and HFD mice to peak at 
one hour post-reperfusion (Figure 5.35), reaching a relative gene expression of 86.2 
±17.76 at 1h in lean mice v/s 10.41 ±2.83 at baseline, p<0.05. In HFD-fed mice, IL-6 
mRNA expression was 95.88 ±14.7 at 1h in post-reperfusion v/s 5.536 ±3.7 prior to 
inset of ischaemia, p<0.01 (Figure 5.35a). There was a trend towards reduction of liver 
IL-6 expression in lean, but not HFD-fed mice transduced with esRAGE (Figure 5.35b-
c) (p=0.02 on ANOVA).  
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 IL-1β expression also peaked early (Figure 5.36) and was increased in the livers 
of HFD-fed mice expressing esRAGE compared with those expressing GFP. Relative 
gene expression in the livers of the esRAGE-HFD group at 1 hour post reperfusion was 
36.3 ±13.87 compared with 13.44 ±7 in the livers of the GFP-HFD mice (p<0.05) 
(Figure 5.36c). TNFα gene expression was upregulated following 
ischaemia/reperfusion, but did not differ significantly between treatment groups (Figure 
5.37).  
 The expression of KC and MCP-1 was elevated from one-hour post-reperfusion. 
As we noted previously, KC was expressed more robustly in lean than in HFD liver. KC 
expression was increased in the livers of HFD-fed mice expressing esRAGE compared 
to those expressing GFP. Relative mRNA expression for KC was 672.6 ±61.17 in the 
esRAGE-HFD group and 380 ±46.86 in the GFP-HFD animals at four hours post 
reperfusion (p<0.05) (Figure 5.38). No changes in MCP-1 expression were noted 
between treatment groups (Figure 5.39). 
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Figure 5.33 qRT-PCR was used to determine the expression of a range of inflammatory 
pathway components. Gene expression was normalised to that of GAPDH. 
RAGE expression in the liver increased following reperfusion in uninjected, lean mice, 
and at 4h post-reperfusion was significantly greater than that in uninjected HFD-fed 
controls (10.96 ±1 v/s 5.8 ±0.5, p<0.01) (a). RAGE expression in lean livers did not vary 
between esRAGE-expressing and GFP-expressing mice (b). At 4h and d1 post-
reperfusion, relative gene expression for RAGE appeared greater in fatty livers transduced 
with esRAGE than in those transduced with GFP (c). This difference was not statistically 
significant. Graphs show the mean ±SEM for each group.  
a 
b 
c 
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Figure 5.34 Relative hepatic gene expression for TLR4 increased following reperfusion in 
lean mice and appeared to be greater in the livers of lean uninjected animals than in those 
of HFD-fed mice at all times post-reperfusion (a). TLR4 gene expression followed a 
parallel trend in esRAGE-expressing and GFP-transduced lean livers-no differences were 
observed between these groups (b). Conversely, TLR4 gene expression was significantly 
elevated in the livers of HFD-fed mice transduced with esRAGE compared to those 
expressing GFP from 1h to d1 post-reperfusion. At 4h post reperfusion, TLR4 expression 
was 16.46 ±2.25 in esRAGE group v/s 6.6 ±1.1 in the GFP group, p<0.01. Graphs show 
the mean ±SEM for each group.    
a 
b 
c 
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Figure 5.35 Gene expression for IL-6 was rapidly upregulated in livers and 
peaked at 1h post-reperfusion in all experimental groups.  
IL-6 expression did not differ between lean and HFD-fed uninjected mice 
(a). IL-6 expression in lean, esRAGE-expressing livers appeared less than 
that in lean GFP-expressing livers at 1h and 4h post-reperfusion (p=0.02 on 
one-way ANOVA) (b), whilst no differences were observed between 
esRAGE-expressing and GFP-expressing steatotic livers (c). Graphs show 
the mean ±SEM for each group.  
a 
b 
c 
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Figure 5.36 Interleukin 1β gene expression reached a peak at 1h 
post-reperfusion. At this time, IL-1β expression appeared greater 
in the livers of lean uninjected mice than in those of HFD-fed 
controls (a). IL-1β expression also seemed greater in lean 
esRAGE-expressing livers than in lean GFP-transduced livers at 
1h and at 4h post-reperfusion (b). In the HFD-fed groups, IL-1β 
gene expression was 36.3 ±13.87 in esRAGE-transduced mice at 
1h post-reperfusion compared to 13.44 ±7 (p<0.05) in GFP-
transduced mice at the same time (c). Graphs show the mean 
±SEM for each group.  
a 
b 
c 
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Figure 5.37 TNFα is another gene which manifests a rapid 
response during IRI. The extent of TNFα gene expression was 
comparable between esRAGE and GFP-transduced livers of 
both lean (b) and HFD-fed (c) mice. Graphs show the mean 
±SEM for each group.  
a 
b 
c 
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Figure 5.38 KC gene expression was greater in lean livers than in the 
livers of HFD-fed controls (a). At 4h following reperfusion, relative 
gene expression of KC was 523.8 ±131 in lean animals and 232.5 
±29.84 (p<0.05) in the HFD-fed mice (a). KC expression in the liver of 
esRAGE-injected lean mice was elevated compared to that in GFP-
transduced lean controls at 1h and 4h post-reperfusion (b). At 1h 
relative gene expression for KC was 694.2 ±115.8 in the esRAGE group 
and 233.9 ±32.44 in the GFP group (p<0.01) (b). Similarly, KC 
expression was consistently elevated in the livers of esRAGE-
expressing HFD-fed mice compared to those of GFP-injected controls 
(c). At 4h post-reperfusion, relative gene expression for KC was 672.6 
±61.17 in the esRAGE group v/s 380 ±46.86 in the GFP group (c). 
Graphs show the mean ±SEM for each group.  
a 
b 
c 
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Figure 5.39 Hepatic gene expression for MCP-1 was moderately 
upregulated during liver IRI. No significant differences in MCP-1 
expression were noted between lean and HFD-fed mice (a) or between 
lean or HFD-fed mice transduced with esRAGE or GPF (b-c). Graphs 
show the mean ±SEM for each group.  
   
a 
b 
c 
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5.15 Discussion 
 The principal purpose of this section of the project was to determine whether 
liver-directed gene transfer of esRAGE could attenuate ischaemia/reperfusion injury in 
lean and/or steatotic livers. Upon analysis of the results, it became apparent that there 
was a discrepancy between the severity of ischaemic injury in the lean and HFD-fed 
control animals in the two experimental series. This disparity will be explored and 
considered further in the general discussion in Chapter 6.  
 Overall, expression of esRAGE in the hepatocytes of lean mice exerted a 
protective effect in this model of partial, warm liver IRI. Peak serum HMGB1 levels 
were reduced, as was liver cell death, whilst hepatocyte regeneration was promoted. 
ALT levels did not reflect this protective effect- a phenomenon which has also been 
observed by others when soluble RAGE was used in models of total warm liver 
ischaemia/reperfusion or massive liver resection, despite clear evidence of significantly 
improved survival in the sRAGE-treated groups [127]. No major effects of esRAGE 
upon proinflammatory gene transcription were noted.  
 In contrast, injury to steatotic hepatocytes was worsened by transduction with 
esRAGE. Body and liver weights were comparable between the esRAGE-injected and 
GFP-injected HFD-fed groups, and so differences in outcome between these groups are 
not likely to be due to variability of liver lipid accumulation.  
 Endoplasmic reticulum stress contributes to the pathogenesis of both NAFLD 
[383] and liver IRI [384, 385]. ER stress leads to a general downmodulation of protein 
synthetic function but to increased sensitivity to TLR4 signalling and to upregulation of 
proinflammatory cytokine expression [385-388]. Defective proteins are exported from 
the endoplasmic reticulum for proteosomal degradation. If the reduction in protein 
synthesis and removal of misfolded or otherwise defective proteins from the 
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endoplasmic reticulum fails to resolve the stressed condition, hepatocyte apoptosis 
ensues.  
 Overexpression of the transgene product in hepatocytes following transduction 
with gene therapy vectors, including AAV, has also been reported to induce ER stress 
[389]. Introduced proteins which enter the secretory pathway (such as esRAGE) may 
have a greater propensity to exacerbate underlying ER stress in steatotic hepatocytes 
than proteins such as GFP which do not traffic to defined subcellular compartments. 
Alternatively, the increased susceptibility to damage in esRAGE-expressing livers may 
relate to a specific property of esRAGE, rather than to its subcellular disposition, and 
these potential effects of esRAGE could operate in combination to sensitize transduced 
steatotic hepatocytes to ischaemic injury.  
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Chapter 6: General discussion 
Liver transplantation is a life-saving treatment for the growing number of 
patients with end-stage liver disease. In most cases, transplant recipients are committed 
to lifelong immunosuppression with its attendant complications of opportunistic 
infections, cancer and metabolic derangement. Spontaneous liver transplant tolerance is 
a well-documented phenomenon in both small and large animals [32, 33, 390]. In the 
clinical setting, up to 20% of liver transplant recipients can be weaned from all 
immunosuppression [35]. Deepening our understanding of the mechanisms underlying 
spontaneous liver transplant tolerance, including the factors which promote or impede 
tolerance induction, may allow a greater proportion of liver transplant recipients to 
avoid the negative consequences of long term immunosuppression.  
Some degree of ischaemia/reperfusion injury inevitably accompanies liver 
transplantation, even in the case of lobar transplantation from a living donor. Most liver 
grafts are sourced from deceased organ donors, and here, the strong upregulation of 
proinflammatory signalling which occurs in response to donor brain death [391, 392] 
can have deleterious effects upon both the immediate function of the transplanted 
organs and the ability to achieve transplantation tolerance [300]. As the demand for 
liver transplantation continues to outstrip the supply of donated livers, the donor pool is 
being broadened to include donors with less than optimal characteristics- “extended 
criteria donors”. In the case of liver transplantation, many of these extended criteria 
donors will have some degree of hepatic steatosis. Steatosis is generally associated with 
poorer outcomes following liver transplantation, but in this regard, the experience of 
different centres has been highly variable [277, 281].  
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In parallel with its increasing prevalence in developed and developing countries, 
fatty liver is increasingly frequent as an incidental finding in organ donors. Uncovering 
the mechanisms whereby hepatic steatosis increases the susceptibility of donor livers to 
damage during brain-death and ischaemia/reperfusion injury, and developing strategies 
to attenuate donor organ damage could allow expanded use of steatotic donor livers 
with safety. Moreover, it is increasingly recognised that proinflammatory conditions in 
the graft microenvironment oppose the development of organ transplant tolerance [393]. 
Reducing inflammation in steatotic donor livers could confer benefits beyond the peri-
transplant period if it also facilitated the emergence of donor-specific tolerance.  
One consistent observation in spontaneous liver transplant tolerance is that 
activated alloreactive T cells undergo clonal exhaustion or deletion and do not mount a 
destructive response against the transplanted liver [41]. Cytokines which signal through 
the common gamma chain provide essential survival signals for activated alloreactive T 
cells [350, 394]. In the first part of the project, we tested the hypothesis that the 
concentration of γc signalling cytokines available to activated alloreactive T cells would 
be reduced in tolerated liver transplants in the PVG to DA rat strain combination, 
compared with kidneys or hearts transplanted across the identical allogeneic mismatch, 
which are rapidly rejected. We confirmed that lower levels of IL-2, IL-4, IL-2Rα and 
IL-15Rα were found in the tolerated liver grafts whilst the level of IL-7Rα, which is 
inversely related to the global extent of γc signalling, was increased. 
Although the precursor frequency of alloreactive T cells is high compared with 
that of T cells recognising conventional antigens [395], alloreactive T cell clones are, 
nonetheless, finite and cannot expand indefinitely. Given that the mass of transplanted 
liver parenchyma is approximately 10 times that of a transplanted heart or kidney, 
dilution of the survival cytokines produced by activated allospecific T cells within the 
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large mass of liver parenchyma may contribute to their subsequent deletion or 
exhaustion.  
Brain death and warm ischaemia/reperfusion injury result in non-alloantigen 
specific T cell activation as well as amplifying the adaptive response to transplanted 
organs. Increased presence of survival cytokines within the liver microenvironment 
following ischaemia/reperfusion may thus oppose some of the processes which underlie 
liver transplant tolerance induction. Innate immune signalling through TLR4, RAGE 
and other Pattern-recognition receptors also impedes the emergence of tolerance. In 
view of the increasing frequency of hepatic steatosis within the pool of potential organ 
donors, we undertook a study examining the effect of simple steatosis without overt 
fibrosis or inflammation, upon the outcomes of partial warm liver ischaemia/reperfusion 
injury in mice.  
A number of previous studies have examined the effects of steatosis on warm 
liver IRI or the function or survival of syngeneic liver grafts [396-401]. No animal 
studies have utilised an allograft model of liver transplantation in conjunction with 
donor steatosis. Features of these studies and of this thesis are compared against each 
other in table 6.1. Many of these studies utilise the leptin-deficient ob/ob model; those 
in which HFD-feeding is used to produce hepatic steatosis have involved short-duration 
feeding of a very high fat content diet. In contrast, this thesis utilises a 45% fat diet 
which is believed to closely mimic the consequences of the western diet and results in 
more gradual liver lipid accumulation. In this thesis, I have broadly characterised the 
proinflammatory signalling pathways contributing to the increased severity of ischaemia 
reperfusion injury in fatty liver. Important findings include increased cytoplasmic 
HMGB1 in steatotic hepatocytes prior
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Study Species and 
strain 
Cause of 
steatosis 
Type of 
ischaemia 
Duration of 
ischaemia 
Scientific questions 
 
readouts 
Birsner et al. 
J Surg Res, 
2004 [396] 
ob/ob donor 
C57BL/6 
recipient (no 
MHC 
difference) 
genetic Orthotopic 
liver transplant 
Warm 32 m 
Cold variable 
(60-90 m) 
Observational study Animal survival 
Serum transaminases 
Histology at 2h post-
reperfusion 
Chavin et al., 
Am J 
Transplant 
2004 [401] 
ob/ob donor 
C57BL/6 
recipient (no 
MHC 
difference) 
genetic Warm total  
or Orthotopic 
liver transplant 
15m 
ischaemic 
times not 
provided 
Would fatty acid 
synthase blockade 
protect livers against 
warm ischaemia-
reperfusion injury?  
Animal Survival 
Serum transaminases 
Serum endotoxin levels 
Gene expression for 
PPAR-  and 
uncoupling protein 2 
Fiorini et al., 
[400] 
ob/ob genetic Warm total 15m Would antibodies 
against endotoxin 
protect against warm IRI 
in steatotic livers? 
Animal Survival 
Serum transaminases 
Circulating endotoxin 
Hepatocyte apoptosis 
(TUNEL) 
Selzner et al. 
J Hepatol, 
2006 [402] 
ob/ob 
(macrovesicular 
pattern of 
steatosis) 
C57BL/6 plus 
choline-
deficient diet 
(predominantly 
microvesicular 
steatosis) 
genetic 
 
 
Diet-induced 
 
 
Warm partial 
 
 
Warm partial 
followed by 
resection of 
non-ischaemic 
part 
45 m 
 
 
60 m 
Would macrovesicular 
steatosis 
be associated with a 
worse outcome 
following warm IRI? 
 
Would ischaemic 
preconditioning improve 
outcomes? 
Animal survival 
Serum transaminases 
Intrahepatic energy 
content (ATP) 
Portal vein and liver 
sinusoidal blood flow 
El-Badry et al., 
Hepatology, 
2007 [399] 
ob/ob 
C56BL/6 plus 
choline-
deficient diet 
genetic 
Diet-induced 
 
Warm partial 45 m Would omega-3 fatty 
acids improve outcome 
of warm liver IRI 
Serum transaminases 
Sinusoidal perfusion 
Phagocytic activity of 
Kupffer Cells 
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He et al., 
J Immunol, 
2009 [397] 
C57BL/6 High-fat diet 
induced. 
Diet provided 
60% of daily 
calories from 
fat for 4 weeks 
Warm total  
or Orthotopic 
liver transplant 
45m 
ischaemic 
times not 
provided 
Does complement 
contribute to the 
enhanced susceptibility 
of fatty livers to 
ischaemia-reperfusion 
injury? 
Animal survival 
Serum transaminases 
Histology 
Measurement of 
neutrophil 
myeloperoxidase 
Serum IL-6 and TNF 
Ellett et al., 
Liver 
transplantation, 
2009 [398] 
C57BL/6 
TLR4-/- 
C57BL/6 
High-fat diet 
induced. 
Diet provided 
60% of daily 
calories from 
fat for 4 weeks 
Warm total 15m or 35 m Is TLR4 signalling 
important in murine 
warm liver IRI? 
Animal Survival 
Serum transaminases 
Serum endotoxin levels 
Histology 
Immunostaining for 
cellular infiltrate 
Gene expression for 
proinflammatory 
cytokines  
This thesis C57BL/6 High-fat diet 
induced 
Diet provided 
45% of daily 
calories from 
fat for 12 
weeks 
Warm partial 30 m What are some of the 
mechanisms increasing 
susceptibility of fatty 
livers to warm ischaemia 
and reperfusion? 
 
Would gene transfer of 
the naturally occurring 
decoy receptor esRAGE 
ameliorate IRI in fatty 
and/or lean livers? 
 
Serum transaminases 
Serum levels of 
HMGB1 
Immunofluorescent 
staining for localisation 
of HMGB1 within 
hepatocytes 
Gene expression for 
innate immune receptors 
TLR4 and RAGE 
Serum levels of a panel 
of proinflammatory 
cytokines and 
chemokines 
Gene expression for a 
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panel of 
proinflammatory 
cytokines and 
chemokines 
Histology for necrosis, 
immunostaining for 
cellular infiltration, 
hepatocyte apoptosis, 
Hepatocyte proliferation 
and oval cell/bile duct 
proliferation. 
Table 6.1 Animal studies that have utilised an allograft model of liver transplantation in conjunction with donor steatosis.
    
 
231 
 
 to reperfusion, along with significantly increased serum HMGB1 levels in the 
early post-reperfusion phase. A reciprocal relationship between hepatocyte proliferation 
and apoptosis was noted in steatotic livers compared with lean livers, and is a likely 
contributor to the reduced ability of fatty livers to regenerate following ischaemia. Ellett 
et al. [398] demonstrated that animal survival was improved, and transaminase release 
and cytokine gene expression were attenuated in steatotic livers genetically deficient in 
TLR4. This thesis builds on these and other works to examine the ability of the 
HMGB1-binding decoy receptor esRAGE to ameliorate liver inflammation and promote 
regeneration of HFD-induced steatotic livers following warm ischaemia and 
reperfusion. 
In the first stage of this study, we established a model of fatty liver through 
feeding male C57BL/6J mice a 45% fat diet. Lean mice and those with fatty livers were 
then subjected to a moderate ischaemic insult, followed by reperfusion. Compared to 
the livers of lean mice, steatotic livers showed a marginal increase in the gene 
expression of HMGB1, and of its receptors RAGE and TLR4. Far more striking was the 
redistribution of HMGB1 from the nucleus to the cytoplasm of steatotic hepatocytes. 
This was reflected in the increased levels of HMGB1 present in the systemic circulation 
of HFD-fed mice as early as 15 minutes following reperfusion. Following IRI, there was 
substantial upregulation of TLR4 expression in the fatty livers at days 1 and 3 post-
reperfusion, which was not observed in the lean livers. Although we did not assess this 
directly, increased intestinal permeability has been described in mouse models of 
NAFLD [380, 381] and also in association with liver IRI [382]. Bacterial products 
entering the systemic circulation could bind to HMGB1, resulting in amplification of 
their proinflammatory signalling potency. The increased release of HMGB1 into the 
extracellular milieu, combined with the likely presence of bacterial products within the 
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systemic circulation and the increased expression of pattern recognition receptors, such 
as TLR4, could, collectively, account for the increased severity of 
ischaemia/reperfusion injury observed in the HFD-fed group. 
Liver injury was considerably more severe in the HFD-fed mice, as assessed by 
release of ALT into the serum, the extent of liver necrosis, neutrophil infiltration, and 
apoptosis, and the synthesis and/or systemic release of proinflammatory cytokines such 
as IL-6, TNFα, IL-1β and IL-17, supporting the contention that  IRI in fatty livers may 
perturb liver transplant tolerance induction mechanisms to a  greater extent than IRI in 
lean livers through the increased production and release of IL-6, thereby favouring the 
differentiation of Th17 cells rather than FoxP3+ Tregs. The γc signalling cytokine IL-7 
is produced by hepatocytes during liver inflammation in response to engagement of 
TLR4 [379]. IL-7 levels were increased in the serum of HFD-fed mice, but not lean 
mice at d1 following reperfusion, coincident with the peak of upregulation of TLR4 
expression in steatotic hepatocytes. Hepatic steatosis may thus also interfere with the 
development of spontaneous liver transplant tolerance by augmenting production of the 
T cell survival factor IL-7.  
Not only is the liver injury in HFD-fed mice more extensive than that in lean 
mice, the ability of hepatocytes to proliferate and regenerate the lost liver mass during 
the recovery phase, as assessed by staining for the proliferation markers PCNA and Ki-
67, is reduced. This is in accordance with previous reports that steatotic hepatocytes are 
in cell-cycle arrest [270].  
In models of total liver IRI or massive liver resection, blockade of RAGE 
signalling significantly improves survival, principally by reducing apoptosis and 
promoting proliferation [128]. Systemic delivery of esRAGE to lean mice or to mice 
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with hepatic steatosis could reduce inflammation and support recovery from the 
ischaemic insult in the following ways: 
1. By acting as decoy receptor and binding proinflammatory mediators such 
as HMGB1, S100B and AGEs.  
 As a consequence of the ligand-promiscuity of RAGE, some ligands such as 
HMGB1, signal through multiple other receptors, and esRAGE administration would 
interrupt signalling through these pathways as well as signalling through RAGE.  
2. By forming heterodimers at the cell surface with membrane-bound 
RAGE, thus interrupting RAGE signal transduction specifically.  
To avoid the need for repeated dosing, an adeno-associated viral vector was used 
to express esRAGE in the liver. Strong, specific hepatocyte expression was conferred 
by the combination of AAV serotype 8 capsid, and the human alpha-1 antitrypsin 
promoter-ApoE enhancer regulatory elements. Although transgene expression was 
hepatocyte-specific, secretion of esRAGE from hepatocytes yielded high levels of 
esRAGE in the systemic circulation.  
 In order to evaluate the effects of AAV-mediated esRAGE gene transfer, we 
undertook an additional series of experiments in which mice first received a high-fat or 
normal diet, and then were subjected to ischaemia-reperfusion injury, with or without 
being inoculated with AAV-esRAGE or the control vector AAV-GFP prior to the 
application of ischaemia.  
 Due to an equipment failure and the discontinuation of the Right-temp warming 
system by the manufacturer, we were required to change to a different homeothermic 
warming system for the experiments carried out for Chapter 5 (Series 3). For this third 
series of IRI experiments, procedures in lean and HFD-fed mice, transduced or not with 
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either vector were intercalated. When we started to analyse the results, it quickly 
became apparent that the results in the two uninjected groups did not recapitulate those 
in the earlier series of experiments (Series 2). In the interim between the two series, we 
had adopted a different warming system where the heating pad maintained a constant 
low temperature of 37°C, and the warming lamp switched on and off very rapidly in 
response to feedback about the core temperature from the rectal probe. Although the 
graphs of core body temperature during the ischaemic periods were not ostensibly 
different between Series 2 and Series 3, it is nonetheless likely that the ischaemic insult 
sustained by the animals during the Series 3 was less than that in Series 2. This 
postulate is supported by the reduced systemic release of HMGB1 and ALT from the 
lean livers noted in Series 3, compared with the earlier experiments.  
 An even greater disparity was noted when the ALT and HMGB1 release from 
untransduced fatty livers were compared between Series 2 and Series 3. This prompted 
us to assess the extent of hepatic steatosis in the livers from the two groups. Liver 
weights at collection were significantly different between the HFD-fed mice from Series 
2 and Series 3, as were the body weights at time of ischaemic insult. These differences 
were reflected in an appearance of reduced lipid deposition in liver samples from sham-
operated mice and those collected very early after reperfusion in Series 3. Upon further 
examination of the weight-gain patterns of several cohorts of our HFD-fed mice, it 
became apparent that mice fed during Autumn and Winter gained more weight than 
those fed during Spring and Summer. Whilst seasonal variation in feeding behaviour 
and weight-gain has been noted in rodents and other small animals [403-405], it is 
surprising that this was observed in a climate-controlled animal facility with fixed light-
dark cycles which do not vary throughout the year.  
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 Considerable variability exists in the frequency of primary non-function of liver 
grafts from steatotic donors reported by different groups [277, 281]. Based on our 
experience with the HFD-fed mouse model of fatty liver, it would appear that fairly 
subtle differences in the ischaemic challenge or in the degree of hepatic steatosis can 
synergise to yield substantial and significant differences in the extent of ischaemic 
damage sustained.  
 The liver was chosen as the site of gene expression for two reasons. Firstly, 
because transgene products expressed in the liver are generally tolerated, without 
provoking an immune response [337, 341], and secondly, because the concentrations of 
esRAGE in the extracellular milieu of the liver would be highest if the esRAGE was 
being secreted by the hepatocytes, favouring binding and inactivation of HMGB1 
released from the liver parenchyma.  
 We chose to express human esRAGE rather than its murine homologue, given 
the high degree of homology between the human and mouse proteins (Figure 6.1), and 
the prior demonstration that human esRAGE was effective in a mouse model of 
angiogenesis [406]. Both ligand-binding and dimerization are functions of the V domain 
of RAGE and esRAGE [121]. Murine esRAGE and human RAGE share 86% amino 
acid identity and 97% similarity in the V domain. 8/9 critical residues for ligand binding 
are identical between the human and murine molecules. In the case of the ninth residue, 
there is a highly conservative substitution of arginine at position 46 of the human 
molecule for glutamine at the equivalent position in mouse RAGE (Figure 6.1). 
 Examining the effects of esRAGE overexpression in either lean or steatotic 
livers subjected to ischaemia-reperfusion injury, we noted a protective effect in the lean 
mice but not in those receiving a high-fat diet. Circulating HMGB1 levels as measured 
by ELISA appeared to be reduced in both lean and HFD-fed mice by esRAGE 
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overexpression, though these differences were only statistically significant in the lean 
mice. It should be noted that esRAGE binding to HMGB1 may block the ability of 
HMGB1 to engage TLR4 and RAGE without necessarily preventing binding of 
HMGB1 to the capture or detection antibodies in the ELISA, such that levels of 
HMGB1 detected by ELISA in the presence of esRAGE may overestimate the amount 
of active HMGB1 present in the serum.  
 The most striking finding in the lean animals was that mice expressing esRAGE 
were much less likely to have necrotic areas detected within the ischaemic liver on d1 
and d3 following reperfusion than either uninjected mice or those inoculated with 
rAAV-GFP. The reduced incidence of overt necrosis was accompanied by a reduction 
in apoptotic cell counts, and an increase in hepatocyte proliferation on d1 and d3 
following reperfusion, as documented by others in various models of hepatic IRI or 
massive liver resection [127, 128].  
 In contrast to this, esRAGE expression in steatotic hepatocytes resulted in a 
greater incidence of frank necrosis, and hepatocyte apoptosis, associated with more 
intense neutrophil infiltration and increased expression of various components of 
inflammatory signalling pathways including TLR4, KC, IL-1β and RAGE.  
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Figure 6.1 Human esRAGE and mouse RAGE proteins have 97% amino acid 
similarity in the V domain. The 9 critical amino acid residues for ligand binding 
are shown in red. 8/9 are identical, while at position 48, glutamine in mouse TM 
RAGE and arginine in human esRAGE are very similar, making this a highly-
conservative substitution.  
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A concomitant increase in hepatocyte and oval cell proliferation may have partially 
offset this increased liver damage, and whilst we did not use animal survival as an 
endpoint in this study, we observed that there was no increase in morbidity following 
ischaemia/reperfusion in esRAGE expressing HFD-fed mice.  
 Liver-directed gene transfer of esRAGE may have failed to protect HFD-fed 
mice for a range of reasons, operating alone or in concert. Whereas the serum levels of 
esRAGE remained stable in lean mice over the 3 days post-reperfusion, levels in HFD-
fed mice declined over this time (Figure 6.2). This decline may be consequent upon the 
loss of esRAGE-producing liver parenchyma due to hepatocyte death and/or to a 
downregulation of esRAGE production in surviving hepatocytes, as part of an 
endoplasmic reticulum stress response.  
 Endoplasmic reticulum (ER) stress, also known as the unfolded protein response 
(UPR), occurs in both NAFLD [383] and during IRI [384, 385, 388]. ER stress 
increases the transcription of proinflammatory cytokines and increases sensitivity to 
signalling through TLR4 [385, 388]. Whilst the purpose of the UPR is to protect the 
organism from release of irreparably damaged or misfolded proteins from the ER, this is 
sometimes achieved through apoptosis of the cell in question (reviewed in [386]). ER 
stress also occurs under conditions where transgene products are overexpressed, and has 
been reported in hepatocytes following transduction with both adenovirus [407] and 
AAV vectors [389].  
 Similar to the “two-hit” theory of NAFLD progression, transduction of steatotic 
hepatocytes with an AAV vector resulting in transgene overexpression may impose an 
additional burden upon cells that are already affected by ER stress. Despite a protective 
effect of the secreted transgene product at an extracellular level, the added metabolic  
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Figure 6.2 Serum levels of esRAGE in 
lean mice remained stable over the 
experimental period of three days. In 
contrast, the esRAGE levels in HFD-fed 
mice declined over the experimental 
period. By d3 post-reperfusion, serum 
esRAGE was 9419 ±416.4ng/ml in the 
lean group and 4780 ±530.2ng/ml in the 
HFD group, p<0.001. The graph shows 
the mean plus the 25-75% range (box) 
and minimum to maximum values for 
each group (whiskers). 
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stress may upregulate inflammatory pathways and render the transduced hepatocytes 
more susceptible to injury. Expression of TLR4 and other proinflammatory genes was 
increased in esRAGE-transduced steatotic livers compared with untransduced livers, but 
it is not possible to determine how much of this results from an effect of esRAGE 
transduction per se or from more extensive lipid accumulation in the heavier livers of 
the esRAGE-expressing group. 
 Whereas esRAGE is a secreted protein that traffics through the ER, GFP has no 
signal sequence, and following translation, is released directly into the cytosol (WoLF 
PSORT protein subcellular localisation prediction programme, Computational Biology 
Research Center, AIST, Japan). Transduction of steatotic hepatocytes with rAAV 2/8 
GFP may not augment the ER stress response in the same manner as a protein which 
transits through the ER, and this may explain why esRAGE-transduced livers were 
more susceptible to damage than GFP-transduced livers.  
 Alternatively, the increase in susceptibility to damage may be specifically 
related to the esRAGE protein itself, rather than to its subcellular compartmentalisation. 
Extracellular HMGB1 is best known  as a proinflammatory mediator in warm liver IRI, 
though protective effects of HMGB1 when applied directly or indirectly as a 
preconditioning stimulus are also reported [308, 309]. Whereas antibody blockade of 
extracellular HMGB1 is generally protective against IRI, a recent study showed that the 
severity of ischaemic damage was significantly increased in mice with a conditional, 
hepatocyte-specific absence of HMGB1 [408]. The exacerbation of hepatic injury was 
principally attributed to disruption of DNA repair mechanisms, poly(ADP-
ribose)polymerase 1 activation, mitochondrial instability and intracellular accumulation 
of reactive oxygen species [408].  
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 During protein synthesis, nascent polypeptides of secreted proteins enter the ER 
via an interaction between their signal sequence and the Sec61 channel [409]. Sec61 
also participates in the retrograde translocation of proteins from the ER into the cytosol 
where they can be degraded [410] and this retrograde transport is increased during ER 
stress [409]. We and others [238] have observed a significant redistribution of HMGB1 
from the nucleus into the cytoplasm of steatotic hepatocytes. It is possible that 
retrograde transport of esRAGE into the cytosol under conditions of cellular stress in 
steatotic hepatocytes results in binding to cytoplasmic HMGB1 and that HMGB1 
inactivation within the hepatocyte contributes to its increased susceptibility to damage 
by mechanisms as yet undetermined. A specific effect of esRAGE transduction per se, 
vs overload of the secretory protein pathway could be distinguished by transducing 
steatotic or lean livers with vectors encoding esRAGE or GFP as above, and 
additionally with vectors encoding other secreted proteins, such as human serum 
albumin, not known to engage with HMGB1 or a cell surface self MHC class I 
molecule such as H-2Kb. Induction of different aspects of the ER stress response could 
be assessed by the measurement of key mediators such as spliced XBP-1, phospho-
elF2α, ATF4, ATF6 and CHOP [383] and the modulation of inflammatory signalling 
and cell death in the presence or absence of ischaemia/reperfusion injury could be 
determined.  
 
 Future directions 
 Given the demonstrated sensitivity of this model to small variations in the extent 
of liver lipid accumulation or in the intensity of the ischaemic stimulus, all future 
studies should pay particularly close attention to controlling these factors to ensure 
comparability between experimental groups.  
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 Whereas we had previously noted that there was no obvious correlation between 
body weight and the extent of hepatic steatosis, this observation was made in mice that 
had all attained body weights ≥45g following 12 weeks of HFD feeding. At body 
weights less than 45g, very few mice had extensive liver lipid accumulation (Figure 
6.3). In future, we will use a cut-off weight of 45g to select candidate animals to be 
utilized in further experiments. In the spring and summer months when weight gain is 
slower, it is not clear whether an extended duration of feeding (say to 16 weeks) will 
result in continued weight gain and increased lipid deposition without supervening 
inflammation or fibrosis, and this will be important to assess. 
 The role of the microbiota in increasing the susceptibility of HFD-fed mice to 
warm liver IRI could be examined by treating HFD-fed and lean mice with a cocktail of 
broad-spectrum antibiotics prior to the IRI procedure, and by reciprocal transfers of gut 
flora between HFD-fed and lean mice.  
 In order to avoid a confounding effect of AAV- or transgene product-related 
endoplasmic reticulum stress added to that already present due to hepatic steatosis, 
future studies could use either repeated administration of recombinant soluble RAGE, 
or, by choosing a different AAV capsid and promoter combination could target systemic 
esRAGE overexpression to a tissue other than liver. Skeletal muscle would be the most 
likely alternative-AAV1 and AAV6 capsids both confer strong tropism for muscle 
[411]. 
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Figure 6.3 Below a body weight of 45g, body 
weight and liver weight appear to increase in 
parallel. Above 45g the rate of liver lipid 
accumulation appears to outstrip that of body 
weight gain. Extensive lipid accumulation was 
only found in mice with body weight ≥45g.  
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 Moreover, the effects of esRAGE could be compared with those of anti-RAGE 
blocking antibodies [412], HMGB1-blocking antibodies [75] or of various small 
molecule RAGE inhibitors [413-415] in order to delineate effects mediated through 
interruption of RAGE signalling from those attributable to other receptors such as 
TLR4, which share common ligands with RAGE.  
 In conclusion, the ability of esRAGE to inhibit signalling by HMGB1 both 
through RAGE and through other key pattern recognition receptors such as TLR4, make 
it an attractive candidate for therapeutic intervention to protect steatotic livers from the 
deleterious consequences of donor brain death and ischaemia/reperfusion injury, and 
improve the clinical outcomes for recipients of liver transplants which utilize these 
organs. Gene transfer of a secreted protein such as esRAGE to steatotic livers may 
render them more susceptible to injury by augmenting a pre-existing unfolded protein 
response in hepatocytes. Moreover, intracellular interactions of esRAGE and HMGB1 
within the steatotic hepatocytes cannot be ruled out as a contributing factor in the 
increased injury we observed. For these reasons, alternative means of delivery of 
esRAGE would be preferable in this situation.  
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APPENDIX 1: COMPOSITION OF BUFFERS AND 
SOLUTIONS 
 
 1% Bovine Serum Albumin solution 
 To make 100ml solution, dissolve 1g bovine serum albumin (BSA) (Sigma, 
USA) in 100ml TBST (0.01% Tween-20) to reach 100ml mixing gently overnight.   
 
 4% paraformaldehyde (PFA) solution 
 To make 100ml 4% PFA solution, heat 80ml of dH2O heat at 60°C, add 4g of 
powdered paraformaldehyde (Sigma, USA), and stir for >24 hours at 60°C. Afterwards, 
add 10ml 10x TBST (0.01% Tween-20) and top up with dH2O to make 100ml of 
solution. Adjust pH to7.4. Handle powdered paraformaldehyde and solution in safety 
fume hood. 
 
 Citrate buffer for antigen retrieval 
 To make 1L 1x citrate buffer solution, dissolve 2.4g tri-sodium citrate dihydrate 
(Merck, USA) in 1L dH2O and adjust to pH6.  
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 Glycine solution 
 To make 50ml 1M stock solution, dissolve 3.75g glycine (Lifetechnologies, 
USA) in 50ml dH2O. Use this stock to dilute blocking solution appropriately to get 
0.3M glycine working solution. 
 
 Immunoperoxidase solution (IP diluent) 
 To make 50ml solution, combine 47.25ml TBST (0.05% Tween-20), 2.5 ml 
heat-inactivated pig serum, 0.25ml 18% sodium azide, and filter through 0.22µm, store 
at 4°C. 
 
 Permeabilisation solution for antigen retrieval 
 To make 100ml solution, dissolve 0.1g sodium citrate and 100 µl Triton-X-100 
(Sigma, USA) add enough TBS to make 100ml. 
 
 Phosphate buffered saline (PBS) with or without 0.01% and 0.05% Tween-
20 (PBST) 
 To make 1L 10x PBS solution, dissolve 80.06g NaCl, 2.01g KCl, 14.19g 
Na2HPO4, 2.44g KH2PO4  and  1ml Tween-20 if preparing TBST 0.01%  solution, or 
5ml if preparing TBST 0.05% solution. Add enough dH2O to make 1L. Adjust pH to 
7.4. To use, dilute 1:10 in dH2O. 
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 Tris buffer for antigen retrieval 
 To make 1L 1x Tris buffer solution, dissolve 1.39g Tris base (Sigma, USA), 
6.06g Tris HCl (Sigma, USA), 6.06g NaCl, add enough dH2O to make 1L. Adjust pH to 
9. 
 
 Tris buffered saline (TBS) with or without 0.01% and 0.05% Tween-20 
(TBST) 
 To make 1L 10x TBS solution, dissolve 24.2g Tris base (Sigma, USA), 80g 
NaCl, 1ml Tween-20 if preparing TBST 0.01%  solution, or 5ml if preparing TBST 
0.05% solution. Add enough dH2O to make 1L. Adjust to pH7.4. To use, dilute 1:10 in 
dH2O. 
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APPENDIX 2: ADDITIONAL IMAGES FOR 
SECTION 5.7 
 
 
  
 
 
  
Lean esRAGE IR1d x40 HE 
Low-power views of liver sections 
from the 7 mice in the lean 
esRAGE injected group at d1 post-
reperfusion. 
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   Lean GFP IR1d x40 HE 
Low-power views of liver sections from the 6 mice in the lean GFP-
injected group at d1 post-reperfusion. 
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   Lean IR1d uninjected x40 HE 
Low-power views of liver sections 
from the 5 mice in the lean 
uninjected group at d1 post-
reperfusion. 
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   HFD esRAGE IR1d x40 HE 
See figure legend overleaf 
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HFD esRAGE IR1d x40 HE (continued) 
Low-power views of liver sections from the 9 mice in the HFD-fed 
esRAGE-injected group at d1 post-reperfusion. 
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   HFD GFP IR1d x40 HE 
Low-power views of liver sections from the 8 mice in the HFD-fed GFP-
injected group at d1 post-reperfusion. 
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   HFD uninjected IR1d x40 HE 
Low-power views of liver sections from the 6 mice in the HFD-fed 
uninjected group at d1 post-reperfusion. 
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   Lean esRAGE IR3d x40 HE 
Low-power views of liver sections 
from the 5 mice in the lean 
esRAGE injected group at d3 post-
reperfusion. 
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   Lean GFP IR3d x40 HE 
Low-power views of liver sections from the 3 mice in the lean GFP injected 
group at d3 post-reperfusion. 
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   Lean uninjected IR3d x40 HE 
Low-power views of liver sections from the 4 mice in the lean uninjected 
group at d3 post-reperfusion. 
    
 
258 
 
 
   HFD esRAGE IR3d x40 HE 
Low-power views of liver sections from the 5 mice in the HFD esRAGE-
injected group at d3 post-reperfusion. 
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   HFD GFP IR3d x40 HE 
Low-power views of liver sections from the 4 mice in the HFD GFP-injected 
group at d3 post-reperfusion. 
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   HFD uninjected IR3d x40 HE 
Low-power views of liver sections from the 4 mice in the HFD uninjected 
group at d3 post-reperfusion. 
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